# Patent

## Title
Substituted 6-amino-nicotinamides as KCNQ2/3 modulators

## Abstract

Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

## Background
This application is a division of U.S. patent application Ser. No. 13/449,472, filed Apr. 18, 2012, now pending, which is, in turn, a continuation-in-part of U.S. patent application Ser. No. 13/276,464, filed Oct. 19, 2011, now U.S. Pat. No. 8,552,200, which, in turn, claims priority of U.S. Provisional Patent Application No. 61/394,868, filed Oct. 20, 2010, and European Patent Application No. 10 013 811.4, filed Oct. 20, 2010, the contents of all of which patent applications are incorporated herein fully by reference.


The invention relates to substituted 6-amino-nicotinamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
The treatment of pain, in particular of neuropathic pain, is of great importance in medicine. There is a worldwide need for effective pain therapies. The urgent need for action for a target-orientated treatment of chronic and non-chronic states of pain appropriate for the patient, by which is to be understood the successful and satisfactory treatment of pain for the patient, is also documented in the large number of scientific works which have recently been published in the field of applied analgesics and of fundamental research into nociception.
A pathophysiological feature of chronic pain is the overexcitability of neurons. Neuronal excitability is influenced decisively by the activity of K+ channels, since these determine decisively the resting membrane potential of the cell and therefore the excitability threshold. Heteromeric K+ channels of the molecular subtype KCNQ2/3 (Kv7.2/7.3) are expressed in neurons of various regions of the central (hippocampus, amygdala) and peripheral (dorsal root ganglia) nervous system and regulate the excitability thereof. Activation of KCNQ2/3 K+ channels leads to a hyperpolarization of the cell membrane and, accompanying this, to a decrease in the electrical excitability of these neurons. KCNQ2/3-expressing neurons of the dorsal root ganglia are involved in the transmission of nociceptive stimuli from the periphery into the spinal marrow (Passmore et al., J. Neurosci. 2003; 23 (18): 7227-36).
It has accordingly been possible to detect an analgesic activity in preclinical neuropathy and inflammatory pain models for the KCNQ2/3 agonist retigabine (Blackburn-Munro and Jensen, Eur J. Pharmacol. 2003; 460 (2-3); 109-16; post et al., Naunyn Schmiedebergs Arch Pharmacol 2004; 369 (4): 382-390).
The KCNQ2/3 K+ channel thus represents a suitable starting point for the treatment of pain; in particular of pain selected from the group consisting of chronic pain, acute pain, neuropathic pain, inflammatory pain, visceral pain and muscular pain (Nielsen et al., Eur J. Pharmacol. 2004; 487 (1-3): 93-103), in particular of neuropathic and inflammatory pain.
Moreover, the KCNQ2/3 K+ channel is a suitable target for therapy of a large number of further diseases, such as, for example, migraine (US2002/0128277), cognitive diseases (Gribkoff, Expert Opin Ther Targets 2003; 7 (6): 737-748), anxiety (Korsgaard et al., J Pharmacol Exp Ther. 2005, 14 (1): 282-92), epilepsy (Wickenden et al., Expert Opin Ther Pat 2004; 14 (4): 457-469; Gribkoff, Expert Opin Ther Targets 2008, 12 (5): 565-81; Miceli et al., Curr Opin Pharmacol 2008, 8 (1): 65-74), urinary incontinence (Streng et al., J Urol 2004; 172: 2054-2058), dependency (Hansen et al., Eur J Pharmacol 2007, 570 (1-3): 77-88), mania/bipolar disorders (Dencker et al., Epilepsy Behav 2008, 12 (1): 49-53) and dystonia-associated dyskinesias (Richter et al., Br J Pharmacol 2006, 149 (6): 747-53).
Substituted compounds that have an affinity for the KCNQ2/3 K+ channel are e.g. known from the prior art (WO 2008/046582, WO 2010/046108, WO 2010/102809 and WO 2002/066036).
DE 25 13 949 and GB 1 420 987 disclose substituted nicotinamides and derivatives thereof as coupling components for the preparation of azo dyes.
There is a demand for further compounds having comparable or better properties, not only with regard to affinity to KCNQ2/3 K+ channels per se (potency, efficacy).
Thus, it may be advantageous to improve the metabolic stability, the solubility in aqueous media or the permeability of the compounds. These factors can have a beneficial effect on oral bioavailability or can alter the PK/PD (pharmacokinetic/pharmacodynamic) profile; this can lead to a more beneficial period of effectiveness, for example. A weak or non-existent interaction with transporter molecules, which are involved in the ingestion and the excretion of pharmaceutical compositions, is also to be regarded as an indication of improved bioavailability and at most low interactions of pharmaceutical compositions. Furthermore, the interactions with the enzymes involved in the decomposition and the excretion of pharmaceutical compositions should also be as low as possible, as such test results also suggest that at most low interactions, or no interactions at all, of pharmaceutical compositions are to be expected.
In addition, it may be advantageous if the compounds show a high selectivity towards other receptors of the KCNQ family (specificity), e.g. towards KCNQ1, KCNQ3/5 or KCNQ4. A high selectivity may have a positive effect on the side effects profile: for example it is known that compounds which (also) have an affinity to KCNQ1 are likely to have a potential for cardial side effects. Therefore, a high selectivity towards KCNQ1 may be desirable. However, it may also be advantageous for the compounds to show a high selectivity towards other receptors. For instance, it may be advantageous for the compounds to show a low affinity for the hERG ion channel or the L-type calcium ion channel (phenylalkylamine-, benzothiazepin-, dihydropyridine-binding site) since these receptors are known to possibly have a potential for cardial side effects. Further, an improved selectivity towards binding to other endogenic proteins (i.e. receptors or enzymes) may result in a better side effects profile and, consequently to an improved tolerance.
It was therefore an object of the invention to provide new compounds having advantages over the compounds of the prior art. These compounds should be suitable in particular as pharmacological active ingredients in pharmaceutical compositions, preferably in pharmaceutical compositions for the treatment and/or prophylaxis of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K+ channels.
That object is achieved by the subject-matter described herein.
It has been found, surprisingly, that substituted compounds of the general formula (I) given below are suitable for the treatment of pain. It has also been found, surprisingly, that substituted compounds of the general formula (I) given below also have an excellent affinity for the KCNQ2/3 K+ channel and are therefore suitable for the prophylaxis and/or treatment of disorders and/or diseases that are mediated at least in part by KCNQ2/3 K+ channels. The substituted compounds thereby act as modulators, i.e. agonists or antagonists, of the KCNQ2/3 K+ channel.
The present invention therefore relates to a substituted compound of general formula (I),




wherein

    R1 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    R2 represents F; Cl; Br; I; CN; CF3; C(═O)H; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a C(═O)—C1-4 aliphatic residue, a C(═O)—O—C1-4 aliphatic residue, a C(═O)—NH—C1-4 aliphatic residue, a C(═O)—N(C1-4 aliphatic residue)2, wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, a S—C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, a S—C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    R4 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged, preferably in each case bridged, via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    
        on the condition that if R4 denotes a 3 to 10 membered heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered heterocycloaliphatic residue or the heteroaryl is linked via a carbon atom;
    
    
    R5 denotes H or a C1-10-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted;
    or
    R4 and R5 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted, which may optionally be condensed with aryl or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted;
    R6 represents a C2-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    
        on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
        or
        denotes S—R7, O—R8 or N(R9R10),
        wherein
        
            R7 and R8 in each case represent a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
            on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
            R9 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
            on the condition that if R9 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom;
            R10 denotes H or a C1-10-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted;
            or
            R9 and R10 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; which may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted;
        
        
    
    


in which an “aliphatic group” and an “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated,
in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated,
in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2;
in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2;
in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2,




an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, an NH—C(═O)—C1-4 aliphatic residue, an NH—S(═O)2—C1-4 aliphatic residue, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, C(═O)H, C(═O)OH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2; with the exception of the following compounds

    N-butyl-4-methyl-2,6-bis(methylamino)nicotinamide and
    N-butyl-2,6-bis(butylamino)-4-methylnicotinamide,


in the form of the free compounds, the racemate, the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of the salts of physiologically acceptable acids or bases, or in the form of the solvates, in particular hydrates.
The terms “C1-10-aliphatic residue”, “C2-10-aliphatic residue”, “C1-8-aliphatic residue”, “C1-6-aliphatic residue” and “C1-4-aliphatic residue” and “C1-2-aliphatic residue” comprise in the sense of this invention acyclic saturated or unsaturated aliphatic hydrocarbon residues, which can be branched or unbranched and also unsubstituted or mono- or polysubstituted, containing 1 to 10, or 2 to 10, or 1 to 8, or 1 to 6, or 1 to 4 or 1 to 2 carbon atoms, respectively, i.e. C1-10 alkanyls, C2-10 alkenyls and C2-10 alkynyls as well as C2-10 alkanyls as well as C1-8 alkanyls, C2-8 alkenyls and C2-8 alkynyls as well as C1-6 alkanyls, C2-6 alkenyls and C2-6 alkynyls as well as C1-4 alkanyls, C2-4 alkenyls and C2-4 alkynyls, as well as C1-2 alkanyls, C2-alkenyls and C2 alkynyls, respectively. In this case, alkenyls comprise at least one C—C double bond (a C═C-bond) and alkynyls comprise at least one C—C triple bond (a C≡C-bond). Preferably, aliphatic residues are selected from the group consisting of alkanyl(alkyl) and alkenyl residues, more preferably are alkanyl residues. Preferred C1-10 alkanyl residues are selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl. Preferred C2-10 alkanyl residues are selected from the group consisting of ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl. Preferred C1-8 alkanyl residues are selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl and n-octyl. Preferred C1-6 alkanyl residues are selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl and n-hexyl. Preferred C1-4 alkanyl residues are selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl and tert.-butyl. Preferred C2-10 alkenyl residues are selected from the group consisting of ethenyl(vinyl), propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), butenyl, pentenyl, hexenyl heptenyl, octenyl, nonenyl and decenyl. Preferred C2-8 alkenyl residues are selected from the group consisting of ethenyl(vinyl), propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), butenyl, pentenyl, hexenyl heptenyl and octenyl. Preferred C2-6 alkenyl residues are selected from the group consisting of ethenyl (vinyl), propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), butenyl, pentenyl and hexenyl. Preferred C2-4 alkenyl residues are selected from the group consisting of ethenyl (vinyl), propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3) and butenyl. Preferred C2-10 alkynyl residues are selected from the group consisting of ethynyl, propynyl (—CH2—C≡CH, —C≡C—CH3), butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl. Preferred C2-8 alkynyl residues are selected from the group consisting of ethynyl, propynyl (—CH2—C≡CH, —C≡C—CH3), butynyl, pentynyl, hexynyl, heptynyl and octynyl. Preferred C2-6 alkynyl residues are selected from the group consisting of ethynyl, propynyl (—CH2—C≡CH, —C≡C—CH3), butynyl, pentynyl and hexynyl Preferred C2-4 alkynyl residues are selected from the group consisting of ethynyl, propynyl (—CH2—C≡CH, —C≡C—CH3) and butynyl.
The terms “C3-6-cycloaliphatic residue” and “C3-10-cycloaliphatic residue” mean for the purposes of this invention cyclic aliphatic hydrocarbons containing 3, 4, 5 or 6 carbon atoms and 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, respectively, wherein the hydrocarbons in each case can be saturated or unsaturated (but not aromatic), unsubstituted or mono- or polysubstituted. The cycloaliphatic residues can be bound to the respective superordinate general structure via any desired and possible ring member of the cycloaliphatic residue. The cycloaliphatic residues can also be condensed with further saturated, (partially) unsaturated, (hetero)cyclic, aromatic or heteroaromatic ring systems, i.e. with cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residues which can in turn be unsubstituted or mono- or polysubstituted. C3-10 cycloaliphatic residue can furthermore be singly or multiply bridged such as, for example, in the case of adamantyl, bicyclo[2.2.1]heptyl or bicyclo[2.2.2]octyl. Preferred C3-10 cycloaliphatic residues are selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantyl,




cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. Preferred C3-6 cycloaliphatic residues are selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl.

The terms “3-6-membered heterocycloaliphatic residue”, “4-7-membered heterocycloaliphatic residue” and “3-10-membered heterocycloaliphatic residue” mean for the purposes of this invention heterocycloaliphatic saturated or unsaturated (but not aromatic) residues having 3-6, i.e. 3, 4, 5 or 6 ring members, and 4-7, i.e. 4, 5, 6 or 7 ring members, and 3-10, i.e. 3, 4, 5, 6, 7, 8, 9 or 10 ring members, respectively, in which in each case at least one, if appropriate also two or three carbon atoms are replaced by a heteroatom or a heteroatom group each selected independently of one another from the group consisting of O, S, S(═O)2, N, NH and N(C1-8 alkyl), preferably N(CH3), wherein the ring members can be unsubstituted or mono- or polysubstituted. The heterocycloaliphatic residue can be bound to the superordinate general structure via any desired and possible ring member of the heterocycloaliphatic residue if not indicated otherwise. The heterocycloaliphatic residues can also be condensed with further saturated, (partially) unsaturated (hetero)cycloaliphatic or aromatic or heteroaromatic ring systems, i.e. with cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residues, which can in turn be unsubstituted or mono- or polysubstituted. The term “condensed” also optionally includes spirocycles, i.e. an at least bicyclic ring system, wherein the heterocycloaliphatic residue is connected through just one (spiro)atom with a further saturated, (partially) unsaturated (hetero)cycloaliphatic or aromatic or heteroaromatic ring system. Example of such spirocycles are e.g.




The heterocycloaliphatic residues can furthermore optionally be singly or multiply bridged with a C1- or C2-aliphatic group such as, for example, in the case of





Preferred heterocycloaliphatic residues are selected from the group consisting of azetidinyl, aziridinyl, azepanyl, azocanyl, diazepanyl, dithiolanyl, dihydroquinolinyl, dihydropyrrolyl, dioxanyl, dioxolanyl, dioxepanyl, dihydroindenyl, dihydropyridinyl, dihydrofuranyl, dihydroisoquinolinyl, dihydroindolinyl, dihydroisoindolyl, imidazolidinyl, isoxazolidinyl, morpholinyl, oxiranyl, oxetanyl, oxazepanyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, piperidinyl, pyrazolidinyl, pyranyl, tetrahydropyrrolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroindolinyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrahydropyridoindolyl, tetrahydronaphthyl, tetrahydrocarbolinyl, tetrahydroisoxazolo-pyridinyl, thiazolidinyl, tetrahydroimidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl and thiomorpholinyl. More preferred heterocycloaliphatic residues are pyrrolidinyl, piperidinyl, oxazepanyl, azetidinyl, morpholinyl, piperazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, and dihydroisoindolyl. Most preferred heterocycloaliphatic residues are pyrrolidinyl, piperidinyl, oxazepanyl, azetidinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, and dihydroisoindolyl.

The term “aryl” means for the purpose of this invention aromatic hydrocarbons having 6 to 14 ring members, including phenyls and naphthyls. Each aryl residue can be unsubstituted or mono- or polysubstituted, wherein the aryl substituents can be the same or different and in any desired and possible position of the aryl. The aryl can be bound to the superordinate general structure via any desired and possible ring member of the aryl residue. The aryl residues can also be condensed with further saturated, (partially) unsaturated, (hetero)cycloaliphatic, aromatic or heteroaromatic ring systems, i.e. with a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residue, which can in turn be unsubstituted or mono- or polysubstituted. Examples of condensed aryl residues are benzodioxolanyl and benzodioxanyl. Preferably, aryl is selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, fluorenyl and anthracenyl, each of which can be respectively unsubstituted or mono- or polysubstituted. A particularly preferred aryl is phenyl, unsubstituted or mono- or polysubstituted.
The term “heteroaryl” for the purpose of this invention represents a 5 or 6-membered cyclic aromatic residue containing at least 1, if appropriate also 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are each selected independently of one another from the group S, N and O and the heteroaryl residue can be unsubstituted or mono- or polysubstituted; in the case of substitution on the heteroaryl, the substituents can be the same or different and be in any desired and possible position of the heteroaryl. The binding to the superordinate general structure can be carried out via any desired and possible ring member of the heteroaryl residue. The heteroaryl can also be part of a bi- or polycyclic system having up to 14 ring members, wherein the ring system can be formed with further saturated, (partially) unsaturated, (hetero)cycloaliphatic or aromatic or heteroaromatic rings, i.e. with a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residue, which can in turn be unsubstituted or mono- or polysubstituted. It is preferable for the heteroaryl residue to be selected from the group consisting of benzofuranyl, benzoimidazolyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, benzooxadiazolyl, quinazolinyl, quinoxalinyl, carbazolyl, quinolinyl, dibenzofuranyl, dibenzothienyl, furyl (furanyl), imidazolyl, imidazothiazolyl, indazolyl, indolizinyl, indolyl, isoquinolinyl, isoxazoyl, isothiazolyl, indolyl, naphthyridinyl, oxazolyl, oxadiazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pyrazolyl, pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, purinyl, phenazinyl, thienyl(thiophenyl), triazolyl, tetrazolyl, thiazolyl, thiadiazolyl and triazinyl. Furyl, pyridyl, oxazolyl, thiazolyl and thienyl are particularly preferred.
The terms “aryl, heteroaryl, a heterocycloaliphatic residue, or a cycloaliphatic residue bridged via a C1-4-aliphatic group or via a C1-8-aliphatic group” mean for the purpose of the invention that the expressions “aryl, heteroaryl, heterocycloaliphatic residue and cycloaliphatic residue” have the above-defined meanings and are bound to the respective superordinate general structure via a C1-4-aliphatic group or via a C1-8-aliphatic group, respectively. The C1-4 aliphatic group and the C1-8-aliphatic group can in all cases be branched or unbranched, unsubstituted or mono- or polysubstituted. The C1-4 aliphatic group can in all cases be furthermore saturated or unsaturated, i.e. can be a C1-4 alkylene group, a C2-4 alkenylene group or a C2-4 alkynylene group. The same applies to a C1-8-aliphatic group, i.e. a C1-8-aliphatic group can in all cases be furthermore saturated or unsaturated, i.e. can be a C1-8 alkylene group, a C2-8 alkenylene group or a C2-8 alkynylene group. Preferably, the C1-4-aliphatic group is a C1-4 alkylene group or a C2-4 alkenylene group, more preferably a C1-4 alkylene group. Preferably, the C1-8-aliphatic group is a C1-8 alkylene group or a C2-8 alkenylene group, more preferably a C1-8 alkylene group. Preferred C1-4 alkylene groups are selected from the group consisting of —CH2—, —CH2—CH2—, —CH(CH3)—, —CH2—CH2—CH2—, —CH(CH3)—CH2—, —CH(CH2CH3)—, —CH2—(CH2)2—CH2—, —CH(CH3)—CH2—CH2—, —CH2—CH(CH3)—CH2—, —CH(CH3)—CH(CH3)—, —CH(CH2CH3)—CH2—, —C(CH3)2—CH2—, —CH(CH2CH2CH3)— and —C(CH3)(CH2CH3)—. Preferred C2-4 alkenylene groups are selected from the group consisting of —CH═CH—, —CH═CH—CH2—, —C(CH3)═CH2—, —CH═CH—CH2—CH2—, —CH2—CH═CH—CH2—, —CH═CH—CH═CH—, —C(CH3)═CH—CH2—, —CH═C(CH3)—CH2—, —C(CH3)═C(CH3)— and —C(CH2CH3)═CH—. Preferred C2-4 alkynylene groups are selected from the group consisting of —C≡C—, —C≡C—CH2—, —C≡C—CH2—CH2—, —C≡C—CH(CH3)—, —CH2—C≡C—CH2— and —C≡C—C≡C—. Preferred C1-8 alkylene groups are selected from the group consisting of —CH2—, —CH2—CH2—, —CH(CH3)—, —CH2—CH2—CH2—, —CH(CH3)—CH2—, —CH(CH2CH3)—, —CH2—(CH2)2—CH2—, —CH(CH3)—CH2—CH2—, —CH2—CH(CH3)—CH2—, —CH(CH3)—CH(CH3)—, —CH(CH2CH3)—CH2—, —C(CH3)2—CH2—, —CH(CH2CH2CH3)—, —C(CH3)(CH2CH3)—, —CH2—(CH2)3—CH2—, —CH(CH3)—CH2—CH2—CH2—, —CH2—CH(CH3)—CH2—CH2—, —CH(CH3)—CH2—CH(CH3)—, —CH(CH3)—CH(CH3)—CH2—, —C(CH3)2—CH2—CH2—, —CH2—C(CH3)2—CH2—, —CH(CH2CH3)—CH2—CH2—, —CH2—CH(CH2CH3)—CH2—, —C(CH3)2—CH(CH3)—, —CH(CH2CH3)—CH(CH3)—, —C(CH3)(CH2CH3)—CH2—, —CH(CH2CH2CH3)—CH2—, —C(CH2CH2CH3)—CH2—, —CH(CH2CH2CH2CH3)—, —C(CH3)(CH2CH2CH3)—, —C(CH2CH3)2— and —CH2—(CH2)4—CH2—. Preferred C2-8 alkenylene groups are selected from the group consisting of —CH═CH—, —CH═CH—CH2—, —C(CH3)═CH2—, —CH═CH—CH2—CH2—, —CH2—CH═CH—CH2—, —CH═CH—CH═CH—, —C(CH3)═CH—CH2—, —CH═C(CH3)—CH2—, —C(CH3)═C(CH3)—, —C(CH2CH3)═CH—, —CH═CH—CH2—CH2—CH2—, —CH2—CH═CH2—CH2—CH2—, —CH═CH═CH—CH2—CH2— and —CH═CH2—CH—CH═CH2—. Preferred C2-8 alkynylene groups are selected from the group consisting of —C≡C—, —C≡C—CH2—, —C≡C—CH2—CH2—, —C≡C—CH(CH3)—, —CH2—C≡C—CH2—, —C≡C—C≡C—, —C≡C—C(CH3)2—, —C≡C—CH2—CH2—CH2—, —CH2—C≡C—CH2—CH2—, —C≡C—C≡C—CH2— and —C≡C—CH2—C≡C.
In relation to “aliphatic residue” and “aliphatic group” the term “mono- or polysubstituted” refers in the sense of this invention, with respect to the corresponding residues or groups, to the single substitution or multiple substitution, e.g. disubstitution, trisubstitution and tetrasubstitution, of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2. The term “polysubstituted” with respect to polysubstituted residues and groups includes the polysubstitution of these residues and groups either on different or on the same atoms, for example trisubstituted on the same carbon atom, as in the case of CF3 or CH2CF3, or at various points, as in the case of CH(OH)—CH═CH—CHCl2. A substituent can if appropriate for its part in turn be mono- or polysubstituted. The multiple substitution can be carried out using the same or using different substituents.
In relation to “cycloaliphatic residue” and “heterocycloaliphatic residue” the term “mono- or polysubstituted” refers in the sense of this invention, with respect to the corresponding residues, to the single substitution or multiple substitution, e.g. disubstitution, trisubstitution and tetrasubstitution, of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2. The term “polysubstituted” with respect to polysubstituted residues and groups includes the polysubstitution of these residues and groups either on different or on the same atoms, for example disubstituted on the same carbon atom, as in the case of 1,1-difluorocyclohexyl, or at various points, as in the case of 1-chloro-3-fluorocyclohexyl. A substituent can if appropriate for its part in turn be mono- or polysubstituted. The multiple substitution can be carried out using the same or using different substituents.
Preferred substituents of “aliphatic residue” and “aliphatic group” are selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, ═O, OH, OCF3, a O—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CONH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2.
Preferred substituents of “cycloaliphatic residue” and “heterocycloaliphatic residue” are selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, ═O, OH, OCF3, a O—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CONH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2.
In relation to “aryl” and “heteroaryl” the term “mono- or polysubstituted” refers in the sense of this invention to the single substitution or multiple substitution, e.g. disubstitution, trisubstitution and tetrasubstitution, of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2,




an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, an NH—C(═O)—C1-4 aliphatic residue, an NH—S(═O)2—C1-4 aliphatic residue, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, C(═O)H, C(═O)OH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2 on one or if appropriate different atoms, wherein a substituent can if appropriate for its part in turn be mono- or polysubstituted. The multiple substitution is carried out employing the same or using different substituents.

Preferred substituents of “aryl” and “heteroaryl” are selected from the group consisting of F, Cl, Br, I, NO2, NH2,




an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, an NH—C(═O)—C1-4 aliphatic residue, an NH—S(═O)2—C1-4 aliphatic residue, OH, OCF3, a O—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, CONH2, a C(═O)—NH(C1-4 aliphatic residue), a C(═O)—N(C1-4 aliphatic residue)2, aryl, preferably phenyl, or benzyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, CF3, CH3, C2H5, iso-propyl, tert.-butyl, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, O—CH3, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, S—CH3, SCF3, NO2, NH2, N(CH3)2, N(CH3)(C2H5) and N(C2H5)2, heteroaryl, preferably pyridyl, thienyl, furyl, thiazolyl or oxazolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, CF3, CH3, C2H5, iso-propyl, tert.-butyl, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, O—CH3, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, S—CH3, SCF3, NO2, NH2, N(CH3)2, N(CH3)(C2H5) and N(C2H5)2.

The compounds according to the invention are defined by substituents, for example by R1, R2 and R3 (1st generation substituents) which are for their part if appropriate substituted (2nd generation substituents). Depending on the definition, these substituents of the substituents can for their part be resubstituted (3rd generation substituents). If, for example, R1=a C1-10 aliphatic residue (1st generation substituent), then the C1-10 aliphatic residue can for its part be substituted, for example with a NH—C1-4 aliphatic residue (2nd generation substituent). This produces the functional group R1=(C1-10 aliphatic residue-NH—C1-4 aliphatic residue). The NH—C1-4 aliphatic residue can then for its part be resubstituted, for example with Cl (3rd generation substituent). Overall, this produces the functional group R1=C1-10 aliphatic residue-NH—C1-4 aliphatic residue, wherein the C1-4 aliphatic residue of the NH—C1-4 aliphatic residue is substituted by Cl.
However, in a preferred embodiment, the 3rd generation substituents may not be resubstituted, i.e. there are then no 4th generation substituents.
In another preferred embodiment, the 2nd generation substituents may not be resubstituted, i.e. there are then not even any 3rd generation substituents. In other words, in this embodiment, in the case of general formula (I), for example, the functional groups for R1 to R6 can each if appropriate be substituted; however, the respective substituents may then for their part not be resubstituted.
In some cases, the compounds according to the invention are defined by substituents which are or carry an aryl or heteroaryl residue, respectively unsubstituted or mono- or polysubstituted, or which form together with the carbon atom(s) or heteroatom(s) connecting them, as the ring member or as the ring members, a ring, for example an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted. Both these aryl or heteroaryl residues and the (hetero)aromatic ring systems formed in this way can if appropriate be condensed with a cycloaliphatic, preferably a C3-6 cycloaliphatic residue, or heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, or with aryl or heteroaryl, e.g. with a C3-6 cycloaliphatic residue such as cyclopentyl, or a 3 to 6 membered heterocycloaliphatic residue such as morpholinyl, or an aryl such as phenyl, or a heteroaryl such as pyridyl, wherein the cycloaliphatic or heterocycloaliphatic residues, aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.
In some cases, the compounds according to the invention are defined by substituents which are or carry a cycloaliphatic residue or a heterocycloaliphatic residue, respectively, in each case unsubstituted or mono- or polysubstituted, or which form together with the carbon atom(s) or heteroatom(s) connecting them, as the ring member or as the ring members, a ring, for example a cycloaliphatic or a heterocycloaliphatic ring system. Both these cycloaliphatic or heterocycloaliphatic ring systems and the (hetero)cycloaliphatic ring systems formed in this manner can if appropriate be condensed with aryl or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl, or with a cycloaliphatic residue, preferably a C3-6 cycloaliphatic residue, or a heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, e.g. with an aryl such as phenyl, or a heteroaryl such as pyridyl, or a cycloaliphatic residue such as cyclohexyl, or a heterocycloaliphatic residue such as morpholinyl, wherein the aryl or heteroaryl residues or cycloaliphatic or heterocycloaliphatic residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.
Within the scope of the present invention, the symbol




used in the formulae denotes a link of a corresponding residue to the respective superordinate general structure.

If a residue occurs multiply within a molecule, then this residue can have respectively different meanings for various substituents: if, for example, both R2 and R3 denote a 3 to 6 membered heterocycloaliphatic residue, then the 3 to 6 membered heterocycloaliphatic residue can e.g. represent morpholinyl for R2 and can represent piperazinyl for R3.
The term “salts of physiologically acceptable acids” refers in the sense of this invention to salts of the respective active ingredient with inorganic or organic acids which are physiologically acceptable—in particular when used in human beings and/or other mammals. Hydrochloride is particularly preferred. Examples of physiologically acceptable acids are: hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, citric acid, glutamic acid, saccharic acid, monomethylsebacic acid, 5-oxoproline, hexane-1-sulphonic acid, nicotinic acid, 2, 3 or 4-aminobenzoic acid, 2,4,6-trimethylbenzoic acid, α-lipoic acid, acetyl glycine, hippuric acid, phosphoric acid, aspartic acid. Citric acid and hydrochloric acid are particularly preferred.
The term “salts of physiologically acceptable bases” refers in the sense of this invention to salts of the respective compound according to the invention—as an anion, e.g. upon deprotonation of a suitable functional group—with at least one cation or base—preferably with at least one inorganic cation—which are physiologically acceptable—in particular when used in human beings and/or other mammals. Particularly preferred are the salts of the alkali and alkaline earth metals, in particular (mono-) or (di)sodium, (mono-) or (di)potassium, magnesium or calcium salts, but also ammonium salts [NHxR4-x]+, in which x=0, 1, 2, 3 or 4 and R represents a branched or unbranched C1-4 aliphatic residue.
Particularly preferred is also a compound according to general formula (I), wherein the particular radicals R1-R6 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof
with the additional exception of the following compounds

    N-ethyl-2,6-bis(butylamino)-4-methylnicotinamide,
    N-(2-methoxyethyl)-2,6-bis(2-methoxyethylamino)-4-methylnicotinamide and
    N-butyl-2,6-bis(butylamino)-4-propylnicotinamide.


In another particularly preferred embodiment of the compound according to general formula (I) radicals R1, R2, R3, R4, R5 and R6 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof, with the proviso that R1 comprises at least 4 atoms selected from the group consisting of carbon and heteroatoms, preferably at least 4 atoms selected from the group consisting of carbon atoms and heteroatoms selected from the group consisting of N, O and S.
The present invention further relates to a substituted compound of general formula (I),




wherein

    R1 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    R2 represents F; Cl; Br; I; CN; CF3; C(═O)H; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a C(═O)—C1-4 aliphatic residue, a C(═O)—O—C1-4 aliphatic residue, a C(═O)—NH—C1-4 aliphatic residue, a C(═O)—N(C1-4 aliphatic residue)2, wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, a S—C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;


R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, a S—C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

    R4 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged, preferably in each case bridged, via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    
        on the condition that if R4 denotes a 3 to 10 membered heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered heterocycloaliphatic residue or the heteroaryl is linked via a carbon atom;
    
    
    R5 denotes H or a C1-10-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted;
    or
    R4 and R5 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted,
    R6 represents a C2-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    
        on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
        or
        denotes S—R7, O—R8 or N(R9R10),
        wherein
        
            R7 and R8 in each case represent a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
            on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
            R9 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
            on the condition that if R9 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom;
            R10 denotes a C1-10-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted;
            or
            R9 and R10 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted;
        
        
    
    


in which an “aliphatic group” and an “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated,
in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated,
in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2;
in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2;
in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2,




an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, an NH—C(═O)—C1-4 aliphatic residue, an NH—S(═O)2—C1-4 aliphatic residue, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, C(═O)H, C(═O)OH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2;

in the form of the free compounds, the racemate, the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of the salts of physiologically acceptable acids or bases, or in the form of the solvates, in particular hydrates.
In another preferred embodiment of the compound according to formula (I), preferred substituents of “cycloaliphatic residue” and “heterocycloaliphatic residue” are selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, CH2OH, CH2—OCH3, C2H4—OH, C2H4—OCH3, CH2—CF3, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2.
In another preferred embodiment of the compound according to formula (I), preferred substituents of “aryl” and “heteroaryl” are selected from the group consisting of F, Cl, Br, I, NO2, NH2,




an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, an NH—C(═O)—C1-4 aliphatic residue, an NH—S(═O)2—C1-4 aliphatic residue, OH, OCFH2, OCF2H, OCF3, a O—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CF2H, CHF2, a C1-4-aliphatic residue, CH2OH, CH2—OCH3, C2H4—OH, C2H4—OCH3, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, CONH2, a C(═O)—NH(C1-4 aliphatic residue), a C(═O)—N(C1-4 aliphatic residue)2, aryl, preferably phenyl, or benzyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, CF3, CH3, C2H5, iso-propyl, tert.-butyl, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, O—CH3, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, S—CH3, SCF3, NO2, NH2, N(CH3)2, N(CH3)(C2H5) and N(C2H5)2, heteroaryl, preferably pyridyl, thienyl, furyl, thiazolyl or oxazolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, CF3, CH3, C2H5, iso-propyl, tert.-butyl, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, O—CH3, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, S—CH3, SCF3, NO2, NH2, N(CH3)2, N(CH3)(C2H5) and N(C2H5)2.

In yet another preferred embodiment of the compound according to general formula (I) the particular radicals R1-R5 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof and

    R6 represents a C2-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
    
        on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
        or
    
    
    denotes S—R7 or O—R8 
    
        wherein R7 and R8 in each case represent a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
        on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.
    
    


In another preferred embodiment of the present invention the compound according to general formula (I) has the general formula (I-a)




wherein

the particular radicals R1-R5 and R7 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.
In another preferred embodiment of the present invention the compound according to general formula (I) has the general formula (I-b)




wherein
the particular radicals R1-R5 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof,

    R11 represents O—R8 or N(R9R10),
    
        wherein R8, R9 and R10 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof,
        or represents a C2-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
        on the condition that if R11 denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue.
    
    


In a particular preferred embodiment of the present invention, radical R11 in general formula (I-b) and radical R6 in general formula (I) represents O—R8, wherein R8 has the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.
In another particular preferred embodiment of the present invention, radical R11 in general formula (I-b) and radical R6 in general formula (I) represents N(R9R10), wherein R9 and R10 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.
In yet another particular preferred embodiment of the present invention, radical R11 in general formula (I-b) and radical R6 in general formula (I) represents a C2-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
on the condition that if R11 denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue.
Another preferred embodiment of the compound according to general formula (I) has the general formula (I-c),




wherein the particular radicals R1, R2, R4, R5 and R6 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.
Another preferred embodiment of the compound according to general formula (I) has the general formula (I-e) or (I-f),




wherein the particular radicals R1, R3, R4, R5 and R6 or R1, R4, R5 and R6, respectively, have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.
In yet another preferred embodiment of the compound according to general formula (I) radicals R2, R3, R4, R5 and R6 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof, and R1 represents aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted.
In case R4 and R5 of the compound of general formula (I) form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted, said heterocycloaliphatic residue may optionally be condensed with aryl or heteroaryl or with a C3-10 cycloaliphatic residue or with a 3 to 10 membered heterocycloaliphatic residue, wherein the aryl, heteroaryl, C3-10 cycloaliphatic or 3 to 10 membered heterocycloaliphatic residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted. Preferably, said heterocycloaliphatic residue formed by R4 and R5 of the compound of general formula (I) together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl, or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.
Particularly preferably, in case R4 and R5 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted, said heterocycloaliphatic residue may optionally be condensed with aryl or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.
In case R9 and R10 of the compound of general formula (I) form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted, said heterocycloaliphatic residue may optionally be condensed with aryl or heteroaryl or with a C3-10 cycloaliphatic residue or with a 3 to 10 membered heterocycloaliphatic residue, wherein the aryl, heteroaryl, C3-10 cycloaliphatic or 3 to 10 membered heterocycloaliphatic residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted. Preferably, said heterocycloaliphatic residue formed by R9 and R10 of the compound of general formula (I) together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl, or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.
Particularly preferably, in case R9 and R10 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted, said heterocycloaliphatic residue may optionally be condensed with aryl or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.
Yet another preferred embodiment of present invention is a compound according to general formula (I), wherein

    R1 denotes a C1-10-aliphatic residue, preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH, preferably denotes a C1-10-aliphatic residue, more preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a S(═O)2—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN and C(═O)—OH,
    
    
    R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a S—C1-4-aliphatic residue, a O—C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted,
    
        preferably represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a S—C1-4-aliphatic residue, a O—C1-4-aliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C1-4-aliphatic residue and an O—C1-4-aliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue, and wherein the C3-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue,
    
    
    R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, a S—C1-4-aliphatic residue,
    
        wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue;
        a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C1-4-aliphatic residue and a O—C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue,
        
        
        and wherein the C3-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue,
    
    
    R4 denotes a C1-10-aliphatic residue, preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, and C(═O)—OH,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C(═O)—O—C1-4-aliphatic residue a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        on the condition that if R4 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
        or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the aryl or the heteroaryl residue may in each case be optionally bridged, preferably in each case is bridged, via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN and C(═O)—OH,
    
    
    R5 denotes H or a C1-10-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
    
    
    or
    R4 and R5 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, preferably selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue and
        wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with a C3-10 cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, wherein the C3-10 cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, ═O, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
    
    
    R6 denotes a C2-10-aliphatic residue, preferably a C2-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, and C(═O)—OH,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
        or
        R6 denotes S—R7, O—R8 or N(R9R10),
        wherein
        
            R7 and R8 in each case represent a C1-10-aliphatic residue, preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
            
            
            or in each case represent a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
            
            
            and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
            on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,
            R9 denotes a C1-10-aliphatic residue, preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, and C(═O)—OH,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
            
            
            or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C(═O)—O—C1-4-aliphatic residue a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
            
            
            and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
            on the condition that if R9 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,
            R10 denotes H or a C1-10-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH; preferably denotes a C1-10-aliphatic residue, more preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
            
            
            or
            R9 and R10 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
            
            
        
        
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R9 and R10 together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH.
        
        
    
    


In a preferred embodiment of the compound according to general formula (I), the residue

    R1 denotes a C1-10-aliphatic residue, preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH, preferably denotes a C1-10-aliphatic residue, more preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a S(═O)2—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN and C(═O)—OH.
    
    


In a further preferred embodiment of the compound according to general formula (I), the residue

    R1 represents the partial structure (T1)






    
    
        wherein
        m denotes 0, 1, 2, 3 or 4, preferably denotes 0, 1, 2 or 3, more preferably denotes 0, 1, or 2,
        R12a and R12b each independently of one another represent H, F, Cl, Br, I, NO2, NH2, a NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4 aliphatic residue or C(═O)—OH, or together denote ═O, preferably each independently of one another represent H, F, Cl, Br, I, NH2, a NH(C1-4 aliphatic residue), a N(C1-4 aliphatic residue)2, OH, O—C1-4 aliphatic residue or a C1-4 aliphatic residue, or together denote ═O, more preferably each independently of one another represent H, F, Cl, Br, I, OH, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue, or together denote ═O,
        
            even more preferably each independently of one another represent H, F, OH, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue, or together denote ═O, and
        
        
        R12c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a S(═O)2—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH, preferably denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
            or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, preferably when m is #0,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
            
            
            or denotes—preferably when m is 0 or 2, more preferably when m is 0—an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a S(═O)2—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
        
        
    
    






    
    
        
        
            benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, preferably denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
        
        
    
    






    
    
        
        
            benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, preferably when m is ═O,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH.
            
            
        
        
    
    


Preferably,

    R1 represents the partial structure (T1),
    
        wherein
        m denotes 0, 1, 2 or 3, preferably denotes 0, 1 or 2,
        
            R12a and R12b each independently of one another represent H, F, Cl, Br, I, OH, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue, or together denote ═O,
            preferably each independently of one another represent H, F, OH, a O—C1-2 aliphatic residue or a C1-2 aliphatic residue, or together denote ═O, and
        
        
        R12c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue and C(═O)—OH, preferably denotes denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3, a C1-4-aliphatic residue and C(═O)—OH,
        
            or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3, a C1-4-aliphatic residue and C(═O)—OH,
            
            
            or denotes—preferably when m is 0 or 2, more preferably when m is 0—an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a S(═O)2—C1-4 aliphatic residue, NO2, N(C1-4 aliphatic residue)2, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5,
        
        
    
    






    
    
        
        
            a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl, preferably denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl, preferably when m is 0,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3,
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3 a C1-4-aliphatic residue and C(═O)—OH.
            
            
        
        
    
    


More preferably,

    R1 represents the partial structure (T1),
    
        wherein
        m denotes 0, 1, or 2 or 3, preferably denotes 0, 1 or 2,
        R12a and R12b each independently of one another represent H, F, Cl, Br, I, OH, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue, or together denote ═O, preferably each independently of one another represent H, F, OH, a O—C1-2 aliphatic residue or a C1-2 aliphatic residue, or together denote ═O, and
        R12c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, CF3, CN, a S(═O)2—C1-4-aliphatic residue and a C1-4-aliphatic residue, preferably denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF3 and an unsubstituted O—C1-4-aliphatic residue,
            or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF3 and an unsubstituted O—C1-4-aliphatic residue,
            
            
            or denotes—preferably when m is 0 or 2, more preferably when m is 0—an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF2H, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, CH2—OH, CH2—OCH3, S(═O)2—CH3, SCF3, NO2, N(C1-4 aliphatic residue)2,
        
        
    
    






    
    
        
        
            C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, preferably denotes—preferably when m is 0 or 2, more preferably when m is 0—an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,
            
                wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3, and
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3 a C1-4-aliphatic residue and C(═O)—OH.
            
            
        
        
    
    


In a further preferred embodiment of the compound according to general formula (I), the residue

    R1 represents the partial structure (T1),
    
        wherein
        m is 0, 1 or 2, preferably 0 or 2, more preferably 2, and
        R12a and R12b each independently of one another represent H, F, OH, a O—C1-4 aliphatic residue or a C1-4 aliphatic residue or together denote ═O; preferably H, F, OH, CH3 or OCH3 or together denote ═0;
        R12c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, an unsubstituted O—C1-4 aliphatic residue, an unsubstituted S(═O)2—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4-aliphatic residue, preferably denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4-aliphatic residue
        
            or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4-aliphatic residue,
        
        
        or
        wherein
        m is 0 or 2, more preferably 0, and
        R12a and R12b each independently of one another represent H, F, OH, a O—C1-4 aliphatic residue or a C1-4 aliphatic residue; preferably H, F, OH, CH3 or OCH3; and
        R12c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, OCF2H, CH2—OH, CH2—OCH3, S(═O)2—CH3, SCF3, NO2, N(C1-4 aliphatic residue)2,
    
    






    
    
        CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5 and phenyl, preferably denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5 and phenyl,
        
            wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3.
        
        
    
    


Preferably,

    R1 represents the partial structure (T1),
    
        wherein
        m is 0, 1 or 2, preferably 0 or 2, more preferably 2, and
        R12a and R12b each independently of one another represent H, F, OH, CH3 or OCH3 or together denote ═O, more preferably H, F, OH or CH3, even more preferably H,
        R12c denotes a C1-4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, S(═O)2—CH3, an unsubstituted O—C1-4 aliphatic residue, preferably O-methyl and O-tert.-butyl, and CF3, preferably denotes a C1-4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, preferably O-methyl and O-tert.-butyl, and CF3 
        
            or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, preferably cyclopropyl, cyclopentyl, cyclohexyl, morpholinyl, oxetanyl, or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, preferably O-methyl and O-ethyl, CF3, and an unsubstituted C1-4-aliphatic residue, preferably methyl or ethyl,
        
        
        or
        wherein
        m is 0 or 2, more preferably 0, and
        R12a and R12b each independently of one another represent H, F, OH, CH3 or OCH3; preferably H, OH or CH3, and
        R12c denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, preferably OCH3, OCF3, OCF2H, CH2—OH, CH2—OCH3, S(═O)2—CH3, SCF3, NO2, N(CH3)2,
    
    






    
    
        CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5 and phenyl, preferably denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5 and phenyl,
        
            wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3.
        
        
    
    


Particularly preferred is a compound according to general formula (I) which has the following general formula (I-d):




wherein the particular radicals and parameters have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.
In a preferred embodiment of the compound according to general formula (I), the residue

    R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a S—C1-4-aliphatic residue, a O—C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted.


Preferably,

    R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a S—C1-4-aliphatic residue, a O—C1-4-aliphatic residue,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue,
        a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C1-4-aliphatic residue and a O—C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue,
        
        
        and wherein the C3-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue.
    
    


More preferably,

    R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a S—C1-4-aliphatic residue, a O—C1-4-aliphatic residue,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue,
        cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue, and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue.
    
    


Even more preferably,

    R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; CH2—OH; CH2—O—CH3; CH2—CH2—OH; CH2—CH2—OCH3; O-methyl; O-ethyl; O—(CH2)2—O—CH3; O—(CH2)2—OH; S-Methyl; S-ethyl; cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; preferably represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; O-methyl; O-ethyl; O—(CH2)2—O—CH3; O—(CH2)2—OH; S-Methyl; S-ethyl; cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl


Still more preferably,

    R2 is selected from the group consisting of F; Cl; CF3; CN; SCF3; OCF3; CH3; C2H5; n-propyl; iso-propyl; t-butyl; CH2—OH; CH2—O—CH3; cyclopropyl; O—CH3 and O—C2H5; preferably is selected from the group consisting of F; Cl; CF3; CN; SCF3; OCF3; CH3; C2H5; n-propyl; iso-propyl; t-butyl; cyclopropyl; O—CH3 and O—C2H5;


In particular,

    R2 is selected from the group consisting of F; Cl; CF3; CH3; C2H5, iso-propyl; CH2—O—CH3; cyclopropyl; and O—CH3; preferably is selected from the group consisting of F; Cl; CF3; CH3; C2H5, iso-propyl; cyclopropyl; and O—CH3;


More particular,

    R2 is selected from the group consisting of CF3; CH3; C2H5, iso-propyl; CH2—O—CH3; and O—CH3; preferably is selected from the group consisting of CH3; C2H5, iso-propyl; CH2—O—CH3; and O—CH3;


In a particular preferred embodiment of the compound according to general formula (I), the residue

    R2 denotes CH3 or CF3, most preferably R2 denotes CH3.


In a further preferred embodiment of the compound according to general formula (I), the residue

    R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, a S—C1-4-aliphatic residue,
    
        wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue;
        a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C1-4-aliphatic residue and a O—C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue,
        
        
        and wherein the C3-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue.
    
    


Preferably,

    R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, a S—C1-4-aliphatic residue,
    
        wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue.
    
    


More preferably,

    R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; O-methyl; O-ethyl; O—(CH2)2—O—CH3; O—(CH2)2—OH; S-Methyl; or S-Ethyl.


Even more preferably

    R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; OCF3; methyl; ethyl; O-methyl; or O-ethyl, preferably represents H; F; Cl; Br; I; CF3; SCF3; OCF3; methyl; ethyl; O-methyl; or O-ethyl,


Still more preferably

    R3 represents H; F; Cl; Br; CN; CF3; SCF3; OCF3; O-methyl or methyl, preferably represents H; F; Cl; CF3; SCF3; OCF3; O-methyl or methyl.


In particular

    R3 represents H; F; Cl; Br; CN; or methyl, preferably H, F, Cl, Br or CN, more preferably H, Cl or Br, most preferably H.


In a further preferred embodiment of the compound according to general formula (I), the residue

    R4 denotes a C1-10-aliphatic residue, preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, and C(═O)—OH,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C(═O)—O—C1-4-aliphatic residue a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        on the condition that if R4 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
        or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the aryl or the heteroaryl residue may in each case be optionally bridged, preferably in each case is bridged, via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN and C(═O)—OH,
    
    
    R5 denotes H or a C1-10-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
    
    
    or
    R4 and R5 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl, pyridyl or thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with a C3-10 cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, wherein the C3-10 cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, ═O, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH.
        
        
    
    


In a further preferred embodiment of the compound according to general formula (I), the residue

    R4 represents the partial structure (T2)






    
    
        wherein
        n denotes 0, 1, 2, or 3, preferably denotes 1, 2 or 3, more preferably denotes 1 or 2, even more preferably denotes 1,
        R13a and R13b each independently of one another represent H, F, Cl, Br, I, NO2, NH2, a NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4 aliphatic residue or C(═O)—OH, or together denote ═O, preferably each independently of one another represent H, F, Cl, Br, I, NH2, a NH(C1-4 aliphatic residue), a N(C1-4 aliphatic residue)2, OH, O—C1-4 aliphatic residue or a C1-4 aliphatic residue or together denote ═O, more preferably each independently of one another represent H, F, Cl, Br, I, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue or together denote ═O,
        
            even more preferably each independently of one another represent H, F, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue or together denote ═O, and
        
        
    
    
    R13c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
    
        or denotes—preferably when n is ≠0, more preferably when n is 1—a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        or denotes—preferably when n is ≠0, more preferably when n is 1,—an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
    
    
    R5 denotes H or a C1-10-aliphatic residue, preferably a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
    
    
    or
    R4 and R5 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, or preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl 4-methylpiperazinyl, oxazepanyl, thiomorpholinyl, azepanyl,






    
    
        more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, C(═O)—OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue, a C3-6 cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cyclopentyl, and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue, preferably selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl, pyridyl or thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, and pyridyl,
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with a C3-10 cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cycclopentyl, or a 3 to 10 membered heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C3-10 cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, ═O, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, and C(═O)—OH, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH.
        
        
    
    


Preferably,

    R4 represents the partial structure (T2),
    
        wherein
        n denotes 0, 1, 2, or 3, preferably denotes 1, 2 or 3, more preferably denotes 1 or 2, even more preferably denotes 1,
        R13a and R13b each independently of one another represent H, F, Cl, Br, I, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue or together denote ═O, preferably each independently of one another represent H, F, a O—C1-2 aliphatic residue or a C1-2 aliphatic residue or together denote ═O, and
        R13c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3, a C1-4-aliphatic residue and C(═O)—OH,
        
            or denotes—preferably when n is ≠0, more preferably when n is 1—a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3, a C1-4-aliphatic residue and C(═O)—OH,
            
            
            or denotes—preferably when n is ≠0, more preferably when n is 1—an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,
            
                wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
                wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3,
                wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3 a C1-4-aliphatic residue and C(═O)—OH,
            
            
        
        
    
    
    R5 denotes H or a C1-6-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
    
    
    or
    R4 and R5 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, or preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, thiomorpholinyl, azepanyl,






    
    
        more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, C(═O)—OH, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue, and a C3-6 cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cyclopentyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, CF3 and an unsubstituted O—C1-4-aliphatic residue, preferably selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
            wherein the C3-6 cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, CF3, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, benzyl, phenyl, thienyl, and pyridyl,
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with a C3-10 cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cyclopentyl, or a 3 to 10 membered heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C3-10 cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, and C(═O)—OH, and
            wherein the C3-6 cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, CF3, a C1-4-aliphatic residue and C(═O)—OH.
        
        
    
    


More preferably,

    R4 represents the partial structure (T2),
    
        wherein
        n denotes 0, 1, 2 or 3, preferably denotes 1 or 2, more preferably denotes 1,
        R13a and R13b each independently of one another represent H, F, Cl, Br, I, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue or together denote ═O, preferably each independently of one another represent H, F, a O—C1-2 aliphatic residue or a C1-2 aliphatic residue or together denote ═O, and
        R13c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, an O—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,
        
            wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3 a C1-4-aliphatic residue and C(═O)—OH,
        
        
    
    
    R5 denotes H or an unsubstituted C1-4-aliphatic residue or a C1-4-aliphatic residue monosubstituted with O-methyl, wherein the C1-4-aliphatic residue is in each case preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl,
    or
    R4 and R5 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, thiomorpholinyl, azepanyl,






    
    
        in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, C(═O)—OH, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl,
        
            wherein the C1-4-aliphatic residue is in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, CF3 and an unsubstituted O—C1-4-aliphatic residue, preferably is in each case unsubstituted,
        
        
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, CF3, a C1-4-aliphatic residue, C(═O)—OH, and a C3-6 cycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, CF3, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R4 and R5 together with the nitrogen atom connecting them may optionally be condensed with a C3-6 cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cyclopentyl, or a 4 to 7 membered heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C3-6 cycloaliphatic residue or the 4 to 7 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an O—C1-4 aliphatic residue, OCF3, SCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5.
    
    


Even more preferably,

    R4 represents the partial structure (T2),
    
        wherein
        n denotes 0, 1, 2 or 3, preferably denotes 1 or 2, more preferably denotes 1,
        R13a and R13b each independently of one another represent H, F, a O—C1-4 aliphatic residue or a C1-4 aliphatic residue or together denote ═O; preferably each independently of one another represent H, F, CH3 or OCH3 or together denote ═O;
        R13c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, an unsubstituted O—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4-aliphatic residue,
        
            or denotes a C3-10-cycloaliphatic residue, preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or a 3 to 10 membered heterocycloaliphatic residue, preferably selected from the group consisting of pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl and tetrahydropyranyl, more preferably tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4-aliphatic residue,
            or denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5 and phenyl,
            
                wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3,
            
            
        
        
    
    
    R5 denotes H or an unsubstituted C1-4-aliphatic residue or a C1-4-aliphatic residue, which is monosubstituted with OCH3, preferably H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl or CH2—OCH3, C2H4—OCH3 or C3H6—OCH3, more preferably H, methyl or ethyl, preferably denotes H or an unsubstituted C1-4-aliphatic residue, preferably H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl, more preferably H, methyl or ethyl,
    or
    R4 and R5 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, thiomorpholinyl, azepanyl,






    
    
        tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroimidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl,
    
    






    
    
        dihydroindolinyl, or dihydroisoindolyl, preferably a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, C(═O)—OH, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl,
        
            wherein the C1-4-aliphatic residue is in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, OH, ═O, CF3 and an unsubstituted O—C1-4-aliphatic residue, preferably is in each case unsubstituted.
        
        
    
    


Still more preferably,

    R4 represents the partial structure (T2),
    
        wherein
        n denotes 0, 1, 2 or 3, preferably denotes 1 or 2, more preferably denotes 1,
        R13a and R13b each independently of one another represent H, F, CH3 or OCH3 or together denote ═O, preferably each independently of one another represent H or CH3, more preferably H,
        R13c denotes a C1-4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, an unsubstituted O—C1-4 aliphatic residue, and CF3,
        
            or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl and tetrahydropyranyl, more preferably tetrahydropyranyl or morpholinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4-aliphatic residue,
            or denotes an aryl or heteroaryl, preferably phenyl or pyridyl, more preferably phenyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, and a C1-4-aliphatic residue,
        
        
    
    
    R5 denotes H, methyl or ethyl or C2H4OCH3 or C3H6OCH3, more preferably H or methyl or ethyl, even more preferably methyl,
    or
    R4 and R5 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiomorpholinyl, azepanyl,






    
    
        tetrahydroimidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl,
    
    






    
    
        dihydroindolinyl, or dihydroisoindolyl, preferably a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, more preferably a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, more preferably a morpholinyl, oxazepanyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, C(═O)—OH, C(═O)—CH3, C(═O)—OCH3, O-methyl, O-ethyl, OCF3, SCF3, CF3, methyl, CH2CF3, CH2OH, CH2—OCH3, CH2CH2—OCH3, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl, preferably selected from the group consisting of F, Cl, OH, ═O, C(═O)—OH, O-methyl, O-ethyl, OCF3, SCF3, CF3, methyl, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl
    
    


In a preferred embodiment of the compound according to general formula (I), the residue

    R6 denotes a C2-10-aliphatic residue, preferably a C2-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, and C(═O)—OH,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,
        or
    
    
    R6 denotes S—R7, O—R8 or N(R9R10),
    
        wherein
        R7 and R8 in each case represent a C1-10-aliphatic residue, preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or in each case represent a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,
        R9 denotes a C1-10-aliphatic residue, preferably a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, and C(═O)—OH,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C(═O)—O—C1-4-aliphatic residue a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        on the condition that if R9 denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,
        R10 denotes H or a C1-10-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH, preferably denotes a C1-10-aliphatic residue, more preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or
        R9 and R10 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
        
        
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R9 and R10 together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH.
        
        
    
    


Preferably,

    R6 denotes a C2-10-aliphatic residue, preferably a C2-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, and a C1-4-aliphatic residue
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue.
        on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
    
    
    or
    R6 denotes S—R7 or O—R8 
    
        wherein
        R7 and R8 in each case represent a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or in each case denote a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a C(═O)—O—C1-4-aliphatic residue, a S—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, and a C1-4-aliphatic residue.
        on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
    
    
    or
    R6 denotes N(R9R10),
    
        wherein
        R9 denotes a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a C(═O)—O—C1-4-aliphatic residue, a S—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
        on the condition that if R9 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
        and wherein
        R10 denotes H or a C1-10-aliphatic residue, preferably a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue, preferably denotes a C1-10-aliphatic residue, more preferably a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or
        R9 and R10 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R9 and R10 together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,
    
    






    
    
        benzyl, phenyl, thienyl, and pyridyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, and C(═O)—OH, and
            wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH.
        
        
    
    


More preferably,

    R6 denotes a C2-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue
    
        wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a C(═O)—O—C1-4-aliphatic residue, a S—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, and a C1-4-aliphatic residue.
        on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
    
    
    or
    R6 denotes S—R7 or O—R8 
    
        wherein
        R7 and R8 in each case denote a C1-8-aliphatic residue, preferably a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, CF3, a C(═O)—O—C1-4-aliphatic residue, and a C1-4-aliphatic residue
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or in each case denote a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may be bridged, preferably is bridged, via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
        on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
    
    
    or
    R6 denotes N(R9R10),
    
        wherein
        R9 denotes a C1-8-aliphatic residue, preferably a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, a C(═O)—O—C1-4-aliphatic residue, and a C1-4-aliphatic residue
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case be bridged, preferably is bridged, via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
        on the condition that if R9 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, and
        R10 denotes H or a C1-6-aliphatic residue, preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue, preferably denotes a C1-6-aliphatic residue, more preferably a C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or
        R9 and R10 form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R9 and R10 together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, residue,
    
    






    
    
        benzyl, phenyl, thienyl, and pyridyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, and C(═O)—OH.
        
        
    
    


Even more preferably,

    R6 denotes a C2-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue
    
        wherein the C1-4-aliphatic residue in each case is unsubstituted,
        or denotes a C3-10-cycloaliphatic residue, preferably a C3-6-cycloaliphatic residue, or a 3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted O—C1-4-aliphatic residue.
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted C1-4 aliphatic group,
    
    


on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

    or
    R6 denotes S—R7 or O—R8 
    
        wherein
        R7 and R8 in each case denote a C1-8-aliphatic residue, preferably a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or in each case denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged, preferably is brisdged, via an unsubstituted C1-8 aliphatic group, preferably an unsubstituted C1-4 aliphatic group,
        on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
    
    
    or
    R6 denotes N(R9R10),
    
        wherein
        R9 denotes a C1-8-aliphatic residue, preferably a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
        
        
        wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted C1-8 aliphatic group, preferably an unsubstituted C1-4 aliphatic group,
        on the condition that if R9 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, and
        R10 denotes H or an unsubstituted C1-4-aliphatic residue, preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl, preferably denotes an unsubstituted C1-4-aliphatic residue, preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl
        or
        R9 and R10 form together with the nitrogen atom connecting them a 3 to 6 membered heterocycloaliphatic residue, preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, and azetidinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,
        
        
        and wherein the 3 to 6 membered heterocycloaliphatic residue formed by R9 and R10 together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, residue, benzyl, phenyl, and pyridyl,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, and an unsubstituted O—C1-4-aliphatic residue, and
            wherein benzyl, phenyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OCH3, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, CF3, and a C1-4-aliphatic residue.
        
        
    
    


Still more preferably,

    R6 denotes a C2-6-aliphatic residue, preferably selected from the group consisting of ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and an O—C1-4-aliphatic residue, preferably O-methyl, even more preferably in each case unsubstituted,
    
        wherein the C1-4-aliphatic residue in each case is unsubstituted,
        or denotes a C3-6-cycloaliphatic residue, preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or a 3 to 6 membered heterocycloaliphatic residue, preferably selected from the group consisting of piperidinyl (preferably piperidin-4-yl or piperidin-3-yl), tetrahydrofuranyl, and tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and an O—C1-4-aliphatic residue, preferably O-methyl, even more preferably in each case unsubstituted,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
        and wherein the C3-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case optionally bridged via an unsubstituted C1-4 aliphatic group, preferably via an unsubstituted Cl2 aliphatic group,
        on the condition that if R6 a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom,
    
    
    or
    R6 denotes S—R7 or O—R8 
    
        wherein
        R7 and R8 in each case denote a C1-6-aliphatic residue, preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, CF3, and a C1-4-aliphatic residue, more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, and an O—C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
        or denotes a C3-6-cycloaliphatic residue, preferably cyclopropyl, or a 3 to 6 membered heterocycloaliphatic residue, preferably oxetanyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted O—C1-4-aliphatic residue,
        
        
        and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged, preferably is bridged, via an unsubstituted C1-4 aliphatic group,
        on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
    
    
    or
    R6 denotes N(R9R10),
    
        wherein
        R9 denotes a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, preferably an unsubstituted C1-6-aliphatic residue, more preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
        or denotes a C3-6-cycloaliphatic residue, preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or a 3 to 6 membered heterocycloaliphatic residue, preferably selected from the group consisting of piperidinyl (preferably piperidin-4-yl or piperidin-3-yl), tetrahydrofuranyl, and tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, a C1-4-aliphatic residue and an O—C1-4-aliphatic residue, even more preferably in each case unsubstituted,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
        and wherein the C3-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case optionally bridged via an unsubstituted C1-4 aliphatic group,
        on the condition that if R9 denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
        R10 denotes H or an unsubstituted C1-4-aliphatic residue, preferably represents an unsubstituted C1-4-aliphatic residue, or denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl, preferably denotes methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl,
        or
        R9 and R10 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, and a C1-4-aliphatic residue wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted O—C1-4-aliphatic residue.
    
    


Most preferred,

    R6 denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl or propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and an O—C1-4-aliphatic residue, preferably O-methyl, more preferably in each case unsubstituted,
    
        wherein the C1-4-aliphatic residue in each case is unsubstituted,
        or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, preferably denotes cyclopropyl or tetrahydropyranyl, more preferably cyclopropyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and an O—C1-4-aliphatic residue, preferably O-methyl, more preferably in each case unsubstituted,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
        and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl may in each case be optionally bridged via an unsubstituted C1-4 aliphatic group, preferably via an unsubstituted C1-2 aliphatic group,
        on the condition that if R6 denotes piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl is linked via a carbon atom,
    
    
    or
    R6 denotes S—R7 or O—R8 
    
        wherein
        R7 and R8 in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, N(C1-4 aliphatic residue)2 and an O—C1-4-aliphatic residue,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
        or in each case denote cyclopropyl, cyclobutyl, cyclopentyl cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, preferably cyclopropyl or oxetanyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and an O—C1-4-aliphatic residue, more preferably in each case unsubstituted,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
        and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl may in each case be optionally bridged via an unsubstituted C1-4 aliphatic group,
        on the condition that if R7 or R8 denotes piperidinyl, oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl, each of these residues is linked via a carbon atom,
    
    
    or
    R6 denotes N(R9R10),
    
        wherein
        R9 denotes a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, ═O, OH, and O-methyl, preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O-methyl, more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F and O-methyl, preferably denotes an unsubstituted C1-6-aliphatic residue, more preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl,
        R10 denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl, more preferably methyl or ethyl,
        or
        R9 and R10 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, and a C1-4-aliphatic residue, more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl and a O—C1-4 aliphatic residue, preferably form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted.
    
    


In particular,

    R6 denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH2—CH(CH3)(C2H5), C(CH3)2(C2H5), ethenyl or propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), CH2—OCH3, C2H4—OCH3, C3H6—OCH3, cyclopropyl, cyclobutyl, or tetrahydropyranyl, in each case unsubstituted,
    or
    R6 denotes S—R7 or O—R8 
    
        wherein R7 and R8 in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, a N(C1-4 aliphatic residue)2, and an O—C1-4-aliphatic residue, preferably with at least one substituent selected from the group consisting of F, OH, N(CH3)2, O-methyl and O-ethyl, or in each case denote CH2-cyclopropyl or oxetanyl, preferably, R7 and R8 in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, CH2—CH2—F, CH2CHF2, CH2-OCH3, CH2CH2—OCH3, CH2CH2—N(CH3)2, CH2-cyclopropyl or oxetanyl,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
    
    
    or
    R6 denotes N(R9R10),
    
        wherein
        R9 denotes methyl, ethyl, C(═O)—CH3, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl,
        R10 denotes H, methyl or ethyl, preferably methyl or ethyl,
        or
        R9 and R10 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted.
    
    


Particularly preferred is a compound according to general formula (I), wherein

    R1 represents the partial structure (T1),






    
    
        wherein
        m is 0, 1 or 2, preferably 0 or 2, more preferably 2, and
        R12a and R12b each independently of one another represent H, F, OH, CH3 or OCH3 or together denote ═O, more preferably H, F, OH or CH3, even more preferably H,
        R12c denotes a C1-4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, S(═O)2—CH3, an unsubstituted O—C1-4 aliphatic residue, preferably O-methyl and O-tert.-butyl, and CF3, preferably denotes a C1-4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, preferably O-methyl and O-tert.-butyl, and CF3,
        
            or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, preferably cyclopropyl, cyclopentyl, cyclohexyl, morpholinyl, oxetanyl or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, preferably O-methyl and O-ethyl, CF3, and an unsubstituted C1-4-aliphatic residue, preferably methyl or ethyl,
        
        
        or
        wherein
        m is 0 or 2, more preferably 0, and
        R12a and R12b each independently of one another represent H, F, CH3 or OCH3; and
        R12c denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, OCF2H, CH2—OH, CH2—OCH3, S(═O)2—CH3, SCF3, NO2, N(CH3)2,
    
    






    
    
        CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5 and phenyl, preferably denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3, C(═O)—O—C2H5 and phenyl,
        
            wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3,
        
        
    
    
    R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; CH2—OH; CH2—O—CH3; CH2—CH2—OH; CH2—CH2—OCH3; O-methyl; O-ethyl; O—(CH2)2—O—CH3; O—(CH2)2—OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; preferably represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; CH2—OH; O-methyl; O-ethyl; O—(CH2)2—O—CH3; O—(CH2)2—OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl,
    R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; O-methyl; O-ethyl; O—(CH2)2—O—CH3; O—(CH2)2—OH; S-Methyl; or S-Ethyl,
    R4 represents the partial structure (T2)






    
    
        wherein
        n denotes 0, 1, 2 or 3, preferably denotes 1 or 2, more preferably denotes 1,
        R13a and R13b each independently of one another represent H, F, CH3 or OCH3, or together denote ═O, preferably each independently of one another represent H or CH3, more preferably H,
        R13c denotes a C1-4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, an unsubstituted O—C1-4 aliphatic residue, and CF3,
        
            or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl and tetrahydropyranyl, more preferably tetrahydropyranyl or morpholinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4-aliphatic residue,
            or denotes an aryl or heteroaryl, preferably phenyl or pyridyl, more preferably phenyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, and a C1-4-aliphatic residue,
        
        
    
    
    R5 denotes H, methyl or ethyl, C2H4OCH3 or C3H6OCH3, more preferably H or methyl, even more preferably methyl,
    or
    R4 and R5 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, preferably a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiomorpholinyl, azepanyl,






    
    
        tetrahydroimidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl,
    
    






    
    
        dihydroindolinyl, or dihydroisoindolyl, preferably a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, more preferably a morpholinyl, oxazepanyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, C(═O)—OH, O-methyl, O-ethyl, OCF3, SCF3, CF3, C(═O)—CH3, C(═O)—OCH3, CH2CF3, CH2OH, CH2—OCH3, CH2CH2—OCH3, methyl, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl, preferably selected from the group consisting of F, Cl, OH, ═O, C(═O)—OH, O-methyl, O-ethyl, OCF3, SCF3, CF3, methyl, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl,
    
    
    R6 denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH2—CH(CH3)(C2H5), C(CH3)2(C2H5), ethenyl or propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), CH2—OCH3, C2H4—OCH3, C3H6—OCH3, cyclopropyl, cyclobutyl, or tetrahydropyranyl, in each case unsubstituted,
    or
    R6 denotes S—R7 or O—R8 
    
        wherein R7 and R8 in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, a N(C1-4 aliphatic residue)2, and an O—C1-4-aliphatic residue, preferably with at least one substituent selected from the group consisting of F, OH, N(CH3)2, O-methyl and O-ethyl, or in each case denote CH2-cyclopropyl or oxetanyl, preferably, R7 and R8 in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, CH2—CH2—F, CH2CHF2, CH2-OCH3, CH2CH2—OCH3, CH2CH2—N(CH3)2, CH2-cyclopropyl or oxetanyl,
        
            wherein the C1-4-aliphatic residue in each case is unsubstituted,
        
        
    
    
    or
    R6 denotes N(R9R10),
    
        wherein
        R9 denotes methyl, C(═O)—CH3, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl,
        R10 denotes H, methyl or ethyl, preferably methyl or ethyl,
        or
        R9 and R10 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted.
    
    


In another particularly preferred embodiment of the compound according to general formula (I),

    R1 represents phenyl or pyridyl, preferably phenyl, in each case unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, OH, OCH3, OCF3, CF3, and CH3,
    R2 represents H; CF3; methyl; ethyl; iso-propyl; O-methyl; or cyclopropyl,
    R3 represents H; F; Cl; Br; I; CN; CF3; methyl; or O-methyl;
    R4 and R5 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted;
    R6 denotes ethyl, n-propyl, 2-propyl(iso-propyl), tert.-butyl, cyclopropyl, cyclobutyl or cyclopentyl or tetrahydropyranyl,
    or
    R6 denotes S—R7 or O—R8 
    
        wherein R7 and R8 in each case denote methyl, ethyl, 2-propyl, or tert.-butyl.
    
    
    or
    R6 denotes N(R9R10),
    
        wherein
        R9 denotes methyl, ethyl, n-propyl, 2-propyl, or tert.-butyl,
        R10 denotes H, methyl or ethyl, preferably methyl or ethyl,
        or
        R9 and R10 form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl.
    
    


Especially particularly preferred are compounds according to general formula (I) selected from the group comprising:

    1 N-[(3,5-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    2 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    3 N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    4 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    5 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(tetrahydro-pyran-2-yl-methyl)-amino]-pyridine-3-carboxylic acid amide;
    6 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-methoxy-azetidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide;
    7 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-hydroxy-azetidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide;
    8 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophenyl)-methylamino]-4-methyl-pyridine-3-carboxylic acid amide;
    9 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-[(E)-prop-1-enyl]-pyridine-3-carboxylic acid amide;
    10 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
    11 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylic acid amide;
    12 N-[(3-Fluorophenyl)-methyl]-4-methyl-2,6-dimorpholin-4-yl-pyridine-3-carboxylic acid amide;
    13 1-[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-carbamoyl]-4-methyl-pyridin-2-yl]-piperidine-4-carboxylic acid methyl ester;
    14 1-[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-carbamoyl]-4-methyl-pyridin-2-yl]-piperidine-4-carboxylic acid;
    15 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(4-hydroxy-piperidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide;
    16 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(4-oxo-piperidin-1-yl)-pyridine-3-carboxylic acid amide;
    17 2-Ethylsulfanyl-N-[(4-fluoro-2-methoxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    18 2-Ethylsulfanyl-N-[(4-fluoro-2-hydroxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    19 N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    20 2-Ethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    21 N-[(3-Fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    22 2-Ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    23 N-[(3-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    24 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-pyrrolidin-1-yl-pyridine-3-carboxylic acid amide;
    25 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-pyrrolidin-1-yl-pyridine-3-carboxylic acid amide;
    26 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(1,2,3,4-tetrahydro-isoquinolin-2-yl)-pyridine-3-carboxylic acid amide;
    27 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[6-(trifluoromethyl)-1,2,3,4-tetrahydro-isoquinolin-2-yl]-pyridine-3-carboxylic acid amide;
    28 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-[(E)-prop-1-enyl]-pyridine-3-carboxylic acid amide;
    29 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide
    30 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-methoxy-pyrrolidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide;
    31 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(4-methyl-piperazin-1-yl)-pyridine-3-carboxylic acid amide;
    32 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-piperidin-1-yl-pyridine-3-carboxylic acid amide;
    33 6-Dimethylamino-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    34 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-methylamino-pyridine-3-carboxylic acid amide;
    35 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(2-methoxy-ethyl-methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide;
    36 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(2-methoxy-ethylamino)-4-methyl-pyridine-3-carboxylic acid amide;
    37 N-[(3-Fluorophenyl)-methyl]-2-(isopropylsulfanyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    38 2-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    39 N-[(4-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    40 N-[(3-Fluorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    41 N-[(3,4-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    42 2-Ethylsulfanyl-4-methyl-N-(3-methyl-butyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    43 N-(Cyclopentyl-methyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    44 N-(2-Cyclopentyl-ethyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    45 2-Ethylsulfanyl-N-[(6-fluoro-pyridin-2-yl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    46 2-Ethylsulfanyl-N-[(5-fluoro-pyridin-2-yl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    47 N-(2,2-Dimethyl-propyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    48 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(2-methyl-morpholin-4-yl)-pyridine-3-carboxylic acid amide;
    49 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(4-methoxy-piperidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide;
    50 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)-methyl]-pyridine-3-carboxylic acid amide;
    51 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[2-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    52 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophenyl)-methyl-methyl-amino]-4-methyl-pyridine-3-carboxylic acid amide;
    53 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(3-phenyl-propyl)-pyridine-3-carboxylic acid amide;
    54 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-phenethyl-pyridine-3-carboxylic acid amide;
    55 N-Benzyl-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
    56 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-(propylsulfanyl)-pyridine-3-carboxylic acid amide;
    57 2-(Butylsulfanyl)-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    58 2-Ethylsulfanyl-5-fluoro-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    59 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[3-(trifluoromethyl)phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    60 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    61 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(tetrahydro-pyran-4-yl-methyl)-amino]-pyridine-3-carboxylic acid amide;
    62 N-[(3-Fluorophenyl)-methyl]-4-methyl-2-(2-methyl-propylsulfanyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    63 N-[(3-Fluorophenyl)-methyl]-2-(2-methoxy-ethylsulfanyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    64 2-Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    65 2-Dimethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    66 6-(2,6-Dimethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    67 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    68 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(2-tetrahydro-pyran-2-yl-ethyl)-pyridine-3-carboxylic acid amide;
    69 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(tetrahydro-pyran-2-yl-methyl)-pyridine-3-carboxylic acid amide;
    70 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(4-methyl-piperidin-1-yl)-pyridine-3-carboxylic acid amide;
    71 2-Ethylsulfanyl-N-[[2-(4-fluorophenyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    72 2-[[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-carbamoyl]-4-methyl-pyridin-2-yl]-methyl-amino]-acetic acid ethyl ester;
    73 6-(4-Cyclopropyl-piperazin-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    74 6-(4,4-Dimethyl-piperidin-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    75 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethylsulfanyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    76 N-(Cyclohexyl-methyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    77 2-Ethylsulfanyl-N-(2-methoxy-ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    78 2-Ethylsulfanyl-N-(3-methoxy-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    79 2-Ethylsulfanyl-4-methyl-N-(4-methyl-pentyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    80 N-Butyl-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    81 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-pentyl-pyridine-3-carboxylic acid amide;
    82 2-Ethylsulfanyl-N-[[4-fluoro-3-(trifluoromethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    83 N-(2-tert-Butoxy-ethyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    84 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    85 2-Ethylsulfanyl-N-[[4-fluoro-2-(4-fluorophenyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    86 N-(4,4-Dimethyl-pentyl)-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    87 N-[(3,4-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    88 2-Methoxy-4-methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)-methyl]-pyridine-3-carboxylic acid amide;
    89 N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    90 N-[(3,5-Difluoro-phenyl)-methyl]-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    91 N-[(3,4-Difluoro-phenyl)-methyl]-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    92 2-Ethoxy-4-methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)-methyl]-pyridine-3-carboxylic acid amide;
    93 2-Ethylsulfanyl-N-[[3-fluoro-5-(trifluoromethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    94 2-Ethylsulfanyl-N-[[2-fluoro-3-(trifluoromethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    95 2-Ethylsulfanyl-N-[[2-fluoro-5-(trifluoromethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    96 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-([1,4]oxazepan-4-yl)-pyridine-3-carboxylic acid amide;
    97 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyloxy)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    98 N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-([1,4]oxazepan-4-yl)-pyridine-3-carboxylic acid amide;
    99 2-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6-([1,4]oxazepan-4-yl)-pyridine-3-carboxylic acid amide;
    100 N-[(2,3-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    101 N-[(2,5-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    102 N-[(3-Cyano-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    103 2-Ethylsulfanyl-N-(2-isopropoxy-ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    104 N-(3,3-Dimethyl-butyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    105 N-(3-Cyclopentyl-propyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    106 N-(2-Cyclohexyl-ethyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    107 N-[(2,4-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    108 2-Ethylsulfanyl-N-[3-(4-fluorophenyl)-propyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    109 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(3-pyridin-2-yl-propyl)-pyridine-3-carboxylic acid amide;
    110 2-Butoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    111 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propoxy-pyridine-3-carboxylic acid amide;
    112 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxo-azetidin-1-yl)-pyridine-3-carboxylic acid amide;
    113 2-Ethylsulfanyl-N-[3-(3-fluorophenyl)-propyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    114 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(3-pyridin-3-yl-propyl)-pyridine-3-carboxylic acid amide;
    115 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(3-pyridin-4-yl-propyl)-pyridine-3-carboxylic acid amide;
    116 N-(5,5-Dimethyl-hexyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    117 2-Methoxy-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    118 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(pyridin-4-yl-methyl)-amino]-pyridine-3-carboxylic acid amide;
    119 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(pyridin-3-yl-methyl)-amino]-pyridine-3-carboxylic acid amide;
    120 2-Ethylsulfanyl-6-[(4-fluoro-benzoyl)-methyl-amino]-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    121 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(pyridin-2-yl-methyl)-amino]-pyridine-3-carboxylic acid amide;
    122 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(pyridin-3-yl-methylamino)-pyridine-3-carboxylic acid amide;
    123 6-(Acetyl-methyl-amino)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    124 N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    125 N-[(3-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    126 6-[Bis(2-methoxy-ethyl)-amino]-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    127 2-(Ethyl-methyl-amino)-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    128 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-methoxy-propyl-methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide;
    129 2-Ethylsulfanyl-N-[3-(2-fluorophenyl)-propyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    130 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[3-(trifluoromethyloxy)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    131 2-Ethylsulfanyl-N-[[3-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    132 2-Ethoxy-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    133 2-Ethoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    134 N-(1,3-Benzodioxol-5-yl-methyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    135 2-Ethylsulfanyl-N-[[2-fluoro-4-(trifluoromethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    136 6-(Azepan-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    137 2-Ethylsulfanyl-N-[(4-methoxyphenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    138 (2S)-2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(2-methyl-morpholin-4-yl)-pyridine-3-carboxylic acid amide;
    139 (2R)-2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(2-methyl-morpholin-4-yl)-pyridine-3-carboxylic acid amide;
    140 2-Methoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    141 N-(3-Cyclopropyl-propyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    142 2-Ethylsulfanyl-N-[[3-fluoro-4-(trifluoromethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    143 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxo-piperazin-1-yl)-pyridine-3-carboxylic acid amide;
    144 6-(4-Acetyl-piperazin-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    145 N-[(4-Cyano-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    146 2-Ethylsulfanyl-N-[[4-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    147 2-Ethylsulfanyl-N-[[3-fluoro-4-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    148 N-[(4-Dimethylaminophenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    149 2-Ethylsulfanyl-N-[[4-fluoro-3-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    150 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(4-methyl-3-oxo-piperazin-1-yl)-pyridine-3-carboxylic acid amide;
    151 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(6-oxa-2-azaspiro[3.3]heptan-2-yl)-pyridine-3-carboxylic acid amide;
    152 N-(4,4-Dimethyl-pentyl)-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    153 4-Methyl-2-methylsulfanyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    154 N-[(4-Fluorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    155 N-[(3,4-Difluoro-phenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    156 N-[(3,5-Difluoro-phenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    157 4-Methyl-2-methylsulfanyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    158 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(6-oxo-2,3,4,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl)-pyridine-3-carboxylic acid amide;
    159 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxa-6-azabicyclo[2.2.1]heptan-6-yl)-pyridine-3-carboxylic acid amide;
    160 N-(3-Cyano-propyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    161 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(p-tolyl-methyl)-pyridine-3-carboxylic acid amide;
    162 2-Ethylsulfanyl-4-methyl-N-(3-methylsulfonyl-propyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    163 N-(4-Cyano-butyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    164 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(m-tolyl-methyl)-pyridine-3-carboxylic acid amide;
    165 N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    166 N-[(4-Chlorophenyl)-methyl]-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    167 6-(2-Ethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    168 N-[(4-Chlorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    169 N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    170 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-pyridin-2-yl-amino)-pyridine-3-carboxylic acid amide;
    171 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-pyridin-3-yl-amino)-pyridine-3-carboxylic acid amide;
    172 2-Dimethylamino-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    173 2-(Ethyl-methyl-amino)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    174 2-(Ethyl-methyl-amino)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    175 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(tetrahydro-pyran-3-yl-methyl)-amino]-pyridine-3-carboxylic acid amide;
    176 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-methylsulfanyl-pyridine-3-carboxylic acid amide;
    177 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    178 6-(3-Ethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    179 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3R)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    180 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    181 N-[(4-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    182 2-Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    183 2-Dimethylamino-N-(4,4-dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    184 N-(4,4-Dimethyl-pentyl)-2-(ethyl-methyl-amino)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    185 N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    186 N-(4,4-Dimethyl-pentyl)-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    187 N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    188 2-(Ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    189 N-(4,4-Dimethyl-pentyl)-2-(ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    190 2-(Ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    191 N-[(4-Chlorophenyl)-methyl]-2-(ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    192 N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-methylsulfanyl-pyridine-3-carboxylic acid amide;
    193 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    194 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-(1-methyl-propyl)-pyridine-3-carboxylic acid amide;
    195 N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-(1-methyl-propyl)-pyridine-3-carboxylic acid amide;
    196 2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    197 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide;
    198 2-Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    199 N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide;
    200 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-pyridin-4-yl-amino)-pyridine-3-carboxylic acid amide;
    201 2-Ethylsulfanyl-N-[(4-fluoro-3-methyl-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    202 2-Ethylsulfanyl-N-(2-hydroxy-3-phenyl-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    203 N-[(3,4-Difluoro-phenyl)-methyl]-2-(ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    204 N-[(3,5-Difluoro-phenyl)-methyl]-2-(ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    205 2-Dimethylamino-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    206 N-[(3,4-Difluoro-phenyl)-methyl]-2-dimethylamino-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    207 N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    208 N-[(3,5-Dimethyl-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    209 2-Ethylsulfanyl-N-heptyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    210 6-Dimethylamino-N-(4,4-dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-pyridine-3-carboxylic acid amide;
    211 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-6-(2-methoxy-ethyl-methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide;
    212 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-6-(3-methoxy-propyl-methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide;
    213 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-propyl-morpholin-4-yl)-pyridine-3-carboxylic acid amide;
    214 N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    215 N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    216 N-[(3-Fluorophenyl)-methyl]-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    217 2-Ethylsulfanyl-N-hexyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    218 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-(methyl-tetrahydro-furan-3-yl-amino)-pyridine-3-carboxylic acid amide;
    219 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-(2-methyl-morpholin-4-yl)-pyridine-3-carboxylic acid amide;
    220 2-tert-Butyl-N-(4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    221 N-(4,4-Dimethyl-pentyl)-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    222 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(2-oxa-6-azaspiro[3.4]octan-6-yl)-pyridine-3-carboxylic acid amide;
    223 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(2R)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    224 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    225 N-[(3,4-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    226 N-[(3,4-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    227 2-Ethylsulfanyl-N-(3-hydroxy-3-phenyl-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    228 2-Ethylsulfanyl-N-(2-hydroxy-4-methyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    229 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[2-(2-methoxy-ethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    230 2-Ethylsulfanyl-N-(5-hydroxy-4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    231 2-Ethylsulfanyl-4-methyl-N-[(3-methylsulfonyl-phenyl)-methyl]-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    232 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,6]naphthyridin-6-yl]-pyridine-3-carboxylic acid amide;
    233 N-[(3,5-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    234 N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    235 2-Ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    236 2-Methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    237 2-Ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    238 2-Methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    239 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[3-(methoxymethyl)-azetidin-1-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    240 6-(2,5-Dimethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    241 2-Dimethylamino-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    242 N-[(3,5-Difluoro-phenyl)-methyl]-2-dimethylamino-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    243 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[2-(trifluoromethyl)-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-7-yl]-pyridine-3-carboxylic acid amide;
    244 N-[(4-Chlorophenyl)-methyl]-2-dimethylamino-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    245 2-Dimethylamino-N-(4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    246 2-Dimethylamino-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    247 2-Ethylsulfanyl-4-methyl-N-[(4-methylsulfonyl-phenyl)-methyl]-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    248 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-6-[(3R)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    249 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-6-[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    250 2-tert-Butyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    251 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl]-pyridine-3-carboxylic acid amide;
    252 6-(2,2-Dimethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    253 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(2-oxo-propyl)-amino]-pyridine-3-carboxylic acid amide;
    254 N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-[(2R)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    255 N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    256 N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-[(3R)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    257 N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    258 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-tetrahydro-pyran-4-yl-amino)-pyridine-3-carboxylic acid amide;
    259 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-methoxy-cyclohexyl)-methyl-amino]-4-methyl-pyridine-3-carboxylic acid amide;
    260 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[2-(trifluoromethyl)-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    261 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-tetrahydro-pyran-3-yl-amino)-pyridine-3-carboxylic acid amide;
    262 6-(3,5-Dimethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    263 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3S)-3-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    264 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3R)-3-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    265 N-[(4-Chlorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    266 N-[(4-Chlorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide;
    267 2-Ethylsulfanyl-N-(3-hydroxy-4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    268 N-[(4-Cyano-3-fluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    269 N-[(4-Chlorophenyl)-methyl]-2-(2-fluoro-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    270 N-[(4-Chlorophenyl)-methyl]-2-(2,2-difluoro-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    271 N-[(4-Chlorophenyl)-methyl]-2-(cyclopropyl-methoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    272 2-(2,2-Difluoro-ethoxy)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    273 N-[(4-Chlorophenyl)-methyl]-2-ethoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    274 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-[(2S)-2-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    275 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-[(2R)-2-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    276 2-(Cyclopropyl-methoxy)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    277 N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    278 N-(4,4-Dimethyl-pentyl)-4-methyl-2-(2-methyl-butyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    279 N-(4,4-Dimethyl-pentyl)-2-(1,1-dimethyl-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    280 N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-(methyl-tetrahydro-pyran-3-yl-amino)-pyridine-3-carboxylic acid amide;
    281 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[(4-nitrophenyl)-methyl]-pyridine-3-carboxylic acid amide;
    282 N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    283 N-[(4-Chlorophenyl)-methyl]-2-(2-dimethylaminoethyloxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    284 2-Ethylsulfanyl-N-[(4-fluoro-3-methoxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    285 N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    286 2-Ethylsulfanyl-N-(3-hydroxy-4-methyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    287 2-Ethylsulfanyl-N-[(3-fluoro-4-methoxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    288 N-[[4-(Difluoro-methoxy)-phenyl]-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    289 N-(1,3-Dihydro-isobenzofuran-5-yl-methyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    290 N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    291 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(2S)-2-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    292 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(2R)-2-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    293 6-(Benzyl-methyl-amino)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    294 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(tetrahydro-furan-2-yl-methyl)-amino]-pyridine-3-carboxylic acid amide;
    295 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    296 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[(3S)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    297 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-[[4-(trifluoromethyl)-phenyl]-methyl]-amino]-pyridine-3-carboxylic acid amide;
    298 6-(1,1-Dioxo-[1,4]thiazinan-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    299 6-(Azetidin-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    301 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-tetrahydro-furan-3-yl-amino)-pyridine-3-carboxylic acid amide;
    302 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(N-methyl-anilino)-pyridine-3-carboxylic acid amide;
    303 6-(2,3-Dihydro-1H-isoindol-2-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    304 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(1,2,3,4-tetrahydro-quinolin-1-yl)-pyridine-3-carboxylic acid amide;
    305 6-(2,3-Dihydro-1H-indol-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide;
    306 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(2,4,4-trimethyl-pentyl)-pyridine-3-carboxylic acid amide;
    307 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3-methoxy-cyclohexyl)-methyl-amino]-4-methyl-pyridine-3-carboxylic acid amide;
    308 N-(4,4-Difluoro-pentyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    309 N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    310 N-[(3,4-Difluoro-phenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    311 2-Isopropyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    312 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxo-morpholin-4-yl)-pyridine-3-carboxylic acid amide;
    313 N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
    314 N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    315 2-Isopropyl-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    316 N-[(3,5-Difluoro-phenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    317 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-(oxetan-3-yloxy)-pyridine-3-carboxylic acid amide;
    318 2-Ethylsulfanyl-N-(4-methoxy-4-methyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    319 2-Ethylsulfanyl-N-(4-fluoro-4-methyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    320 4-Methyl-6-morpholin-4-yl-2-propyl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    321 N-[(3,4-Difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
    322 N-[(3,5-Difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
    323 4-Methyl-6-morpholin-4-yl-2-propyl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    324 N-(4,4-Dimethyl-2-oxo-pentyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    325 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-pyridine-3-carboxylic acid amide;
    326 N-[(4-Chlorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
    327 N-[(4-Chlorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    328 2-Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    329 2-Cyclopropyl-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
    330 2-Cyclopropyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    331 2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    332 2-Cyclopropyl-N-[(3,4-difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    333 2-Cyclopropyl-N-[(3,5-difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    334 2-Cyclopropyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
    335 N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    336 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methoxy-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    337 N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethylsulfanyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    338 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophenyl)-methyl-(3-methoxy-propyl)-amino]-4-methyl-pyridine-3-carboxylic acid amide;
    339 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(3,4,4-trimethyl-pentyl)-pyridine-3-carboxylic acid amide;
    340 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[3-(2-methoxy-ethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
    341 2-(Acetyl-methyl-amino)-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    342 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophenyl)-methyl-(2-methoxy-ethyl)-amino]-4-methyl-pyridine-3-carboxylic acid amide;
    343 2-Ethylsulfanyl-4-methyl-N-[3-(3-methyl-oxetan-3-yl)-propyl]-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    344 N-(4,4-Dimethyl-pent-2-ynyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    345 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-pyridine-3-carboxylic acid amide;
    346 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-(methoxymethyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    347 N-[(4-Chlorophenyl)-methyl]-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    348 N-(4,4-Dimethyl-hexyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    349 N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    350 2-Ethylsulfanyl-4-methyl-N-[3-(1-methyl-cyclopropyl)-propyl]-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    351 2-Cyclopropyl-N-[[4-fluoro-3-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    352 2-Ethylsulfanyl-N-[[4-fluoro-3-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
    353 2-Ethylsulfanyl-N-[[4-fluoro-3-(hydroxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    354 N-(4,4-Dimethyl-pentyl)-2-(3-methoxy-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    355 2-Cyclopropyl-N-[[3-fluoro-4-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    356 N-[(3-Fluorophenyl)-methyl]-2-(methoxymethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    357 N-[(4-Chlorophenyl)-methyl]-2,4-diisopropyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    358 N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    359 N-[(4-Chlorophenyl)-methyl]-2,4-diethyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
    362 N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-2-tetrahydro-pyran-4-yl-pyridine-3-carboxylic acid amide,

respectively in the form of the free compounds; the racemate; the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio or of an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases; or in the form of solvates, in particular hydrates.



The substituted compounds according to the invention of the aforementioned general formula (I) and corresponding stereoisomers and also the respective corresponding salts and solvates are toxicologically safe and are therefore suitable as pharmaceutical active ingredients in pharmaceutical compositions.
The present invention therefore further relates to a pharmaceutical composition containing at least one compound according to general formula (I), in each case if appropriate in the form of one of its pure stereoisomers, in particular enantiomers or diastereomers, its racemates or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or respectively in the form of a physiologically acceptable salt, or respectively in the form of a corresponding solvate, and also if appropriate one or more pharmaceutically acceptable auxiliaries.
These pharmaceutical compositions according to the invention are suitable in particular for the modulation of KCNQ2/3 K+ channels, preferably for KCNQ2/3 K+ channel inhibition and/or KCNQ2/3 K+ channel stimulation, i.e. they exert an agonistic or antagonistic effect.
Likewise, the pharmaceutical compositions according to the invention are preferably suitable for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K+ channels.
The pharmaceutical composition according to the invention is suitable for administration to adults and children, including toddlers and babies.
The pharmaceutical composition according to the invention may be prepared as a liquid, semisolid or solid pharmaceutical form, for example in the form of injection solutions, drops, juices, syrups, sprays, suspensions, tablets, patches, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions, aerosols or in multiparticulate form, for example in the form of pellets or granules, if appropriate pressed into tablets, decanted in capsules or suspended in a liquid, and also be administered as much.
In addition to at least one substituted compound of general formula (I), if appropriate in the form of one of its pure stereoisomers, in particular enantiomers or diastereomers, its racemate or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio, or if appropriate in the form of a corresponding salt or respectively in the form of a corresponding solvate, the pharmaceutical composition according to the invention conventionally may contain further physiologically acceptable pharmaceutical auxiliaries which, for example, can be selected from the group consisting of excipients, fillers, solvents, diluents, surface-active substances, dyes, preservatives, blasting agents, slip additives, lubricants, aromas and binders.
The selection of the physiologically acceptable auxiliaries and also the amounts thereof to be used depend on whether the pharmaceutical composition is to be applied orally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to infections of the skin, the mucous membranes and of the eyes. Preparations in the form of tablets, dragées, capsules, granules, pellets, drops, juices and syrups are preferably suitable for oral application; solutions, suspensions, easily reconstitutable dry preparations and also sprays are preferably suitable for parenteral, topical and inhalative application. The substituted compounds according to the invention used in the pharmaceutical composition according to the invention in a repository, in a dissolved form or in a plaster, and further agents promoting skin penetration being added if appropriate, are suitable percutaneous application preparations. Orally or percutaneously applicable preparation forms can release the respective substituted compound according to the invention also in a delayed manner.
The pharmaceutical compositions according to the invention can be prepared with the aid of conventional means, devices, methods and process known in the art, such as are described for example in “Remington's Pharmaceutical Sciences”, A. R. Gennaro (Editor), 17th edition, Mack Publishing Company, Easton, Pa., 1985, in particular in Part 8, Chapters 76 to 93. The corresponding description is introduced herewith by way of reference and forms part of the disclosure. The amount to be administered to the patient of the respective substituted compounds according to the invention of the above-indicated general formula (I) may vary and is for example dependent on the patient's weight or age and also on the type of application, the indication and the severity of the disorder. Conventionally, 0.001 to 100 mg/kg, preferably 0.05 to 75 mg/kg, particularly preferably 0.05 to 50 mg of at least one compound according to the invention are applied per kg of the patient's body weight.
The pharmaceutical composition according to the invention is preferably suitable for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K+ channels. The pharmaceutical composition according to the invention is more preferably suitable for the treatment and/or prophylaxis of one or more diseases and/or disorders selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.
The pharmaceutical composition according to the invention is suitable particularly preferably for the treatment of pain, more particularly preferably of acute pain, chronic pain, neuropathic pain, visceral pain, inflammatory pain and muscular pain, and most particularly for the treatment of neuropathic pain.
The pharmaceutical composition according to the invention is also preferably suitable for the treatment and/or prophylaxis of epilepsy.
The present invention further relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for use in the modulation of KCNQ2/3 K+ channels, preferably for use in KCNQ2/3 K+ channel inhibition and/or stimulation.
The present invention therefore further relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for use in the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K+ channels.
Preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.
Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, most particularly neuropathic pain.
Particular preference is also given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the prophylaxis and/or treatment of epilepsy.
The present invention further relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for the modulation of KCNQ2/3 K+ channels, preferably for KCNQ2/3 K+ channel inhibition and/or stimulation.
The present invention therefore further relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K+ channels.
Preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, especially pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.
Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, most particularly neuropathic pain.
Particular preference is also given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of epilepsy.
The present invention further relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K+ channels.
Preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.
Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, most particularly neuropathic pain.
Particular preference is also given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of epilepsy.
Another aspect of the present invention is a method of treatment and/or prophylaxis of disorders and/or diseases, which are mediated, at least in part, by KCNQ2/3 K+ channels, in a mammal, preferably of disorders and/or diseases selected from the group consisting of pain, preferably pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias, which comprises administering an effective amount of at least one compound of general formula (I) to the mammal.
The effectiveness against pain can be shown, for example, in the Bennett or Chung model (Bennett, G. J. and Xie, Y. K., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, Pain 1988, 33 (1), 87-107; Kim, S. H. and Chung, J. M., An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain 1992, 50 (3), 355-363), by tail flick experiments (e.g. according to D'Amour und Smith (J. Pharm. Exp. Ther. 72, 74 79 (1941)) or by the formalin test (e.g. according to D. Dubuisson et al., Pain 1977, 4, 161-174). The effectiveness against epilepsy can be demonstrated, for example, in the DBA/2 mouse model (De Sarro et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 2001, 363, 330-336).
The compounds according to the invention preferably have a EC50 value of not more than 10000 nM or not more than 8000 nM, more preferably not more than 7000 nM or not more than 6000 nM, yet more preferably not more than 5000 nM or not more than 3000 nM, even more preferably not more than 2000 nM or not more than 1000 nM, yet even more preferably not more than 800 nM or not more than 700 nM, still more preferably not more than 600 nM or not more than 500 nM, yet still more preferably not more than 400 nM or not more than 300 nM, most preferably not more than 200 nM or not more than 150 nM and especially not more than 120 nM or not more than 100 nM. Methods for determining the EC50 value are known to the person skilled in the art. The EC50 value is preferably determined by fluorimetry, particularly preferably as described below under “pharmacological experiments”.
The invention further provides processes for the preparation of the substituted compounds according to the invention.
The chemicals and reaction components used in the reactions and schemes described below are available commercially or in each case can be prepared by conventional methods known to the person skilled in the art.
The reactions described can each be carried out under the conventional conditions with which the person skilled in the art is familiar, for example with regard to pressure or the order in which the components are added. If appropriate, the person skilled in the art can determine the optimum procedure under the respective conditions by carrying out simple preliminary tests. The intermediate and end products obtained using the reactions described hereinbefore can each be purified and/or isolated, if desired and/or required, using conventional methods known to the person skilled in the art. Suitable purifying processes are for example extraction processes and chromatographic processes such as column chromatography or preparative chromatography. All of the process steps described below, as well as the respective purification and/or isolation of intermediate or end products, can be carried out partly or completely under an inert gas atmosphere, preferably under a nitrogen atmosphere.
If the substituted compounds according to the invention of the aforementioned general formula (I) are obtained, after preparation thereof, in the form of a mixture of their stereoisomers, preferably in the form of their racemates or other mixtures of their various enantiomers and/or diastereomers, they can be separated and if appropriate isolated using conventional processes known to the person skilled in the art. Examples include chromatographic separating processes, in particular liquid chromatography processes under normal pressure or under elevated pressure, preferably MPLC and HPLC processes, and also fractional crystallisation processes. These processes allow individual enantiomers, for example diastereomeric salts formed by means of chiral stationary phase HPLC or by means of crystallisation with chiral acids, for example (+)-tartaric acid, (−)-tartaric acid or (+)-10-camphorsulphonic acid, to be separated from one another.
General Reaction Scheme I (Synthesis of Precursor SM01):




A plurality of syntheses of and synthesis paths to compounds of the general formula SM01 with a very broad substitution pattern for residues R2 and R3 are known in the current specialist literature. Previously unknown intermediates of the general formula SM01 with similar substitution patterns for residues R2 and R3 as outlined thereafter and whose syntheses are not described in greater detail, can be produced by the person skilled in the art according to these known methods or by combination of the known methods.




In stage03, stage05, stage07 and stage10, acids of the general formulae IM01, IM02, IM03 and IM05, respectively, can be transformed into amides of the general formulae IM04, IM06, IM07 and I respectively, with amines of the general formula R1—CH2—NH2 according to methods known to the person skilled in the art, for example, using a suitable coupling reagent, for example HATU.
In stage011, stage06, stage08 and stage12, 6-chloro-pyridines of the general formulae IM01, IM03, IM04 and IM07 respectively, can be transformed into 6-amino-pyridines of the general formulae IM02, IM05, IM06 and I respectively, with amines of the general formula HNR4R5 according to methods known to the person skilled in the art, for example by conventional or microwave heating, neat or in solution, for example in MeCN, DMF or THF, optionally in the presence of a suitable base, for example NEt3, DIPEA, K2CO3, Cs2CO3, NaOtBu or KOtBu, optionally by addition of a suitable coupling reagent, for example Pd(PPh3)4.
In stage02, stage04, stage09, and stage11, 2-chloro-pyridines of the general formulae IM01, IM02, IM04, and IM06 respectively, can be transformed into 2-substituted-pyridines of the general formulae IM03, IM05, IM07 and I respectively, with compounds of the general formula X—R6, where X denotes H, a metal, for example sodium, or a residue to form an organometal reagent, for example MgBr or MgCl, according to methods known to the person skilled in the art, for example by conventional or microwave heating, neat or in solution, for example in MeCN, DMF, THF, MeOH or EtOH, optionally in the presence of a suitable base, for example NEt3, DIPEA, K2CO3, Cs2CO3, NaOtBu or KOtBu, optionally by addition of a suitable coupling reagent, for example Pd(PPh3)4, Ni(dppp)C2 or Fe(acac)3.




In stage13 and stage16, 2-chloro-pyridines of the general formulae IM08 and IM10 respectively, can be transformed into 2-substituted-pyridines of the general formulae IM09 and IM11 respectively, with compounds of the general formula X—R6, where X denotes H, a metal, for example sodium, or a residue to form an organometal reagent, for example MgBr or MgCl, according to methods known to the person skilled in the art, for example by conventional or microwave heating, neat or in solution, for example in MeCN, DMF, THF, MeOH or EtOH, optionally in the presence of a suitable base, for example NEt3, DIPEA, K2CO3, Cs2CO3, NaOtBu or KOtBu, optionally by addition of a suitable coupling reagent, for example Pd(PPh3)4, Ni(dppp)C2 or Fe(acac)3.
In stage14 and stage15, 6-chloro-pyridines of the general formulae IM08 and IM09 respectively, can be transformed into 6-Amino-pyridines of the general formulae IM10 and IM11 respectively, with amines of the general formula HNR4R5 according to methods known to the person skilled in the art, for example by conventional or microwave heating, neat or in solution, for example in MeCN, DMF or THF, optionally in the presence of a suitable base, for example NEt3, DIPEA, K2CO3, Cs2CO3, NaOtBu or KOtBu, optionally by addition of a suitable coupling reagent, for example Pd(PPh3)4.
In stage17 esters of the general formula IM11 can be transformed into acids of the general formula IM12 according to methods known to the person skilled in the art, for example, by employing a base, for example lithium hydroxide.
In stage18 esters of the general formula IM11 can be converted to yield amides of the general formula I, with amines of the general formula R1—CH2—NH2 according to methods known to the person skilled in the art, for example by the addition of trimethyl aluminium.
In stage19 acids of the general formula IM12 can be transformed into amides of the general formula I with amines of the general formula R1—CH2—NH2 according to methods known to the person skilled in the art, for example, using a suitable coupling reagent, for example, HATU.
Thus obtained compounds of the general formula I can be further transformed to introduce and/or exchange one or more of the substituents R1, R2, R3, R4, R5 and R6 by simple derivatization reactions known to the person skilled in the art, for example, esterification, ester formation, amide formation, etherification, ether cleavage, oxidation, reduction, substitution or cross-coupling reactions.
The invention will be described hereinafter with the aid of a number of examples. This description is intended merely by way of example and does not limit the general idea of the invention.


EXAMPLES
The indication “equivalents” (“eq.”) means molar equivalents, “RT” means room temperature (23±7° C.), “M” are indications of concentration in mol/l, “aq.” means aqueous, “sat.” means saturated, “sol.” means solution, “conc.” means concentrated.
Further Abbreviations:

    acac acetylacetone=2,4-pentanedione
    AcOH acetic acid
    d days
    dppp 1,3-bis(diphenylphosphino)propane
    brine saturated aqueous sodium chloride solution
    CC column chromatography on silica gel
    DCM dichloromethane
    DIPEA N,N-diisopropylethylamine
    DMF N,N-dimethylformamide
    ether diethyl ether
    EtOAc ethyl acetate
    EtOH ethanol
    h hour(s)
    H2O water
    HATU O-(7-aza-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate
    m/z mass-to-charge ratio
    MeOH methanol
    MeCN acetonitrile
    min minutes
    MS mass spectrometry
    N/A not available
    NEt3 triethylamine
    NMP N-methyl-2-pyrrolidone
    RM reaction mixture
    THF tetrahydrofuran
    v/v volume to volume
    w/w weight in weight


The yields of the compounds prepared were not optimized.
All temperatures are uncorrected.
All starting materials which are not explicitly described were either commercially available (the details of suppliers such as for example Acros, Avocado, Aldrich, Bachem, Fluka, Lancaster, Maybridge, Merck, Sigma, TCl, Oakwood, etc. can be found in the Symyx® Available Chemicals Database of MDL, San Ramon, US or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database of Elsevier, Amsterdam, NL or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art.
The stationary phase used for the column chromatography was silica gel 60 (0.04-0.063 mm) from E. Merck, Darmstadt.
For microwave reactions a Discover® microwave, from the CEM Corporation, Matthews, US, was used.
The mixing ratios of solvents or eluents for chromatography are specified in v/v.
All the intermediate products and exemplary compounds were analytically characterised by means of 1H-NMR spectroscopy. In addition, mass spectrometry tests (MS, m/z for [M+H]+) were carried out for all the exemplary compounds and selected intermediate products.
Synthesis of Exemplary Compounds
Synthesis of Example 1
N-[(3,5-difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-2-ethylsulfanyl-4-methyl-pyridine-3-carboxylic acid
6.1 g (153 mmol, 60% w/w in mineral oil) NaH were dissolved in THF (90 ml) at 0° C. At this temperature 3.4 g (54.7 mmol) ethane thiol were added. After stirring for 15 min at 0° C., 12.4 g (60.2 mmol) 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid were added portionwise. The RM was allowed to warm to RT and stirring was continued at RT for 16 h. Then the reaction was quenched with a 2M aq. HCl and diluted with EtOAc. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. Crystallisation (DCM/hexane) of the residue yielded 12.0 g (51.7 mmol, 95%) 6-chloro-2-ethylsulfanyl-4-methyl-pyridine-3-carboxylic acid.
b) Synthesis of 2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid
A mixture of 12.0 g (51.7 mmol) 6-chloro-2-ethylsulfanyl-4-methyl-pyridine-3-carboxylic acid and 33.7 g (387 mmol) morpholine was heated to 105° C. for 5 d. After cooling to RT a 2M aq. NaOH sol. (200 ml) was added, followed by washing with ether (3×200 ml). The aqueous layer was then acidified with a 2M aq. HCl to pH 5 and extracted with EtOAc. In the same manner pH 4 was adjusted followed by extraction with EtOAc. The combined EtOAc extracts were dried over MgSO4 and concentrated in vacuo. Crystallisation (DCM/hexane) of the residue yielded 7.2 g (25.3 mmol, 49%) 2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid.
c) Synthesis of N-[(3,5-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
To a solution of 250 mg (0.89 mmol) 2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid in THF (7 ml), 124 μl (0.97 mmol) 3,5-difluorobenzylamine, 335 mg (0.89 mmol) HATU and 367 μl (2.66 mmol) NEt3 were added and the RM was heated at 70° C. for 5 d. Subsequently the mixture was diluted with EtOAc and washed with a 4M aq. NH4Cl sol., a 1M aq. NaHCO3 sol. and brine. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:2) provided 187 mg (0.46 mmol, 52%) N-[(3,5-difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 1). [M+H]+ 408.1.
Synthesis of Example 2
2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 2,6-dichloro-N-(3-fluorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide
To a solution of 17.4 g (84.4 mmol) of 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid in THF (340 ml) were added 10.6 ml (92.9 mmol) 3-fluorobenzylamine, 32.0 g (84.4 mmol) HATU and 35.0 ml (253.3 mmol) NEt3. The RM was then heated at 70° C. for 16. After dilution with EtOAc (350 ml) the mixture was washed with a 4M aq. NH4Cl sol., a 1M aq. NaHCO3 sol. and brine. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:2) provided 19.5 g (62.3 mmol, 74%) 2,6-dichloro-N-(3-fluorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide.
b) Synthesis of 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide
A solution of 4.0 g (12.8 mmol) 2,6-dichloro-N-(3,5-difluorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide in DMF (30 ml) was treated with 2.6 g (19.2 mmol) K2CO3 and 1.2 ml (16.0 mmol) ethanethiol, followed by stirring in a closed vessel at RT for 16 h. Then water (35 ml) was added and the mixture was extracted with EtOAc (2×70 ml). The combined organic layers were washed with water, a 2M aq. NaOH sol. and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:1) provided 3.3 g (9.7 mmol, 76%) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide.
c) Synthesis of 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
A mixture of 1.5 g (4.4 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide and 1.9 ml (22.1 mmol) morpholine was heated in the microwave at 120° C. for 30 min. Subsequently the RM was diluted with water and EtOAc and the layers were separated. The organic layer was washed with a 1M aq. NaOH sol. and brine, dried over MgSO4 and concentrated in vacuo. Crystallisation (hexane/EtOAc 3:1) of the residue yielded 1.3 g (3.3 mmol, 75%) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 2). [M+H]+ 390.2.
Synthesis of Example 3
N-[(3,5-difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-2-methoxy-4-methyl-pyridine-3-carboxylic acid
To a suspension of 9.3 g (231 mmol, 60% w/w in mineral oil) NaH in THF (200 ml) was added a solution of 3.8 ml (93 mmol) Methanol in THF (200 ml) while the temperature was kept at 10-20° C. Subsequently a solution of 20.0 g (97 mmol) of 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid in THF (200 ml) was added and the RM was heated to 70° C. for 16 h. After cooling to RT the mixture was acidified with a 2M aq. HCl to pH 3-4 and was then extracted with EtOAc (2×600 ml). The combined organic layers were washed with water and brine, dried over MgSO4 and concentrated in vacuo. The obtained crude 22.6 g 6-chloro-2-methoxy-4-methyl-pyridine-3-carboxylic acid was used in subsequent reactions without further purification.
b) Synthesis of 2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid
To a solution of 302 mg crude 6-chloro-2-methoxy-4-methyl-pyridine-3-carboxylic acid in THF (12 ml) were added 568 mg (1.5 mmol) HATU and 934 μl (6.8 mmol) NEt3. The RM was stirred at 50° C. for 3 h followed by the addition of 268 mg (1.9 mmol) 3,5-difluorobenzylamine. Stirring was continued at 50° C. for 72 h. The RM was then diluted with EtOAc (50 ml) and subsequently washed with a 4M aq. NH4Cl sol., a 1M aq. NaHCO3 sol. and brine. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:1) provided 237 mg (0.7 mmol, 54% over 2 steps) 2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid.
c) Synthesis of N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
A mixture of 237 mg (0.7 mmol) 2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid and 474 μl (5.4 mmol) morpholine was heated in the microwave at 90° C. for 150 min. Subsequently the RM was diluted EtOAc and the layers were separated. The organic layer was washed with a 1M aq. NaHCO3 and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 7:3) provided 100 mg (0.26 mmol, 38%) N-[(3,5-difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 3). [M+H]+ 378.2.
Synthesis of Example 4
2-ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




A solution of 254 mg (0.75 mmol) 6-chloro-2-ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesized according to the methods described in sections a) and b) of example 2), 196 μl (2.25 mmol) morpholine and 392 μl (2.25 mmol) DIPEA in MeCN (2 ml) was heated in the microwave at 180° C. for 4 h. Subsequently the RM was diluted with water and EtOAc and the layers were separated. The organic layer was washed with water and brine, dried over MgSO4 and concentrated in vacuo. Crystallisation (hexane/EtOAc 1:1) of the residue yielded 154 mg (0.40 mmol, 53%) 2-ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 4). [M+H]+ 390.2.
Synthesis of Example 5
2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(tetrahydro-pyran-2-yl-methyl)-amino]-pyridine-3-carboxylic acid amide




A solution of 254 mg (0.75 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 2), 322 mg (2.25 mmol) N-methyl-1-(tetrahydro-2H-pyran-2-yl)methanamine and 392 μl (2.25 mmol) DIPEA in MeCN (2 ml) was heated in the microwave at 150° C. for 4.5 h. Subsequently the RM was diluted with a 2M aq. NaOH sol and EtOAc and the layers were separated. The organic layer was washed with water and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) provided 122 mg (0.28 mmol, 38%) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(tetrahydro-pyran-2-yl-methyl)-amino]-pyridine-3-carboxylic acid amide (example 5). [M+H]+ 432.2.
Synthesis of Example 6
2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-methoxy-azetidine-1-yl)-4-methyl-pyridine-3-carboxylic acid amide




A solution of 410 mg (1.2 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 2), 125 mg (1.0 mmol) 3-methoxy-azetidine and 824 mg (2.53 mmol) Cs2CO3 in 1,4-dioxane (7 ml) was heated at 110° C. for 24 h. Subsequently the RM was concentrated in vacuo. The residue obtained was partitioned between water and EtOAc. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:1) provided 122 mg (0.31 mmol, 31%) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-methoxy-azetidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide (example 6). [M+H]+ 390.2.
Synthesis of Example 7
2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-hydroxy-azetidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide




A mixture of 439 mg (1.2 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 2), 284 mg (2.6 mmol) 3-hydroxy-azetidine, 2.1 g (6.5 mmol) Cs2CO3 and 149 mg (0.13 mmol) Pd(PPh3)2 in 1,4-dioxane (4 ml) was heated at 110° C. for 16 h. Subsequently the RM was diluted with brine (30 ml) and extracted with EtOAc (3×40 ml). The combined organic layers were dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) and subsequent crystallization (hexane/EtOAc) provided 66 mg (0.18 mmol, 15%) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-hydroxy-azetidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide (example 7). [M+H]+ 376.1.
Synthesis of Example 8
2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophenyl)-methylamino]-4-methyl-pyridine-3-carboxylic acid amide




A mixture of 200 mg (0.59 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 2), 340 μl (2.96 mmol) 3-fluorobenzylamine and 240 mg (1.77 mmol) K2CO3 were heated in a sealed tube at 160° C. for 16 h. Subsequently the RM was diluted with water (50 ml) and extracted with EtOAc (3×40 ml). The combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:1) provided 120 mg (0.28 mmol, 47%) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophenyl)-methylamino]-4-methyl-pyridine-3-carboxylic acid amide (example 8). [M+H]+ 428.2.
Synthesis of Example 9
(E)-N-(3-fluorobenzyl)-4-methyl-6-morpholino-2-(prop-1-enyl)-pyridine-3-carboxylic acid amide
a) Synthesis of 6-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-2-morpholin-4-yl-pyridine-3-carboxylic acid amide and 2-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
To a solution of 2.0 g (6.4 mmol) 2,6-dichloro-N-(3-fluorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 2) in DMF (19 ml) were added 1.32 g (9.6 mmol) K2CO3 and 660 mg (7.7 mmol) morpholine and the RM was stirred at 90° C. for 16 h. Then the RM was poured into ice water (40 ml), followed by extraction with EtOAc (3×40 ml). The combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:2) provided 1.14 g (3.2 mmol, 49%) 6-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-2-morpholin-4-yl-pyridine-3-carboxylic acid and 400 mg (1.1 mmol, 17%) 2-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide.
b) Synthesis of (E)-N-(3-fluorobenzyl)-4-methyl-6-morpholino-2-(prop-1-enyl)-pyridine-3-carboxylic acid amide
To a solution of 400 mg (1.1 mmol) 2-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide in toluene (15 ml) were added 140 mg (1.7 mmol) (E)-prop-1-enylboronic acid, 1.1 g (3.3 mmol) CsCO3 and EtOH (1.5 ml). After degassing with argon for 15 min 370 mg (0.32 mmol) Pd(PPh3)4 were added and the RM was heated to 110° C. for 5 h. Subsequently the RM was filtered through celite and the filtrate was concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:1) provided 300 mg (0.8 mmol, 74%) (E)-N-(3-fluorobenzyl)-4-methyl-6-morpholino-2-(prop-1-enyl)-pyridine-3-carboxylic acid amide (example 9). [M+H]+ 370.2.
Synthesis of Example 10
N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide




A solution of 300 mg (0.81 mmol) (E)-N-(3-fluorobenzyl)-4-methyl-6-morpholino-2-(prop-1-enyl)-pyridine-3-carboxylic acid amide (example 9) in MeOH (9 ml) was degassed with argon for 15 min. Then 0.065 g Pd/C (10% w/w) was added and the RM was stirred for 3 h under hydrogen atmosphere by use of an H2 balloon. Subsequently the mixture was filtered through celite and the filtrate was concentrated in vacuo. Purification of the residue by CC (hexane/acetone 17:3) provided 170 mg (0.5 mmol, 56%) N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide (example 10). [M+H]+ 372.2.
Synthesis of Example 11
2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylic acid amide




a) Synthesis of methyl 6-chloro-2-(ethylsulfanyl)-4-(trifluoromethyl)-pyridine-3-carboxylate
To a solution of 2.5 g (9.1 mmol) methyl 2,6-dichloro-4-(trifluoromethyl)-pyridine-3-carboxylate in DMF (21 ml) were added 1.9 g (13.7 mmol) K2CO3 and 843 μl (11.4 mmol) ethanethiol. After stirring in a closed vessel at RT for 4 h, the RM was extracted twice with EtOAc. The combined organic layers were washed with water and a 2M aq. NaOH sol., dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 99:1) provided 2.25 g of a  ̃1:1 mixture of methyl 6-chloro-2-(ethylsulfanyl)-4-(trifluoromethyl)-pyridine-3-carboxylate and methyl 2,6-bis(ethylsulfanyl)-4-(trifluoromethyl)-pyridine-3-carboxylate, which was used in the next step without further purification.
b) Synthesis of methyl 2-(ethylsulfanyl)-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylate
A solution of 2 g of a  ̃1:1 mixture of methyl 6-chloro-2-(ethylsulfanyl)-4-(trifluoromethyl)-pyridine-3-carboxylate and methyl 2,6-bis(ethylsulfanyl)-4-(trifluoromethyl)-pyridine-3-carboxylate, 1.7 ml (20.0 mmol) morpholine and 3.5 ml (20.0 mmol) DIPEA in MeCN (10 ml) was heated in the microwave to 150° C. for 4 h. The RM was then diluted with water and EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 4:1) provided 440 mg (1.3 mmol, 16% over 2 steps) methyl 2-(ethylsulfanyl)-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylate.
c) Synthesis of 2-(ethylsulfanyl)-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylic acid
A solution of 440 mg (1.3 mmol) methyl 2-(ethylsulfanyl)-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylate in a MeOH/THF mixture (6 ml, 1:1 v/v) was treated with a 2M aq. LiOH sol. (3 ml) and was then stirred at 60° C. for 5 d. After cooling to RT the RM was acidified with a 2M aq. HCl sol. to pH 2. Upon dilution with EtOAc the precipitate formed was filtered off to give 176 mg (0.5 mmol, 42%) 2-(ethylsulfanyl)-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylic acid, which was used in the next step without further purification.
d) Synthesis of 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylic acid amide
To a solution of 170 mg (0.5 mmol) 2-(ethylsulfanyl)-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylic acid in THF (3 ml) were added 192 mg (0.5 mmol) HATU and 210 μl (1.5 mmol) NEt3 and the RM was stirred at 50° C. for 90 min. Then 69 μl (0.6 mmol) 3-fluorobenzylamine were added and stirring was continued at 50° C. for 5 d. After cooling to RT the mixture was partitioned between water and EtOAc. The organic layer was separated, washed with a 4N aq. NH4Cl sol. and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:1) provided 57 mg (0.13 mmol, 26%) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-morpholin-4-yl-4-(trifluoromethyl)-pyridine-3-carboxylic acid amide (example 11). [M+H]+ 444.1.
Synthesis of Example 12
N-[(3-Fluorophenyl)-methyl]-4-methyl-2,6-dimorpholin-4-yl-pyridine-3-carboxylic acid amide




A mixture of 300 mg (0.82 mmol) 6-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-2-morpholin-4-yl-pyridine-3-carboxylic acid (synthesis is described in section a) of example 9) and 1.4 g (16.5 mmol) morpholine was heated in the microwave to 120° C. for 2 h. The RM was then diluted with EtOAc and a 2M aq. NaOH sol. was added. The organic layer was separated, washed with water and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:2) provided 253 mg (0.61 mmol, 74%) N-[(3-Fluorophenyl)-methyl]-4-methyl-2,6-dimorpholin-4-yl-pyridine-3-carboxylic acid amide (example 12). [M+H]+ 415.2.
Synthesis of Example 14
1-[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-carbamoyl]-4-methyl-pyridin-2-yl]-piperidine-4-carboxylic acid




A solution of 146 mg (0.32 mmol) 1-[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-carbamoyl]-4-methyl-pyridin-2-yl]-piperidine-4-carboxylic acid methyl ester (example 13) in a MeOH/THF mixture (1:1 v/v, 2 ml) was treated with 1 ml (2.0 mmol) 2M aq. LiOH sol. and heated to 70° C. for 16 h. Subsequently pH 3-4 was adjusted with a 2M aq. HCl sol., followed by extraction with EtOAc. The organic layer was washed with brine, dried over MgSO4 and concentrated in vacuo. As residue 112 mg (0.26 mmol, 79%) 1-[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-carbamoyl]-4-methyl-pyridin-2-yl]-piperidine-4-carboxylic acid (example 14) were obtained. [M+H]+ 432.2.
Synthesis of Example 16
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(4-oxo-piperidin-1-yl)-pyridine-3-carboxylic acid amide




A solution of 201 mg (0.5 mmol) 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(4-hydroxy-piperidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide (example 15) in DCM (7 ml) was treated with 1.84 g (0.65 mmol, 15% w/w in DCM) Dess-Martin periodinane and stirred at RT for 3 h. The RM was then quenched by addition of a 10% (w/w) aq. Na2S2O3 sol. and diluted with DCM (30 ml). The organic layer was separated, washed with a 2M aq. NaOH sol. and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) provided 88 mg (0.22 mmol, 44%) 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(4-oxo-piperidin-1-yl)-pyridine-3-carboxylic acid amide (example 16). [M+H]+ 402.2.
Synthesis of Example 18
2-Ethylsulfanyl-N-[(4-fluoro-2-hydroxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




To a cooled solution of 209 mg (0.5 mmol) 2-Ethylsulfanyl-N-[(4-fluoro-2-methoxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 17) in DCM (7 ml) were added dropwise 5 ml (5.0 mmol, 1M in DCM) BBr3 at −50° C. The RM was then allowed to reach 0° C. and stirring was continued at this temperature for 3 h. Then a 1M aq. NaHCO3 sol. (15 ml) was added at 0° C. and the mixture was diluted with MeOH (10 ml) and DCM (10 ml). The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 7:3) provided 81 mg (0.2 mmol, 40%) 2-Ethylsulfanyl-N-[(4-fluoro-2-hydroxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 18). [M+H]+ 406.2.
Synthesis of Example 19
N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-Chloro-N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-pyridine-3-carboxylic acid amide
330 mg (8.3 mmol, 60% w/w in mineral oil) NaH were slowly added to Methanol (30 ml) at RT and stirring was continued at RT for 45 min. Then 2.35 g (7.5 mmol) 2,6-dichloro-N-(3-fluorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 2) were added and the RM was heated to 70° C. for 24 h. After cooling to RT water (10 ml) was added and most of the MeOH was removed in vacuo. The mixture was then extracted with EtOAc and the organic layer was washed twice with brine, dried over MgSO4 and concentrated in vacuo. Crystallisation (hexane/EtOAc 3:1) of the residue yielded 1.24 g (0.4 mmol, 54%) 6-Chloro-N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-pyridine-3-carboxylic acid amide.
b) Synthesis of N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide and N-[(3-Fluorophenyl)-methyl]-2-hydroxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
A mixture of 1.37 g (4.4 mmol) 6-Chloro-N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-pyridine-3-carboxylic acid amide and 2.9 ml (33.2 mmol) morpholine was heated in the microwave to 120° C. for 30 min. The RM was then diluted with EtOAc (50 ml) and a 1M aq. NaOH sol. (20 ml) was added. The precipitate formed was filtered off to give 715 mg (2.0 mmol, 47%) N-[(3-Fluorophenyl)-methyl]-2-hydroxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide. The organic layer was separated from the filtrate, washed with water and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:2) provided 397 mg (1.1 mmol, 25%) N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 19). [M+H]+ 360.2.
Synthesis of Example 20
2-Ethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-2-ethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide
A suspension of 626 mg (2.0 mmol) 2,6-dichloro-N-(3-fluorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 2), 244 mg (2.4 mmol) ethylamine hydrochloride and 689 mg (5.0 mmol) K2CO3 in DMF (6 ml) was heated to 100° C. for 3 d. Then the RM was poured into ice water (10 ml), followed by extraction with EtOAc (3×15 ml). The combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) provided 84 mg (0.26 mmol, 13%) 6-chloro-2-ethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide.
b) Synthesis of 2-Ethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
A mixture of 80 mg (0.25 mmol) 6-chloro-2-ethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide and 433 mg (5.0 mmol) morpholine was heated in the microwave to 120° C. for 10 h. After cooling to RT, purification of the residue by CC (hexane/EtOAc 2:1) provided 73 mg (0.2 mmol, 78%) 2-Ethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 20). [M+H]+ 373.2.
Synthesis of Example 21
N-[(3-Fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




To a solution of 200 mg (0.58 mmol) N-[(3-Fluorophenyl)-methyl]-2-hydroxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 19) in DMF (8 ml) 15 mg (0.64 mmol, 60% w/w in mineral oil) NaH were added, followed by stirring at RT for 30 min. Then 88 mg (0.64 mmol) 2-bromoethyl-methylether were added and the RM was heated to 50° C. for 16 h. Subsequently water (10 ml) and EtOAc were added and the layers were separated. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:7) provided 90 mg (0.22 mmol, 39%) N-[(3-Fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 21). [M+H]+ 404.2.
Synthesis of Example 22
2-Ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




To a solution of 200 mg (0.55 mmol) 2-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 9) in THF (5 ml) were added 30 mg (0.055 mmol) Ni(dppp)Cl2 and 330 μl (0.66 mmol, 2M in THF) ethylmagnesiumbromide. The RM was heated to 80° C. for 8 h, followed by quenching with a sat. aq. NH4Cl sol. and extraction with EtOAc (3×20 ml). The combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 7:3) provided 50 mg (0.14 mmol, 25%) Ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 22). [M+H]+ 358.2.
Synthesis of Example 23
N-[(3-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




A solution of 300 mg (0.83 mmol) 2-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 9) in THF/NMP (6:1 v/v, 14 ml) was cooled to −30° C. At this temperature were successively added 58 mg (0.16 mmol) Fe(acac)3 and 6 ml (12.0 mmol, 2M in THF) iso-propyl-magnesium-chloride. The RM was then allowed to warm to 0° C. within 1 h. Then sat. aq. NH4Cl sol. was added the mixture was extracted with EtOAc (3×20 ml). The combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 7:3) provided 110 mg (0.30 mmol, 36%) N-[(3-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 23). [M+H]+ 372.2.
Synthesis of Example 24
N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-pyrrolidin-1-yl-pyridine-3-carboxylic acid amide




To a solution of 254 mg (0.7 mmol) 2-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 9) in MeCN (0.5 ml) were added 115 μl (1.4 mmol) pyrrolidine and 290 μl (2.1 mmol) NEt3. The RM was heated in the microwave to 120° C. for 30 min and subsequently to 140° C. for 45 min. Then the mixture was filtered through celite and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 2:1), followed by crystallization (hexane/EtOAc) provided 164 mg (0.41 mmol, 59%) N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-pyrrolidin-1-yl-pyridine-3-carboxylic acid amide (example 24). [M+H]+ 399.2.
Synthesis of Example 117
2-Methoxy-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoro-methyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-2-methoxy-4-methylpyridine-3-carboxylic acid methylester
A solution of 8.8 (43.7 mmol) 6-chloro-2-methoxy-4-methyl-3-carboxylic acid amide (synthesis is described in section a) of example 3) in DMF (110 ml) was treated with 9.0 g (65.5 mmol) K2CO3 and subsequently stirred at RT for 30 min. Then 5.4 ml (65.5 mmol) Iodomethan were added and stirring was continued at RT for 16 h. After quenching with water the mixture was extracted twice with EtOAc and the combined organic layer was washed with brine, dried over MgSO4 and concentrated in vacuo. As residue 9.1 g (39.6 mmol, 91%) 6-chloro-2-methoxy-4-methylpyridine-3-carboxylic acid methylester was obtained which was used in next step without further purification.
b) Synthesis of 2-methoxy-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester
A solution of 5.0 g (21.8 mmol) 6-chloro-2-methoxy-4-methylpyridine-3-carboxylic acid methylester, 2.0 g (24.0 mmol) morpholine and 6.0 ml (43.5 mmol) NEt3 in NMP (21 ml) was heated at 90° C. for 2 d. After cooling to RT the mixture was partiotionated between EtOAc and a 1M aq. NaHCO3 sol. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 4:1) provided 2.7 g (9.8 mmol, 45%) 2-methoxy-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester.
c) Synthesis of 2-Methoxy-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoro-methyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide
2-methoxy-4-methyl-6-morpholino-pyridine-3-carboxylic acid amide (example 117), [M+H]+ 410.2) was synthesized from 2-methoxy-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester according to the methods described in sections c) of example 11 and section c) of example 1.
Synthesis of Example 120
2-Ethylsulfanyl-6-[(4-fluoro-benzoyl)-methyl-amino]-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide




To a solution of 150 mg (0.45 mmol) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 123) in DCM (3 ml) and THF (3 ml) was added 160 μl (0.95 mmol) DIPEA. At 0° C. 56 μl (0.47 mmol) 4-fluoro-benzoylchloride was added dropwise and stirring was continued at 0° C. for 2 h and RT for 16 h. Then the mixture was partiotionated between EtOAc and a 1M aq. NaHCO3 sol. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) provided 171 mg (0.38 mmol, 83%) 2-Ethylsulfanyl-6-[(4-fluoro-benzoyl)-methyl-amino]-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (example 120). [M+H]+ 456.1
Synthesis of Example 123
6-(Acetyl-methyl-amino)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide




a) Synthesis of 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide
A mixture of 750 mg (2.2 mmol) and 2.7 ml (22.1 mmol, 33% w/w in H2O) was heated to 150° C. in the MW for 3 h. The mixture was then diluted with EtOAc and water and the organic layer was separated, washed with a 2M aq. NaOH sol. and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) and subsequent crystallization (hexane/EtOAc) provided 454 mg (1.36 mmol, 62%) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide.
b) Synthesis of 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide
To a solution of 250 mg (0.75 mmol) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide in DCM (5 ml) and THF (5 ml) was added 267 μl (1.58 mmol) DIPEA. At 0° C. 74 μl (0.79 mmol) acetanhydride was added dropwise and stirring was continued at RT for 16 h. Then another 297 μl (3.2 mmol) acetanhydride and 535 μl (3.2 mmol) DIPEA were added at RT and the mixture was stirred at 35° C. for 2 d. The solution was diluted with water and a 1M aq. NaOH sol. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:2) provided 226 mg (0.6 mmol, 80%) 6-(Acetyl-methyl-amino)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (example 123). [M+H]+ 376.1
Synthesis of Example 138 & 139
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[(2S)-2-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide & 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[(2R)-2-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide




558 mg racemic 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(2-methyl-morpholin-4-yl)-pyridine-3-carboxylic acid amide (example 48) was separated by chiral HPLC to provide 183 mg 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[(2S)-2-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide (example 138), [M+H]+ 404.2 and 184 mg 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[(2R)-2-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide (example 139), [M+H]+ 404.2
Synthesis of Example 154
N-[(4-Fluorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-2-methylsulfanyl-4-methyl-pyridine-3-carboxylic acid
To a cooled (ice-bath) solution of 3.8 g (54.7 mmol) NaSMe in THF (85 ml) 12.4 g (60.2 mmol) 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid was added. After stirring at RT for 2 h, 1.3 g (xx mmol) NaH (60% w/w in mineral oil, 32.5 mmol) and 1.6 g (23.0 mmol) NaSMe were added and stirring was continued at RT for 16 h. Then the mixture was diluted with THF (45 ml) and again 1.3 g (xx mmol) NaH (60% w/w in mineral oil, 32.5 mmol) and 3.4 g (48.9 mmol) NaSMe were added and stirring was continued at RT for 16 h. Then the reaction was quenched with a 2M aq. HCl and diluted with EtOAc. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. Crystallisation (DCM/hexane) of the residue yielded 7.34 g (33.7 mmol, 62%) 6-chloro-2-methylsulfanyl-4-methyl-pyridine-3-carboxylic acid.
b) Synthesis of N-[(4-Fluorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
N-[(4-Fluorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 154), [M+H]+ 376.1, was synthesized from 6-chloro-2-methylsulfanyl-4-methyl-pyridine-3-carboxylic acid according to the methods described in sections b) & c) of example 1.
Synthesis of Example 169
N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide




a) Synthesis of 2-chloro-N-(4-fluorobenzyl)-4-methyl-6-[(3R)-3-methylmorpholino]-pyridine-3-carboxylic amide
A mixture of 6.0 g (19.2 mmol) 2,6-dichloro-N-(4-fluorobenzyl)-4-methyl-pyridine-3-carboxylic amide (synthesized according to the methods described in section a) of example 2), 3.9 g (28.7 mmol) (R)-3-methylmorpholine hydrochloride, 13.0 ml (76.6 mmol) and NMP (18.4 ml) was heated in the MW to 180° C. for 16 h. After cooling to RT the mixture was partiotionated between EtOAc and a 2M aq. NaOH sol. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) provided 1.4 g (3.7 mmol, 20%) 2-chloro-N-(4-fluorobenzyl)-4-methyl-6-[(3R)-3-methylmorpholino]-pyridine-3-carboxylic amide.
b) Synthesis of N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide
2-chloro-N-(4-fluorobenzyl)-4-methyl-6-[(3R)-3-methylmorpholino]-pyridine-3-carboxylic amide was converted into N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide (example 169), [M+H]+ 386.2, according to the method described for example 23.
Synthesis of Example 171
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-pyridin-3-yl-amino)-pyridine-3-carboxylic acid amide




A mixture of 338 mg (1.0 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 2), 237 mg (2.2 mmol) 2-methylamino-pyridine, 1.8 g (5.4 mmol) Cs2CO3 and 125 mg (0.11 mmol) Pd(PPh3)2 in 1,4-dioxane (4 ml) was heated at 110° C. for 2 h and stirred at RT for 16 h. The mixture was then filtered through celite and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) provided 243 mg (0.59 mmol, 59%) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-pyridin-3-yl-amino)-pyridine-3-carboxylic acid amide (example 171). [M+H]+ 411.2
Synthesis of Example 172
2-Dimethylamino-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide




2-chloro-N-(4-fluorobenzyl)-4-methyl-6-[(3R)-3-methylmorpholino]-pyridine-3-carboxylic amide (synthesis is described in section a) of example 169) was converted with a 2M solution of dimethylamine in THF into 2-dimethylamino-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide (example 172), [M+H]+ 387.2, according to the method described for example 24.
Synthesis of Example 174
2-(Ethyl-methyl-amino)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-2-(ethyl(methyl)amino)-4-methyl-pyridine-3-carboxylic acid ethylester
A mixture of 8.2 g (35.0 mmol) 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid ethylester, 3.7 ml (43.8 mmol) N-methylethylamine and 8.9 ml (52.5 mmol) DIPEA in NMP (25 ml) was heated in the MW to 90° C. for 1 h. Then the solution was diluted with water, a 1M aq. NaOH sol. and EtOAc. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 9:1) provided 4.0 g (15.6 mmol, 44%) 6-chloro-2-(ethyl(methyl)amino)-4-methyl-pyridine-3-carboxylic acid ethylester.
b) Synthesis of 2-(ethyl(methyl)amino)-4-methyl-6-morpholino-pyridine-3-carboxylic acid ethylester
A mixture of 4.0 g (15.6 mmol) 6-chloro-2-(ethyl(methyl)amino)-4-methyl-pyridine-3-carboxylic acid ethylester and 13.6 ml (155.8 mmol) morpholine was heated in the MW to 135° C. for 2 h. Then the mixture was diluted with a 1M aq. NaOH sol. and EtOAc. The organic layer was separated, washed with brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 9:1) provided 2.0 g (6.4 mmol, 41%) 2-(ethyl(methyl)amino)-4-methyl-6-morpholino-pyridine-3-carboxylic acid ethylester.
c) Synthesis of -(Ethyl-methyl-amino)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
A solution of 249 mg (0.81 mmol) 2-(ethyl(methyl)amino)-4-methyl-6-morpholino-pyridine-3-carboxylic acid ethylester and 924 μl (8.1 mmol) 4-fluoro-benzylamine in toluene (17 ml) was treated with 2.85 ml (2M in toluene, 5.7 mmol) AlMe3 and was subsequently heated to 120° C. for 4 d. Then the solution was diluted with water, a 1M aq. NaOH sol. and EtOAc. The organic layer was separated, washed with a 2M aq. NaOH sol. and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:1) provided 127 mg (0.33 mmol, 40%) 2-(Ethyl-methyl-amino)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 174). [M+H]+ 387.2
Synthesis of Example 176
N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-methylsulfanyl-pyridine-3-carboxylic acid amide




To a solution of 200 mg (0.52 mmol) 2-chloro-N-(4-fluorobenzyl)-4-methyl-6-[(3R)-3-methylmorpholino]-pyridine-3-carboxylic amide (synthesis is described in section a) of example 169) in THF (3 ml) was added 46 μg (0.66 mmol) NaSMe. The reaction mixture was stirred in a closed vessel at 80° C. for 3 d. Subsequently the mixture was diluted with water and a 2M aq. NaOH sol. and extracted twice with EtOAc. The combined organic layers were washed with water, dried over MgSO4 and concentrated in vacuo. Crystallisation (EtOAc/pentane) of the residue yielded 128 mg (0.33 mmol, 62%) N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-methylsulfanyl-pyridine-3-carboxylic acid amide (example 176). [M+H]+ 390.2
Synthesis of Example 214
N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide




6-Chloro-N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 19) was converted with (R)-3-methylmorpholine into N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide (example 214), [M+H]+ 374.2, according to the method described for example 171.
Synthesis of Example 253
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(2-oxo-propyl)-amino]-pyridine-3-carboxylic acid amide




To a solution of 150 mg (0.45 mmol) 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 123) in NMP (1 ml) were added 229 μl (1.35 mmol) DIPEA and 39 μl (0.50 mmol) chloroacetone. The mixture was heated in the MW to 140° C. for 40 min and subsequently partiotionated between a 1M aq. NaOH sol and EtOAc. The organic layer was separated, washed with a 1M aq. NaOH sol, water and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 13:7) provided 53 mg (0.14 mmol, 30%) 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl-(2-oxo-propyl)-amino]-pyridine-3-carboxylic acid amide (example 253). [M+H]+ 390.2
Synthesis of Example 258
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-tetrahydro-pyran-4-yl-amino)-pyridine-3-carboxylic acid amide




A solution of 338 mg (1.0 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 2), 172 mg (1.5 mmol) N-methyl-tetrahydro-2H-pyran-4-amine and 509 μl (3.0 mmol) DIPEA in NMP (1 ml) was heated in the microwave at 180° C. for 2 h. Subsequently the RM was diluted with a 2M aq. NaOH sol, water and EtOAc and the layers were separated. The organic layer was washed with water and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 13:7) provided 77 mg (0.18 mmol, 18%) 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-tetrahydro-pyran-4-yl-amino)-pyridine-3-carboxylic acid amide (example 258). [M+H]+ 418.2
Synthesis of Example 263
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3S)-3-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide




To a cooled (ice-bath) solution of 450 mg (1.32 mmol) (S)-morpholin-3-yl-methanol in THF (5 ml) were added at 0° C. 570 μl (2.78 mmol) 1,1,1,3,3,3 hexamethyldisilazane and 33 μl (0.26 mmol) trimethylchlorosilane. The mixture was then stirred at RT for 1 h. Then another 33 μl (0.26 mmol) trimethylchlorosilane was added and stirring was continued at RT for 1 h followed by concentration in vacuo. The residue, 450 mg (1.3 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 2) and 903 μl (5.3 mmol) DIPEA were suspended in NMP (1.5 ml). Then the reaction mixture was heated at 180° C. for 32 h and stirred at RT for 72 h. Subsequently a 1M hydrochlorid acid was added and the mixture was stirred at RT for 15 min. After neutralization with a sat. aq. NaHCO3 sol. EtOAc was added and the layers were separated. The organic layer was washed with water and brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by CC (cyclohexane/EtOAc 1:1) provided 70 mg (0.17 mmol, 13%) 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3S)-3-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide (example 263). [M+H]+ 420.2
Synthesis of Example 285
N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-N-(4-chlorobenzyl)-2-isopropyl-4-methyl-pyridine-3-carboxylic amide
A solution of 6.0 g (18.3 mmol) 2,6-dichloro-N-(4-chlorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide (synthesized according to the method described in section a) of example 2) in THF (180 ml) and NMP (60 ml) was degassed for 30 min followed by the addition of 1.3 g (3.7 mmol) Fe(acac)3. This mixture was degassed again for 20 min. At −40° C. 137 ml (2M in THF, 274 mmol) isopropylmagnesiumchloride was added dropwise over 1 h. The reaction mixture was allowed to reach 0° C. and was quenched at this temperature with a sat. aq. NH4Cl sol. followed by stirring at 10° C. for 30 min. Then the mixture was diluted with EtOAc and the organic layer was separated, washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 9:1) provided 2.45 g (7.3 mmol, 40%) 6-chloro-N-(4-chlorobenzyl)-2-isopropyl-4-methyl-pyridine-3-carboxylic amide.
b) Synthesis of N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide
6-chloro-N-(4-chlorobenzyl)-2-isopropyl-4-methyl-pyridine-3-carboxylic amide was converted into N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide (example 285), [M+H]+ 432.2, according to the method described for example 258.
Synthesis of Example 298
6-(1,1-Dioxo-[1,4]thiazinan-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide




a) Synthesis of 2-chloro-N-(3-fluorobenzyl)-4-methyl-6-thiomorpholino-pyridine-3-carboxylic acid amide
A solution of 700 mg (2.24 mmol) 2,6-dichloro-N-(3-fluorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 2), 280 μl (2.9 mmol) thiomorpholine and 3.95 g (12.1 mmol) Cs2CO3 in dioxane (60 ml) was degassed for 30 min followed by the addition of 285 mg (0.25 mmol) Pd(PPh3)4. Subsequently the reaction solution was heated to 120° C. for 16 h. Then the mixture was filtered through celite and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 19:1) provided 420 mg (1.1 mmol, 49%) 2-chloro-N-(3-fluorobenzyl)-4-methyl-6-thiomorpholino-pyridine-3-carboxylic acid amide.
b) Synthesis of 2-chloro-6-(1,1-Dioxo-[1,4]thiazinan-4-yl)-2-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide
To a solution of 420 mg (1.1 mmol) 2-chloro-N-(3-fluorobenzyl)-4-methyl-6-thiomorpholino-pyridine-3-carboxylic acid amide in DCM (13 ml) was added 640 mg (60% pure, 2.2 mmol) mCPBA at 0° C. and stirring was continued at this temperature for 2 h. The mixture was then diluted with DCM and washed with a sat. aq. Na2CO3 sol., water and brine, dried over Na2SO4 and concentrated in vacuo. The obtained crude 450 mg 2-chloro-6-(1,1-Dioxo-[1,4]thiazinan-4-yl)-2-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide was used in subsequent reactions without further purification.
c) Synthesis of 6-(1,1-Dioxo-[1,4]thiazinan-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide
A solution of 450 mg (crude,  ̃1.1 mmol) 2-chloro-6-(1,1-Dioxo-[1,4]thiazinan-4-yl)-2-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide, 750 mg (5.5 mmol) K2CO3 and 400 μL (5.5 mmol) ethylmercaptane in DMF (4 ml) was heated to 60° C. for 2 h. Subsequently the mixture was poured into water. The mixture was extracted with EtOAc and the organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 1:1) provided 205 mg (0.47 mmol, 43%) 6-(1,1-Dioxo-[1,4]thiazinan-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide. [M+H]+ 438.1
Synthesis of Example 307
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3-methoxy-cyclohexyl)-methyl-amino]-4-methyl-pyridine-3-carboxylic acid amide




a) Synthesis of 2-chloro-N-(3-fluorobenzyl)-6-((3-methoxycyclohexyl)(methyl)amino)-4-methyl-pyridine-3-carboxylic acid amide
To a solution of 1.19 g (3.8 mmol) 2,6-dichloro-N-(3-fluorobenzyl)-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 2) in DMF (12 ml) were added 1.05 g (7.6 mmol) K2CO3 and 683 mg (3.8 mmol) 3-methoxy-N-methylcyclohexanamine and the reaction mixture was heated at 110° C. for 16 h. The mixture was then poured into water and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 4:1) provided 850 mg (2.7 mmol, 32%) 2-chloro-N-(3-fluorobenzyl)-6-((3-methoxycyclohexyl)(methyl)amino)-4-methyl-pyridine-3-carboxylic acid amide.
b) Synthesis of 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3-methoxy-cyclohexyl)-methyl-amino]-4-methyl-pyridine-3-carboxylic acid amide
To a solution of 148 mg (0.35 mmol) 2-chloro-N-(3-fluorobenzyl)-6-((3-methoxy-cyclohexyl)(methyl)amino)-4-methyl-pyridine-3-carboxylic acid amide in DM (1 ml) were added 488 mg (3.53 mmol) K2CO3 and 260 μl (3.53 mmol) mmol) ethylmercaptane and the reaction mixture was heated at 80° C. for 16 h. The mixture was then poured into water and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 17:3) provided 90 mg (0.2 mmol, 58%) 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3-methoxy-cyclohexyl)-methyl-amino]-4-methyl-pyridine-3-carboxylic acid amide (example 307). [M+H]+ 446.2
Synthesis of Example 312
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxo-morpholin-4-yl)-pyridine-3-carboxylic acid amide




A solution of 1.0 g (2.95 mmol) 6-chloro-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesis is described in section b) of example 2) in propionitrile (20 ml) was treated with 1.33 g (8.87 mmol) NaI and 1.0 ml (8.28 mmol) trichloromethylsilane. Subsequently the solution was heated at 110° C. for 16 h. The mixture was then partitionated between a 2M aq. NaOH sol and EtOAc. The organic layer was separated, washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in dioxane (10 ml) and 2.26 g (7.0 mmol) Cs2CO3 and 114 mg (0.92 mmol) picolinic acid were added. This mixture was degassed for 30 min followed by the addition of 88 mg (0.46 mmol) CuI and 470 mg (4.65 mmol) 3-morpholinone. The reaction solution was then heated to 100° C. for 16 h and subsequently concentrated in vacuo. The residue was dissolved in water and was extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 7:3) provided 60 mg (0.15 mmol, 5%) 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxo-morpholin-4-yl)-pyridine-3-carboxylic acid amide (example 312). [M+H]+ 404.1.
Synthesis of Example 317
N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-(oxetan-3-yloxy)-pyridine-3-carboxylic acid amide




A solution of 209 mg (2.82 mmol) 3-hydroxy-oxetane in THF (6 ml) was treated with 316 mg (2.81 mmol) KOtBu and was heated at 50° C. for 15 min. After cooling to RT a solution of 205 mg (0.56 mmol) 2-chloro-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (synthesis is described in section a) of example 9) in THF (3 ml) was added and the mixture was heated at 80° C. for 8 h. The mixture was then poured into water and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 7:3) provided 190 mg (0.47 mmol, 84%) N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-(oxetan-3-yloxy)-pyridine-3-carboxylic acid amide (example 317). [M+H]+ 402.2.
Synthesis of Example 336
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methoxy-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 2,6-dichloro-4-methoxy-pyridine-3-carboxylic acid
To a solution of 4.0 g (22.5 mmol) 2,6-dichloro-4-methoxy-pyridine in THF (20 ml) was added 10.0 ml (2.47 M in hexane, 24.7 mmol) n-butyllithium at −78° C. After stirring for 1 h at −78° C. excess dry ice was added and the mixture was allowed to warm to RT. Then the mixture was acidified with 6N aqueous hydrochlorid acid to pH 3-4 followed by extraction with EtOAc. The organic layer was dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 4:1) provided 3.5 g (15.8 mmol, 70%) 2,6-dichloro-4-methoxy-pyridine-3-carboxylic acid.
b) Synthesis of 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methoxy-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
2,6-dichloro-4-methoxy-pyridine-3-carboxylic acid was converted into 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methoxy-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 336), [M+H]+ 406.2, according to the methods described for example 2.
Synthesis of Example 341
2-(Acetyl-methyl-amino)-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-N-(3-fluorobenzyl)-4-methyl-2-(N-methylacetamido)-pyridine-3-carboxylic acid amide
To a solution of 240 μl (1.69 mmol) diisopropylamine in THF (5 ml) was added 680 μl (2.47 M in hexane, 1.69 mmol) n-butyllithium at −78° C. After stirring for 15 min at −78° C. a solution of 520 mg (1.69 mmol) 6-chloro-2-methylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide (synthesized according to the method described in section a) of example 20) in THF (5 ml) was added at −78° C. The mixture was then allowed to warm to 0° C. At this temperature 160 μl (1.69 mmol) acetanhydride was added and stirring was continued at RT for 4 h. After quenching with a sat. aq. NH4Cl sol the mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 13:7) provided 200 mg (0.57 mmol, 34%) 6-chloro-N-(3-fluorobenzyl)-4-methyl-2-(N-methylacetamido)-pyridine-3-carboxylic acid amide.
b) Synthesis of 2-(Acetyl-methyl-amino)-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
6-chloro-N-(3-fluorobenzyl)-4-methyl-2-(N-methylacetamido)-pyridine-3-carboxylic acid amide was converted into 2-(Acetyl-methyl-amino)-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 341), [M+H]+ 401.2, according to the method described for example 258.
Synthesis of Example 346
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-(methoxymethyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 4-(bromomethyl)-2,6-dichloro-pyridine-3-carboxylic acid methylester
To a solution of 5.3 g (24.1 mmol) 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid methylester in CCl4 (92 ml) were added 3.1 g (26.5 mmol) N-Bromosuccinimide, 395 mg (2.4 mmol) AIBN and 1.45 ml (25.3 mmol) acetic acid. The mixture was irradiated with a 200 W Wolfram lamp at 60° C. for 24 h. Subsequently the mixture was filtered through celite and the filtrate was concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 97:3) provided 5.2 g of a mixture of 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid methylester and 4-(bromomethyl)-2,6-dichloro-pyridine-3-carboxylic acid methylester which was used in subsequent reactions without further purification.
b) Synthesis of 2,6-dichloro-4-(methoxymethyl)-pyridine-3-carboxylic acid methylester
320 mg Sodium was dissolved in MeOH (40 ml) at 0° C. followed by the addition of a solution of 5.2 g of the crude mixture from section a) in MeOH (30 ml) at 0° C. The reaction solution was stirred at RT for 2 h and was then poured into water. This mixture was extracted with EtOAc and the organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 97:3) provided 830 mg (11.9 mmol, 10% over 2 steps) 2,6-dichloro-4-(methoxymethyl)-pyridine-3-carboxylic acid methylester.
c) Synthesis of 2,6-dichloro-4-(methoxymethyl)-pyridine-3-carboxylic acid
To a solution of 630 mg (2.5 mmol) 2,6-dichloro-4-(methoxymethyl)-pyridine-3-carboxylic acid methylester in dioxane (16 ml) was added a aq. 1M NaOH sol. and the reaction solution was heated to 100° C. for 4 h. The mixture was then diluted with water and washed with EtOAc. The aqueous layer was acidified with 2M HCl to pH 3 to 4 and was extracted with DCM. The organic layer was dried over Na2SO4 and concentrated in vacuo. The obtained 520 mg (2.4 mmol, 94%) 2,6-dichloro-4-(methoxymethyl)-pyridine-3-carboxylic acid was used in subsequent reactions without further purification.
d) Synthesis of 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-(methoxymethyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
2,6-dichloro-4-(methoxymethyl)-pyridine-3-carboxylic acid was converted into 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-(methoxymethyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 346), [M+H]+ 420.2, according to the method described for example 2.
Synthesis of Example 354
N-(4,4-Dimethyl-pentyl)-2-(3-methoxy-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid methylester  
To a solution of 5.0 g (24.3 mmol) 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid in DMF (73 ml) were added 5.0 g (36.4 mmol) K2CO3 and 7.6 ml (121.3 mmol) iodomethane at 0° C. The reaction mixture was stirred at RT for 3 h and was subsequently poured into water. This mixture was extracted with EtOAc and the organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 19:1) provided 5.2 g (23.7 mmol, 98%) 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid methylester.
b) Synthesis of 2-chloro-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester
A solution of 5.2 g (23.7 mmol) 2,6-dichloro-4-methyl-pyridine-3-carboxylic acid methylester, 3.94 g (28.5 mmol) K2CO3 and 2.06 ml (23.7 mmol) morpholine in DMF (48 ml) was heated to 60° C. for 16 h. Then the mixture was poured into water and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 4:1) provided 1.95 g (7.2 mmol, 30%) 2-chloro-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester.
c) Synthesis of 2-(3-methoxyprop-1-ynyl)-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester
To a solution of 700 mg (2.6 mmol) 2-chloro-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester and 1.39 g (3.9 mmol) tributyl(3-methoxyprop-1-ynyl)stannane in dioxane (10 ml) was added 273 mg (0.39 mmol) PdCl2(PPh3)2. Then the reaction solution was heated at 100° C. for 16 h. After cooling to RT the mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was dissolved in EtOAc and washed with water. The organic layer was dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (5% KF-silica, hexane/EtOAc 19:1) provided 500 mg (1.64 mmol, 63%) 2-(3-methoxyprop-1-ynyl)-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester.
d) Synthesis of 2-(3-methoxypropyl)-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester
To a solution of 500 mg (1.64 mmol) 2-(3-methoxyprop-1-ynyl)-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester in MeOH (30 ml) was added 170 mg 10%-Pd/C. The reaction solution was stirred under hydrogen atmosphere (balloon) at RT for 16 h. Then the mixture was filtered through celite and the filtrate was concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 9:1) provided 480 mg (1.55 mmol, 95%) 2-(3-methoxypropyl)-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester.
e) Synthesis of N-(4,4-Dimethyl-pentyl)-2-(3-methoxy-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
2-(3-methoxypropyl)-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester was converted into N-(4,4-Dimethyl-pentyl)-2-(3-methoxy-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 354), [M+H]+ 392.3, according to the methods described in sections c) and d) of example 11.
Synthesis of Example 355
2-Cyclopropyl-N-[[3-fluoro-4-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 2-cyclopropyl-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester
To a solution of 1.0 g (3.69 mmol) 2-chloro-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester (synthesis is described in section b) of example 354) in toluene (20 ml) were added 634 mg (7.38 mmol) cyclopropyl boronic acid, 2.74 g (12.9 mmol) K3PO4, 104 mg (0.37 mmol) tri-cyclohexyl-phosphine and water (1 ml). After degassing for 30 min 82 mg (0.37 mmol) Pd(OAc)2 were added and the reaction solution was heated at 120° C. for 16 h. The mixture was then poured into water and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 17:3) provided 500 mg (1.84 mmol, 80%) 2-cyclopropyl-4-methyl-6-morpholino-pyridine-3-carboxylic acid methylester
b) Synthesis of 2-Cyclopropyl-N-[[3-fluoro-4-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
2-Cyclopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid methylester was converted into 2-Cyclopropyl-N-[[3-fluoro-4-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 355), [M+H]+ 414.2, according to the methods described in sections c) and d) of example 11.
Synthesis of Example 356
N-[(3-Fluorophenyl)-methyl]-2-(methoxymethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide  




a) Synthesis of 2-(methoxymethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid methylester
To a solution of 710 mg, (3.6 mmol) 6-chloro-2,4-dimethyl-pyridine-3-carboxylic acid methylester in CCl4 (16 ml) were added 688 mg (3.90 mmol) N-bromosuccinimide, 59 mg (0.36 mmol) AIBN and 210 μl (3.72 mmol) acetic acid. The reaction mixture was irradiated with a 200 W Wolfram lamp at 60° C. for 24 h. The mixture was then filtered through celite, washed with CCl4 and concentrated in vacuo. After CC (hexane/EtOAc 97:3) of the residue a mixture of 6-chloro-2,4-dimethyl-pyridine-3-carboxylic acid methylester, 4-(bromomethyl)-6-chloro-2-methyl-pyridine-3-carboxylic acid methylester and 2-(bromomethyl)-6-chloro-4-methyl-pyridine-3-carboxylic acid methylester was obtained. This mixture was dissolved in dioxane (10 ml) and added at 0° C. to a solution prepared by dissolving 594 mg (25.8 mmol) sodium in MeOH (11 ml) at 0° C. This reaction mixture was stirred at RT for 3 h. Then the reaction solution was poured into water and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. After CC (hexane/EtOAc 97:3) of the residue again a mixture of 6-chloro-4-(methoxymethyl)-2-methyl-pyridine-3-carboxylic acid methylester and 6-chloro-2-(methoxymethyl)-4-methyl-pyridine-3-carboxylic acid methylester was obtained. This material was dissolved in NMP (7.8 ml) and 860 μl (9.85 mmol) morpholine and 1.36 g (9.85 mmol) K2CO3 were added followed by heating at 100° C. for 5 h. Then the mixture was poured into water and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 9:1) provided 90 mg (0.32 mmol, 9%) 2-(methoxymethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid methylester.
b) Synthesis of N-[(3-Fluorophenyl)-methyl]-2-(methoxymethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
2-(methoxymethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid methylester was converted into N-[(3-Fluorophenyl)-methyl]-2-(methoxymethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 356), [M+H]+ 373.2, according to the methods described in sections c) and d) of example 11.
Synthesis of Example 357
N-[(4-Chlorophenyl)-methyl]-2,4-diisopropyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide  




a) Synthesis of 2,4-diisopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid ethylester
To a solution of 20.0 g, (126.4 mmol) ethyl 4-methyl-3-oxopentanoate in methanol (100 ml) was added 48.72 g, (632.2 mmol) ammonium acetate. The reaction mixture was stirred at RT for 3 d. Then the mixture was concentrated in vacuo. The residue was taken up with DCM (300 ml) and filtered. The filtrate is water and brine, dried over Na2SO4 and concentrated in vacuo. This residue was dissolved in toluene (100 ml), followed by the addition of HCl (saturated solution in dioxane, 65 ml) at 0° C. The reaction mixture was heated at 120° C. for 20 h and subsequently filtered and the solid is washed with toluene. The filtrate was concentrated in vacuo. Purification of the residue by CC (hexane/EtOAc 3:2) provided 2.2 g (8.76 mmol, 7%) 2,4-diisopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid ethylester.
b) Synthesis of 6-chloro-2,4-diisopropyl-pyridine-3-carboxylic acid ethylester
A solution of 2.2 g (8.76 mmol) 2,4-diisopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid ethylester in POCl3 (43.8 ml) was stirred at 120° C. for 2 h. Then excess POCl3 was evaporated. The residue was dissolved in EtOAc (60 ml) and the solution was washed with a sat. NaHCO3 sol, water and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. Purification of this residue by CC (hexane/EtOAc 97:3) provided 2.0 g (7.43 mmol, 85%) 6-chloro-2,4-diisopropyl-pyridine-3-carboxylic acid ethylester.
c) Synthesis of N-[(4-Chlorophenyl)-methyl]-2,4-diisopropyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
6-chloro-2,4-diisopropyl-pyridine-3-carboxylic acid ethylester was converted into N-[(4-Chlorophenyl)-methyl]-2,4-diisopropyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 357), [M+H]+ 415.2, according to the methods described in sections b) of example 117 followed by the methods described in section c) and d) of example 11.
Synthesis of Example 358
N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




To a solution of 750 mg, (2.17 mmol) N-(4,4-dimethylpentyl)-4-methyl-6-morpholino-2-vinyl-pyridine-3-carboxylic acid amide (synthesized according to the methods described for example 9) in THF (10 ml) was added dropwise 730 μl (7.6 mmol) at 0° C. and the resulting mixture was stirred at RT for 16 h. The reaction mixture was cooled to 0° C. and a 1N aq. NaOH sol (4 ml) was added dropwise over a period of 0.5 h, followed by the addition of H2O2 (30% in water, 4 ml). Then the reaction mixture was stirred at RT for 4 h and was then extracted with EtOAc. The organic layer was dried over Na2SO4 and concentrated in vacuo. After CC (hexane/EtOAc 3:7) a mixture of N-(4,4-dimethylpentyl)-2-(2-hydroxyethyl)-4-methyl-6-morpholino-pyridine-3-carboxylic acid amide and N-(4,4-dimethylpentyl)-2-(1-hydroxyethyl)-4-methyl-6-morpholino-pyridine-3-carboxylic acid amide was obtained. This mixture was dissolved in THF (6 ml) and benzene (6 ml) and 24 mg, 0.0716 mmol) TBAHS was added at RT followed by the addition of a 25% aq. NaOH sol (6 ml) and 0.450 μl (7.16 mmol) iodomethane. Then the reaction mixture was slowly heated to 70° C. and stirred at the same temperature for 3 h. The additional 0.450 μl (7.16 mmol) iodomethane was added and stirring was continued at 70° C. for another 3 h. Then the organic layer was separated and the aq. layer was extracted with EtOAc. The combined organic layer was washed with water, and brine, dried over Na2SO4 and concentrated in vacuo. Purification of this residue by CC (hexane/EtOAc 3:2) provided 60 mg (0.16 mmol, 6%) N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 358). [M+H]+ 377.3
Synthesis of Example 359
N-[(4-Chlorophenyl)-methyl]-2,4-diethyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide




a) Synthesis of 6-chloro-2,4-diethyl-pyridine-3-carboxylic acid ethylester
To a solution of 2.73 g (14.12 mmol) 2,4-diethyl-pyridine-3-carboxylic acid ethylester in chloroform (109 ml) was added 6.97 g, (70% pure, 28.29 mmol) mCPBA at 0° C. The reaction mixture was stirred at RT for 6 h and was then diluted with chloroform and washed with a sat. NaHCO3 sol and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in POCl3 (70 ml) and the reaction mixture was heated at 110° C. for 6.5 h. Then excess POCl3 was evaporated and cold water was added to the residue. The mixture was basified with a sat. NaHCO3 sol to pH ̃10 and was extracted EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Purification of this residue by CC (hexane/EtOAc 9:1) provided 1.6 g (7.02 mmol, 20%) 6-chloro-2,4-diethyl-pyridine-3-carboxylic acid ethylester.
b) Synthesis of N-[(4-Chlorophenyl)-methyl]-2,4-diethyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide
6-chloro-2,4-diethyl-pyridine-3-carboxylic acid ethylester was converted into N-[(4-Chlorophenyl)-methyl]-2,4-diethyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 359), [M+H]+ 387.2, according to the methods described in sections b) of example 117 followed by the methods described in section c) and d) of example 11.
Synthesis of Further Examples
The synthesis of further examples was carried out according to the methods already described. Table 1 shows which compound was produced according to which method. It is evident to the person skilled in the art which educts and reagents were used in each case.










TABLE 1







Preparation





according to
MS m/z


Example
Chemical name
example
[M + H]+


















13
1-[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-
5
446.2



carbamoyl]-4-methyl-pyridin-2-yl]-piperidine-4-



carboxylic acid methyl ester


15
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
5
404.2



(4-hydroxy-piperidin-1-yl)-4-methyl-pyridine-3-



carboxylic acid amide


17
2-Ethylsulfanyl-N-[(4-fluoro-2-methoxy-
1
420.2



phenyl)-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


25
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
8
374.2



methyl-6-pyrrolidin-1-yl-pyridine-3-carboxylic



acid amide


26
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
8
436.2



methyl-6-(1,2,3,4-tetrahydro-isoquinolin-2-yl)-



pyridine-3-carboxylic acid amide


27
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
504.2



methyl-6-[6-(trifluoromethyl)-1,2,3,4-



tetrahydro-isoquinolin-2-yl]-pyridine-3-



carboxylic acid amide


28
(E)-N-(4-fluorobenzyl)-4-methyl-6-morpholino-
9
370.2



2-(prop-1-enyl)-pyridine-3-carboxylic acid



amide


29
N-[(4-Fluorophenyl)-methyl]-4-methyl-6-
10
372.2



morpholin-4-yl-2-propyl-pyridine-3-carboxylic



acid amide


30
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
6
404.2



(3-methoxy-pyrrolidin-1-yl)-4-methyl-pyridine-



3-carboxylic acid amide


31
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
4
403.2



methyl-6-(4-methyl-piperazin-1-yl)-pyridine-3-



carboxylic acid amide


32
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
4
388.2



methyl-6-piperidin-1-yl-pyridine-3-carboxylic



acid amide


33
6-Dimethylamino-2-ethylsulfanyl-N-[(3-
4
348.1



fluorophenyl)-methyl]-4-methyl-pyridine-3-



carboxylic acid amide


34
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
4
334.1



methyl-6-methylamino-pyridine-3-carboxylic



acid amide


35
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
4
392.2



(2-methoxy-ethyl-methyl-amino)-4-methyl-



pyridine-3-carboxylic acid amide


36
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
4
378.2



(2-methoxy-ethylamino)-4-methyl-pyridine-3-



carboxylic acid amide


37
N-[(3-Fluorophenyl)-methyl]-2-
2
404.2



(isopropylsulfanyl)-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


38
2-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-
19
374.2



6-morpholin-4-yl-pyridine-3-carboxylic acid



amide


39
N-[(4-Fluorophenyl)-methyl]-2-methoxy-4-
19
360.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


40
N-[(3-Fluorophenyl)-methyl]-4-methyl-2-
2
376.1



methylsulfanyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


41
N-[(3,4-Difluoro-phenyl)-methyl]-2-
1
408.1



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


42
2-Ethylsulfanyl-4-methyl-N-(3-methyl-butyl)-6-
1
352.2



morpholin-4-yl-pyridine-3-carboxylic acid



amide


43
N-(Cyclopentyl-methyl)-2-ethylsulfanyl-4-
1
364.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


44
N-(2-Cyclopentyl-ethyl)-2-ethylsulfanyl-4-
1
378.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


45
2-Ethylsulfanyl-N-[(6-fluoro-pyridin-2-yl)-
1
391.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


46
2-Ethylsulfanyl-N-[(5-fluoro-pyridin-2-yl)-
1
391.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


47
N-(2,2-Dimethyl-propyl)-2-ethylsulfanyl-4-
1
352.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


48
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
404.2



methyl-6-(2-methyl-morpholin-4-yl)-pyridine-3-



carboxylic acid amide


49
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
4
418.2



(4-methoxy-piperidin-1-yl)-4-methyl-pyridine-3-



carboxylic acid amide


50
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
448.2



[(2-phenyl-phenyl)-methyl]-pyridine-3-



carboxylic acid amide


51
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
440.2



[[2-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-



carboxylic acid amide


52
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
4
442.2



[(4-fluorophenyl)-methyl-methyl-amino]-4-



methyl-pyridine-3-carboxylic acid amide


53
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
400.2



(3-phenyl-propyl)-pyridine-3-carboxylic acid



amide


54
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
386.2



phenethyl-pyridine-3-carboxylic acid amide


55
N-Benzyl-2-ethylsulfanyl-4-methyl-6-
1
372.2



morpholin-4-yl-pyridine-3-carboxylic acid



amide


56
N-[(3-Fluorophenyl)-methyl]-4-methyl-6-
2
404.2



morpholin-4-yl-2-(propylsulfanyl)-pyridine-3-



carboxylic acid amide


57
2-(Butylsulfanyl)-N-[(3-fluorophenyl)-methyl]-4-
2
418.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


58
2-Ethylsulfanyl-5-fluoro-N-[(3-fluorophenyl)-
2
408.1



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


59
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
440.2



[[3-(trifluoromethyl)phenyl]-methyl]-pyridine-3-



carboxylic acid amide


60
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
440.2



[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-



carboxylic acid amide


61
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
432.2



methyl-6-[methyl-(tetrahydro-pyran-4-yl-



methyl)-amino]-pyridine-3-carboxylic acid



amide


62
N-[(3-Fluorophenyl)-methyl]-4-methyl-2-(2-
2
418.2



methyl-propylsulfanyl)-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


63
N-[(3-Fluorophenyl)-methyl]-2-(2-methoxy-
2
420.2



ethylsulfanyl)-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


64
2-Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-
19
374.2



6-morpholin-4-yl-pyridine-3-carboxylic acid



amide


65
2-Dimethylamino-N-[(3-fluorophenyl)-methyl]-
24
373.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


66
6-(2,6-Dimethyl-morpholin-4-yl)-2-
5
418.2



ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-



methyl-pyridine-3-carboxylic acid amide


67
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-
1
380.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


68
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
394.2



(2-tetrahydro-pyran-2-yl-ethyl)-pyridine-3-



carboxylic acid amide


69
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
380.2



(tetrahydro-pyran-2-yl-methyl)-pyridine-3-



carboxylic acid amide


70
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
402.2



methyl-6-(4-methyl-piperidin-1-yl)-pyridine-3-



carboxylic acid amide


71
2-Ethylsulfanyl-N-[[2-(4-fluorophenyl)-phenyl]-
1
466.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


72
2-[[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-
5
420.2



carbamoyl]-4-methyl-pyridin-2-yl]-methyl-



amino]-acetic acid ethyl ester


73
6-(4-Cyclopropyl-piperazin-1-yl)-2-
5
429.2



ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-



methyl-pyridine-3-carboxylic acid amide


74
6-(4,4-Dimethyl-piperidin-1-yl)-2-ethylsulfanyl-
5
416.2



N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-



3-carboxylic acid amide


75
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
472.1



[[4-(trifluoromethylsulfanyl)-phenyl]-methyl]-



pyridine-3-carboxylic acid amide


76
N-(Cyclohexyl-methyl)-2-ethylsulfanyl-4-
1
378.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


77
2-Ethylsulfanyl-N-(2-methoxy-ethyl)-4-methyl-
1
340.2



6-morpholin-4-yl-pyridine-3-carboxylic acid



amide


78
2-Ethylsulfanyl-N-(3-methoxy-propyl)-4-
1
354.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


79
2-Ethylsulfanyl-4-methyl-N-(4-methyl-pentyl)-
1
366.2



6-morpholin-4-yl-pyridine-3-carboxylic acid



amide


80
N-Butyl-2-ethylsulfanyl-4-methyl-6-morpholin-
1
338.2



4-yl-pyridine-3-carboxylic acid amide


81
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
352.2



pentyl-pyridine-3-carboxylic acid amide


82
2-Ethylsulfanyl-N-[[4-fluoro-3-(trifluoromethyl)-
1
458.1



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


83
N-(2-tert-Butoxy-ethyl)-2-ethylsulfanyl-4-
1
382.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


84
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
392.2



(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid



amide


85
2-Ethylsulfanyl-N-[[4-fluoro-2-(4-fluorophenyl)-
1
484.2



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


86
N-(4,4-Dimethyl-pentyl)-2-methoxy-4-methyl-
3
350.2



6-morpholin-4-yl-pyridine-3-carboxylic acid



amide


87
N-[(3,4-Difluoro-phenyl)-methyl]-2-methoxy-4-
3
378.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


88
2-Methoxy-4-methyl-6-morpholin-4-yl-N-[(2-
3
418.2



phenyl-phenyl)-methyl]-pyridine-3-carboxylic



acid amide


89
N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-
3
364.3



morpholin-4-yl-pyridine-3-carboxylic acid



amide


90
N-[(3,5-Difluoro-phenyl)-methyl]-2-ethoxy-4-
3
392.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


91
N-[(3,4-Difluoro-phenyl)-methyl]-2-ethoxy-4-
3
392.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


92
2-Ethoxy-4-methyl-6-morpholin-4-yl-N-[(2-
3
432.2



phenyl-phenyl)-methyl]-pyridine-3-carboxylic



acid amide


93
2-Ethylsulfanyl-N-[[3-fluoro-5-(trifluoromethyl)-
1
458.1



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


94
2-Ethylsulfanyl-N-[[2-fluoro-3-(trifluoromethyl)-
1
458.1



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


95
2-Ethylsulfanyl-N-[[2-fluoro-5-(trifluoromethyl)-
1
458.1



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


96
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
404.2



methyl-6-([1,4]oxazepane-4-yl)-pyridine-3-



carboxylic acid amide


97
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
456.1



[[4-(trifluoromethyloxy)-phenyl]-methyl]-



pyridine-3-carboxylic acid amide


98
N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-
5
374.2



methyl-6-([1,4]oxazepan-4-yl)-pyridine-3-



carboxylic acid amide


99
2-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-
5
388.2



6-([1,4]oxazepan-4-yl)-pyridine-3-carboxylic



acid amide


100
N-[(2,3-Difluoro-phenyl)-methyl]-2-
1
408.1



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


101
N-[(2,5-Difluoro-phenyl)-methyl]-2-
1
408.1



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


102
N-[(3-Cyano-phenyl)-methyl]-2-ethylsulfanyl-4-
1
397.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


103
2-Ethylsulfanyl-N-(2-isopropoxy-ethyl)-4-
1
368.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


104
N-(3,3-Dimethyl-butyl)-2-ethylsulfanyl-4-
1
366.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


105
N-(3-Cyclopentyl-propyl)-2-ethylsulfanyl-4-
1
392.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


106
N-(2-Cyclohexyl-ethyl)-2-ethylsulfanyl-4-
1
392.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


107
N-[(2,4-Difluoro-phenyl)-methyl]-2-
1
408.1



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


108
2-Ethylsulfanyl-N-[3-(4-fluorophenyl)-propyl]-4-
1
418.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


109
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
401.2



(3-pyridin-2-yl-propyl)-pyridine-3-carboxylic



acid amide


110
2-Butoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-
21
402.2



6-morpholin-4-yl-pyridine-3-carboxylic acid



amide


111
N-[(3-Fluorophenyl)-methyl]-4-methyl-6-
21
388.2



morpholin-4-yl-2-propoxy-pyridine-3-carboxylic



acid amide


112
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
16
374.1



methyl-6-(3-oxo-azetidin-1-yl)-pyridine-3-



carboxylic acid amide


113
2-Ethylsulfanyl-N-[3-(3-fluorophenyl)-propyl]-4-
1
418.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


114
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
401.2



(3-pyridin-3-yl-propyl)-pyridine-3-carboxylic



acid amide


115
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
401.2



(3-pyridin-4-yl-propyl)-pyridine-3-carboxylic



acid amide


116
N-(5,5-Dimethyl-hexyl)-2-ethylsulfanyl-4-
1
394.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


118
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
425.2



methyl-6-[methyl-(pyridin-4-yl-methyl)-amino]-



pyridine-3-carboxylic acid amide


119
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
425.2



methyl-6-[methyl-(pyridin-3-yl-methyl)-amino]-



pyridine-3-carboxylic acid amide


121
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
425.2



methyl-6-[methyl-(pyridin-2-yl-methyl)-amino]-



pyridine-3-carboxylic acid amide


122
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
411.2



methyl-6-(pyridin-3-yl-methylamino)-pyridine-



3-carboxylic acid amide


124
N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-
1
406.1



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


125
N-[(3-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-
1
406.1



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


126
6-[Bis(2-methoxy-ethyl)-amino]-2-
5
436.2



ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-



methyl-pyridine-3-carboxylic acid amide


127
2-(Ethyl-methyl-amino)-N-[(3-fluorophenyl)-
20
387.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


128
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
5
406.2



(3-methoxy-propyl-methyl-amino)-4-methyl-



pyridine-3-carboxylic acid amide


129
2-Ethylsulfanyl-N-[3-(2-fluorophenyl)-propyl]-4-
1
418.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


130
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
456.1



[[3-(trifluoromethyloxy)-phenyl]-methyl]-



pyridine-3-carboxylic acid amide


131
2-Ethylsulfanyl-N-[[3-(methoxymethyl)-phenyl]-
1
416.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


132
2-Ethoxy-4-methyl-6-morpholin-4-yl-N-[[4-
117
424.2



(trifluoromethyl)-phenyl]-methyl]-pyridine-3-



carboxylic acid amide


133
2-Ethoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-
117
376.2



trifluoro-butyl)-pyridine-3-carboxylic acid



amide


134
N-(1,3-Benzodioxol-5-yl-methyl)-2-
1
416.2



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


135
2-Ethylsulfanyl-N-[[2-fluoro-4-(trifluoromethyl)-
1
458.1



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


136
6-(Azepan-1-yl)-2-ethylsulfanyl-N-[(3-
5
402.2



fluorophenyl)-methyl]-4-methyl-pyridine-3-



carboxylic acid amide


137
2-Ethylsulfanyl-N-[(4-methoxyphenyl)-methyl]-
1
402.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


140
2-Methoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-
117
362.2



trifluoro-butyl)-pyridine-3-carboxylic acid



amide


141
N-(3-Cyclopropyl-propyl)-2-ethylsulfanyl-4-
1
364.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


142
2-Ethylsulfanyl-N-[[3-fluoro-4-(trifluoromethyl)-
1
458.1



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


143
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
258
403.2



methyl-6-(3-oxo-piperazin-1-yl)-pyridine-3-



carboxylic acid amide


144
6-(4-Acetyl-piperazin-1-yl)-2-ethylsulfanyl-N-
258
431.2



[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-



carboxylic acid amide


145
N-[(4-Cyano-phenyl)-methyl]-2-ethylsulfanyl-4-
1
397.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


146
2-Ethylsulfanyl-N-[[4-(methoxymethyl)-phenyl]-
1
416.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


147
2-Ethylsulfanyl-N-[[3-fluoro-4-
1
434.2



(methoxymethyl)-phenyl]-methyl]-4-methyl-6-



morpholin-4-yl-pyridine-3-carboxylic acid



amide


148
N-[(4-Dimethylaminophenyl)-methyl]-2-
1
415.2



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


149
2-Ethylsulfanyl-N-[[4-fluoro-3-
1
434.2



(methoxymethyl)-phenyl]-methyl]-4-methyl-6-



morpholin-4-yl-pyridine-3-carboxylic acid



amide


150
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
417.2



methyl-6-(4-methyl-3-oxo-piperazin-1-yl)-



pyridine-3-carboxylic acid amide


151
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
402.2



methyl-6-(6-oxa-2-azaspiro[3.3]heptan-2-yl)-



pyridine-3-carboxylic acid amide


152
N-(4,4-Dimethyl-pentyl)-4-methyl-2-
1
366.2



methylsulfanyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


153
4-Methyl-2-methylsulfanyl-6-morpholin-4-yl-N-
1
378.1



(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid



amide


155
N-[(3,4-Difluoro-phenyl)-methyl]-4-methyl-2-
154
394.1



methylsulfanyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


156
N-[(3,5-Difluoro-phenyl)-methyl]-4-methyl-2-
154
394.1



methylsulfanyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


157
4-Methyl-2-methylsulfanyl-6-morpholin-4-yl-N-
154
426.1



[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-



carboxylic acid amide


158
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
443.2



methyl-6-(6-oxo-2,3,4,7,8,8a-hexahydro-1H-



pyrrolo[1,2-a]pyrazin-2-yl)-pyridine-3-



carboxylic acid amide


159
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
402.2



methyl-6-(3-oxa-6-azabicyclo[2.2.1]heptan-6-



yl)-pyridine-3-carboxylic acid amide


160
N-(3-Cyano-propyl)-2-ethylsulfanyl-4-methyl-6-
1
349.2



morpholin-4-yl-pyridine-3-carboxylic acid



amide


161
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
386.2



(p-tolyl-methyl)-pyridine-3-carboxylic acid



amide


162
2-Ethylsulfanyl-4-methyl-N-(3-methylsulfonyl-
1
402.1



propyl)-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


163
N-(4-Cyano-butyl)-2-ethylsulfanyl-4-methyl-6-
1
363.2



morpholin-4-yl-pyridine-3-carboxylic acid



amide


164
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
386.2



(m-tolyl-methyl)-pyridine-3-carboxylic acid



amide


165
N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-
117
376.1



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


166
N-[(4-Chlorophenyl)-methyl]-2-ethoxy-4-
117
390.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


167
6-(2-Ethyl-morpholin-4-yl)-2-ethylsulfanyl-N-
5
418.2



[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-



carboxylic acid amide


168
N-[(4-Chlorophenyl)-methyl]-4-methyl-2-
154
392.1



methylsulfanyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


170
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
411.2



methyl-6-(methyl-pyridin-2-yl-amino)-pyridine-



3-carboxylic acid amide


173
2-(Ethyl-methyl-amino)-N-[(4-fluorophenyl)-
172
401.2



methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-



4-yl]-pyridine-3-carboxylic acid amide


175
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
432.2



methyl-6-[methyl-(tetrahydro-pyran-3-yl-



methyl)-amino]-pyridine-3-carboxylic acid



amide


177
2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-
176
404.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


178
6-(3-Ethyl-morpholin-4-yl)-2-ethylsulfanyl-N-
258
418.2



[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-



carboxylic acid amide


179
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
258
434.2



[(3R)-3-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


180
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
258
434.2



[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


181
N-[(4-Fluorophenyl)-methyl]-2-methoxy-4-
176
374.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


182
2-Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-
176
388.2



6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-



carboxylic acid amide


183
2-Dimethylamino-N-(4,4-dimethyl-pentyl)-4-
172
377.3



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


184
N-(4,4-Dimethyl-pentyl)-2-(ethyl-methyl-
172
391.3



amino)-4-methyl-6-[(3R)-3-methyl-morpholin-



4-yl]-pyridine-3-carboxylic acid amide


185
N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl-
169
376.3



6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-



carboxylic acid amide


186
N-(4,4-Dimethyl-pentyl)-2-methoxy-4-methyl-
176
364.3



6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-



carboxylic acid amide


187
N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-
176
378.3



[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-



carboxylic acid amide


188
2-(Ethyl-methyl-amino)-4-methyl-6-morpholin-
174
437.2



4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-



pyridine-3-carboxylic acid amide


189
N-(4,4-Dimethyl-pentyl)-2-(ethyl-methyl-
174
377.3



amino)-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


190
2-(Ethyl-methyl-amino)-4-methyl-6-morpholin-
174
389.2



4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-



carboxylic acid amide


191
N-[(4-Chlorophenyl)-methyl]-2-(ethyl-methyl-
174
403.2



amino)-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


192
N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-
176
380.2



methyl-morpholin-4-yl]-2-methylsulfanyl-



pyridine-3-carboxylic acid amide


193
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-
176
394.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


194
N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-
169
400.2



3-methyl-morpholin-4-yl]-2-(1-methyl-propyl)-



pyridine-3-carboxylic acid amide


195
N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-
169
390.3



methyl-morpholin-4-yl]-2-(1-methyl-propyl)-



pyridine-3-carboxylic acid amide


196
2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-
169
384.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


197
N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-
169
386.2



3-methyl-morpholin-4-yl]-2-propyl-pyridine-3-



carboxylic acid amide


198
2-Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-
169
374.3



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


199
N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-
169
376.3



methyl-morpholin-4-yl]-2-propyl-pyridine-3-



carboxylic acid amide


200
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
171
411.2



methyl-6-(methyl-pyridin-4-yl-amino)-pyridine-



3-carboxylic acid amide


201
2-Ethylsulfanyl-N-[(4-fluoro-3-methyl-phenyl)-
1
404.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


202
2-Ethylsulfanyl-N-(2-hydroxy-3-phenyl-propyl)-
1
416.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


203
N-[(3,4-Difluoro-phenyl)-methyl]-2-(ethyl-
174
405.2



methyl-amino)-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


204
N-[(3,5-Difluoro-phenyl)-methyl]-2-(ethyl-
174
405.2



methyl-amino)-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


205
2-Dimethylamino-N-[(4-fluorophenyl)-methyl]-
174
373.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


206
N-[(3,4-Difluoro-phenyl)-methyl]-2-
174
391.2



dimethylamino-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


207
N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-
5
420.1



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


208
N-[(3,5-Dimethyl-phenyl)-methyl]-2-
1
400.2



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


209
2-Ethylsulfanyl-N-heptyl-4-methyl-6-
1
380.2



morpholin-4-yl-pyridine-3-carboxylic acid



amide


210
6-Dimethylamino-N-(4,4-dimethyl-pentyl)-2-
5
338.2



ethylsulfanyl-4-methyl-pyridine-3-carboxylic



acid amide


211
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-6-(2-
5
382.2



methoxy-ethyl-methyl-amino)-4-methyl-



pyridine-3-carboxylic acid amide


212
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-6-(3-
5
396.3



methoxy-propyl-methyl-amino)-4-methyl-



pyridine-3-carboxylic acid amide


213
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
258
432.2



methyl-6-(3-propyl-morpholin-4-yl)-pyridine-3-



carboxylic acid amide


215
N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-
214
390.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


216
N-[(3-Fluorophenyl)-methyl]-4-methyl-2-(1-
23
386.2



methyl-propyl)-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


217
2-Ethylsulfanyl-N-hexyl-4-methyl-6-morpholin-
1
366.2



4-yl-pyridine-3-carboxylic acid amide


218
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-
5
394.2



methyl-6-(methyl-tetrahydro-furan-3-yl-amino)-



pyridine-3-carboxylic acid amide


219
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-
5
394.2



methyl-6-(2-methyl-morpholin-4-yl)-pyridine-3-



carboxylic acid amide


220
2-tert-Butyl-N-(4,4-dimethyl-pentyl)-4-methyl-
23
376.3



6-morpholin-4-yl-pyridine-3-carboxylic acid



amide


221
N-(4,4-Dimethyl-pentyl)-4-methyl-2-(1-methyl-
23
376.3



propyl)-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


233
N-[(3,5-Difluoro-phenyl)-methyl]-2-
176
422.2



ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-



morpholin-4-yl]-pyridine-3-carboxylic acid



amide


234
N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-
176
392.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


235
2-Ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-
176
406.2



morpholin-4-yl]-N-(4,4,4-trifluoro-butyl)-



pyridine-3-carboxylic acid amide


236
2-Methoxy-4-methyl-6-[(3R)-3-methyl-
176
376.2



morpholin-4-yl]-N-(4,4,4-trifluoro-butyl)-



pyridine-3-carboxylic acid amide


237
2-Ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-
176
454.2



morpholin-4-yl]-N-[[4-(trifluoromethyl)-phenyl]-



methyl]-pyridine-3-carboxylic acid amide


238
2-Methoxy-4-methyl-6-[(3R)-3-methyl-
176
424.2



morpholin-4-yl]-N-[[4-(trifluoromethyl)-phenyl]-



methyl]-pyridine-3-carboxylic acid amide


239
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
5
404.2



[3-(methoxymethyl)-azetidin-1-yl]-4-methyl-



pyridine-3-carboxylic acid amide


240
6-(2,5-Dimethyl-morpholin-4-yl)-2-
258
418.2



ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-



methyl-pyridine-3-carboxylic acid amide


241
2-Dimethylamino-4-methyl-6-morpholin-4-yl-N-
174
423.2



[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-



carboxylic acid amide


242
N-[(3,5-Difluoro-phenyl)-methyl]-2-
174
391.2



dimethylamino-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


243
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
494.2



methyl-6-[2-(trifluoromethyl)-5,6,7,8-



tetrahydro-imidazo[1,2-a]pyrazin-7-yl]-



pyridine-3-carboxylic acid amide


244
N-[(4-Chlorophenyl)-methyl]-2-dimethylamino-
174
389.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


245
2-Dimethylamino-N-(4,4-dimethyl-pentyl)-4-
174
363.3



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


246
2-Dimethylamino-4-methyl-6-morpholin-4-yl-N-
174
375.2



(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid



amide


247
2-Ethylsulfanyl-4-methyl-N-[(4-methylsulfonyl-
1
450.1



phenyl)-methyl]-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


248
2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-6-
258
434.2



[(3R)-3-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


249
2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-6-
258
434.2



[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


250
2-tert-Butyl-N-[(3-fluorophenyl)-methyl]-4-
23
386.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


251
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
258
471.2



methyl-6-[4-(2,2,2-trifluoro-ethyl)-piperazin-1-



yl]-pyridine-3-carboxylic acid amide


252
6-(2,2-Dimethyl-morpholin-4-yl)-2-
258
418.2



ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-



methyl-pyridine-3-carboxylic acid amide


254
N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-
258
450.2



[(2R)-2-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


255
N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-
258
450.2



[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


256
N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-
258
450.2



[(3R)-3-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


257
N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-
258
450.2



[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


259
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
258
446.2



[(4-methoxy-cyclohexyl)-methyl-amino]-4-



methyl-pyridine-3-carboxylic acid amide


260
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
258
458.1



methyl-6-[2-(trifluoromethyl)-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


261
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
258
418.2



methyl-6-(methyl-tetrahydro-pyran-3-yl-



amino)-pyridine-3-carboxylic acid amide


262
6-(3,5-Dimethyl-morpholin-4-yl)-2-
258
418.2



ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-



methyl-pyridine-3-carboxylic acid amide


264
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
263
420.2



[(3R)-3-(hydroxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


265
N-[(4-Chlorophenyl)-methyl]-2-isopropyl-4-
169
402.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


266
N-[(4-Chlorophenyl)-methyl]-4-methyl-6-[(3R)-
169
402.2



3-methyl-morpholin-4-yl]-2-propyl-pyridine-3-



carboxylic acid amide


267
2-Ethylsulfanyl-N-(3-hydroxy-4,4-dimethyl-
1
396.2



pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


268
N-[(4-Cyano-3-fluoro-phenyl)-methyl]-2-
1
415.2



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


269
N-[(4-Chlorophenyl)-methyl]-2-(2-fluoro-
176
408.1



ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


270
N-[(4-Chlorophenyl)-methyl]-2-(2,2-difluoro-
176
426.1



ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


271
N-[(4-Chlorophenyl)-methyl]-2-(cyclopropyl-
176
416.2



methoxy)-4-methyl-6-morpholin-4-yl-pyridine-



3-carboxylic acid amide


272
2-(2,2-Difluoro-ethoxy)-N-[(4-fluorophenyl)-
176
410.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


273
N-[(4-Chlorophenyl)-methyl]-2-ethoxy-4-
176
404.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


274
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-
138
394.2



methyl-6-[(2S)-2-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


275
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-
139
394.2



methyl-6-[(2R)-2-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


276
2-(Cyclopropyl-methoxy)-N-[(4-fluorophenyl)-
176
400.2



methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


277
N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-
258
432.2



[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


278
N-(4,4-Dimethyl-pentyl)-4-methyl-2-(2-methyl-
23
390.3



butyl)-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


279
N-(4,4-Dimethyl-pentyl)-2-(1,1-dimethyl-
23
390.3



propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


280
N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-
258
408.3



methyl-6-(methyl-tetrahydro-pyran-3-yl-



amino)-pyridine-3-carboxylic acid amide


281
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
417.2



[(4-nitrophenyl)-methyl]-pyridine-3-carboxylic



acid amide


282
N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-
169
400.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


283
N-[(4-Chlorophenyl)-methyl]-2-(2-
176
433.2



dimethylaminoethyloxy)-4-methyl-6-morpholin-



4-yl-pyridine-3-carboxylic acid amide


284
2-Ethylsulfanyl-N-[(4-fluoro-3-methoxy-
1
420.2



phenyl)-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


286
2-Ethylsulfanyl-N-(3-hydroxy-4-methyl-pentyl)-
1
382.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


287
2-Ethylsulfanyl-N-[(3-fluoro-4-methoxy-
1
420.2



phenyl)-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


288
N-[[4-(Difluoro-methoxy)-phenyl]-methyl]-2-
1
438.2



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


289
N-(1,3-Dihydro-isobenzofuran-5-yl-methyl)-2-
1
414.2



ethylsulfanyl-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


290
N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-6-
285
430.2



[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


291
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
263
420.2



[(2S)-2-(hydroxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


292
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
263
420.2



[(2R)-2-(hydroxymethyl)-morpholin-4-yl]-4-



methyl-pyridine-3-carboxylic acid amide


294
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
5
418.2



methyl-6-[methyl-(tetrahydro-furan-2-yl-



methyl)-amino]-pyridine-3-carboxylic acid



amide


295
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
171
404.2



methyl-6-[(3R)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


296
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
171
404.2



methyl-6-[(3S)-3-methyl-morpholin-4-yl]-



pyridine-3-carboxylic acid amide


297
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
171
492.2



methyl-6-[methyl-[[4-(trifluoromethyl)-phenyl]-



methyl]-amino]-pyridine-3-carboxylic acid



amide


299
6-(Azetidin-1-yl)-2-ethylsulfanyl-N-[(3-
293
360.1



fluorophenyl)-methyl]-4-methyl-pyridine-3-



carboxylic acid amide


301
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
171
404.2



methyl-6-(methyl-tetrahydro-furan-3-yl-amino)-



pyridine-3-carboxylic acid amide


302
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
171
410.2



methyl-6-(N-methyl-anilino)-pyridine-3-



carboxylic acid amide


303
6-(2,3-Dihydro-1H-isoindol-2-yl)-2-
171
422.2



ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-



methyl-pyridine-3-carboxylic acid amide


304
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
171
436.2



methyl-6-(1,2,3,4-tetrahydro-quinolin-1-yl)-



pyridine-3-carboxylic acid amide


305
6-(2,3-Dihydro-1H-indol-1-yl)-2-ethylsulfanyl-
171
422.2



N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-



3-carboxylic acid amide


306
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
394.2



(2,4,4-trimethyl-pentyl)-pyridine-3-carboxylic



acid amide


308
N-(4,4-Difluoro-pentyl)-2-ethylsulfanyl-4-
1
388.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


309
N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-
23
372.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


310
N-[(3,4-Difluoro-phenyl)-methyl]-2-isopropyl-4-
23
390.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


311
2-Isopropyl-4-methyl-6-morpholin-4-yl-N-[[4-
23
422.2



(trifluoromethyl)-phenyl]-methyl]-pyridine-3-



carboxylic acid amide


313
N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-
23
362.3



4-yl-2-propyl-pyridine-3-carboxylic acid amide


314
N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl-
23
362.3



6-morpholin-4-yl-pyridine-3-carboxylic acid



amide


315
2-Isopropyl-4-methyl-6-morpholin-4-yl-N-
23
374.2



(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid



amide


316
N-[(3,5-Difluoro-phenyl)-methyl]-2-isopropyl-4-
23
390.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


318
2-Ethylsulfanyl-N-(4-methoxy-4-methyl-
1
396.2



pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


319
2-Ethylsulfanyl-N-(4-fluoro-4-methyl-pentyl)-4-
1
384.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


320
4-Methyl-6-morpholin-4-yl-2-propyl-N-(4,4,4-
23
374.2



trifluoro-butyl)-pyridine-3-carboxylic acid



amide


321
N-[(3,4-Difluoro-phenyl)-methyl]-4-methyl-6-
23
390.2



morpholin-4-yl-2-propyl-pyridine-3-carboxylic



acid amide


322
N-[(3,5-Difluoro-phenyl)-methyl]-4-methyl-6-
23
390.2



morpholin-4-yl-2-propyl-pyridine-3-carboxylic



acid amide


323
4-Methyl-6-morpholin-4-yl-2-propyl-N-[[4-
23
422.2



(trifluoromethyl)-phenyl]-methyl]-pyridine-3-



carboxylic acid amide


324
N-(4,4-Dimethyl-2-oxo-pentyl)-2-ethylsulfanyl-
1
394.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


325
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
258
416.2



methyl-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-



yl)-pyridine-3-carboxylic acid amide


326
N-[(4-Chlorophenyl)-methyl]-4-methyl-6-
23
388.2



morpholin-4-yl-2-propyl-pyridine-3-carboxylic



acid amide


327
N-[(4-Chlorophenyl)-methyl]-2-isopropyl-4-
23
388.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


328
2-Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-
355
360.3



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


329
2-Cyclopropyl-4-methyl-6-morpholin-4-yl-N-
355
372.2



(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid



amide


330
2-Cyclopropyl-N-[(3-fluorophenyl)-methyl]-4-
355
370.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


331
2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-
355
370.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


332
2-Cyclopropyl-N-[(3,4-difluoro-phenyl)-methyl]-
355
388.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


333
2-Cyclopropyl-N-[(3,5-difluoro-phenyl)-methyl]-
355
388.2



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


334
2-Cyclopropyl-4-methyl-6-morpholin-4-yl-N-[[4-
355
420.2



(trifluoromethyl)-phenyl]-methyl]-pyridine-3-



carboxylic acid amide


335
N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-
355
386.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


337
N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-
2
410.2



ethylsulfanyl)-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


338
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
258
500.2



[(4-fluorophenyl)-methyl-(3-methoxy-propyl)-



amino]-4-methyl-pyridine-3-carboxylic acid



amide


339
2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-
1
394.2



(3,4,4-trimethyl-pentyl)-pyridine-3-carboxylic



acid amide


340
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
258
448.2



[3-(2-methoxy-ethyl)-morpholin-4-yl]-4-methyl-



pyridine-3-carboxylic acid amide


342
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-
258
486.2



[(4-fluorophenyl)-methyl-(2-methoxy-ethyl)-



amino]-4-methyl-pyridine-3-carboxylic acid



amide


343
2-Ethylsulfanyl-4-methyl-N-[3-(3-methyl-
1
394.2



oxetan-3-yl)-propyl]-6-morpholin-4-yl-pyridine-



3-carboxylic acid amide


344
N-(4,4-Dimethyl-pent-2-ynyl)-2-ethylsulfanyl-4-
1
376.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


345
2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-
258
416.2



methyl-6-(3-oxa-8-azabicyclo[3.2.1]octan-8-



yl)-pyridine-3-carboxylic acid amide


347
N-[(4-Chlorophenyl)-methyl]-4-methyl-2-(1-
23
402.2



methyl-propyl)-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


348
N-(4,4-Dimethyl-hexyl)-2-ethylsulfanyl-4-
1
394.2



methyl-6-morpholin-4-yl-pyridine-3-carboxylic



acid amide


349
N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethoxy)-
176
394.3



4-methyl-6-morpholin-4-yl-pyridine-3-



carboxylic acid amide


350
2-Ethylsulfanyl-4-methyl-N-[3-(1-methyl-
1
378.2



cyclopropyl)-propyl]-6-morpholin-4-yl-pyridine-



3-carboxylic acid amide


351
2-Cyclopropyl-N-[[4-fluoro-3-(methoxymethyl)-
355
414.2



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


352
2-Ethylsulfanyl-N-[[4-fluoro-3-
1
448.2



(methoxymethyl)-phenyl]-methyl]-4-methyl-6-



[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-



carboxylic acid amide


353
2-Ethylsulfanyl-N-[[4-fluoro-3-(hydroxymethyl)-
1
420.2



phenyl]-methyl]-4-methyl-6-morpholin-4-yl-



pyridine-3-carboxylic acid amide


362
N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-
354
403.3



4-yl-2-tetrahydro-pyran-4-yl-pyridine-3-



carboxylic acid amide









Pharmacological Experiments
Method I
Fluorescence Assay Using a Voltage Sensitive Dye (Fluorimetry)
Human CHO-K1 cells expressing KCNQ2/3 channels are cultivated adherently at 37° C., 5% CO2 and 95% humidity in cell culture bottles (e.g. 80 cm2 TC flasks, Nunc) with DMEM-high glucose (Sigma Aldrich, D7777) including 10% FCS (PAN Biotech, e.g. 3302-P270521) or alternatively MEM Alpha Medium (1×, liquid, Invitrogen, #22571), 10% fetal calf serum (FCS) (Invitrogen, #10270-106, heat-inactivated) and the necessary selection antibiotics.
Before being sown out for the measurements, the cells are washed with 1×DPBS buffer Ca2+/Mg2+-free (e.g. Invitrogen, #14190-094) and detached from the bottom of the culture vessel by using Accutase (PAA Laboratories, #L11-007) (incubation with Accutase for 15 min at 37° C.). The cell number is determined using a CASYTM cell counter (TCC, Schärfe System). Depending on the optimal density for each individual cell line, 20,000-30,000 cells/well/100 μl are seeded onto 96-well CorningTM CellIBINDTM assay plates (Flat Clear Bottom Black Polystyrene Microplates, #3340). Freshly seeded cells are then left to settle for one hour at room temperature, followed by incubation for 24 hours at 37° C., 5% CO2 and 95% humidity.
The voltage-sensitive fluorescent dye from the Membrane Potential Assay Kit (RedTM Bulk format part R8123 for FLIPR, MDS Analytical TechnologiesTM) is prepared by dissolving the contents of one vessel Membrane Potential Assay Kit Red Component A in 200 ml of extracellular buffer (ES buffer, 120 mM NaCl, 1 mM KCl, 10 mM HEPES, 2 mM CaCl2, 2 mM MgCl2, 10 mM glucose; pH 7.4). After removal of the nutrient medium, the cells are washed once with 200 μl of ES buffer, then loaded for 45 min at room temperature in 100 μl of dye solution in the dark.
Fluorescence measurements are carried out in a BMG Labtech FLUOstarTM, BMG Labtech NOVOstarTM or BMG Labtech POLARstarTM instrument (525 nm excitation, 560 nm emission, Bottom Read mode). After incubation with the dye, 50 μl of the test substances in the desired concentrations, or 50 μl of ES buffer for control purposes, are applied to the wells of the assay plate and incubated for 30 min at room temperature while being shielded from light. The fluorescence intensity of the dye is then measured for 5 min and the fluorescence value F1 of each well is thus determined at a given, constant time. 15 μl of a KCl solution are then added to each well (final concentration of potassium ions 92 mM). The change in fluorescence intensity is subsequently monitored until all the relevant values have been obtained (mainly 5-30 min). At a given time post KCl application, a fluorescence value F2 is determined, in this case at the time of the fluorescence peak.
For calculation, the fluorescence intensity F2 is corrected for the fluorescence intensity F1, and the activity (ΔF/F) of the target compound on the potassium channel is determined as follows:




  
    
      (
      
        
          
            F
            2
          
          -
          
            F
            1
          
        
        
          F
          1
        
      
      )
    
    ×
    100
  
  =
  
    
      
        Δ
        ⁢
        
          
        
        ⁢
        F
      
      F
    
    ⁢
    
      (
      %
      )
    
  




In order to determine whether a substance has agonistic activity,




  
    Δ
    ⁢
    
      
    
    ⁢
    F
  
  F




can be related to





  
    (
    
      
        Δ
        ⁢
        
          
        
        ⁢
        F
      
      F
    
    )
  
  K




of control wells.





  
    (
    
      
        Δ
        ⁢
        
          
        
        ⁢
        F
      
      F
    
    )
  
  K




is determined by adding to the well only the buffer solution instead of the test substance, determining the value F1K of the fluorescence intensity, adding the potassium ions as described above, and measuring a value F2K of the fluorescence intensity. F2K and F1K are then calculated as follows:





  
    
      (
      
        
          
            F
            
              2
              ⁢
              K
            
          
          -
          
            F
            
              1
              ⁢
              K
            
          
        
        
          F
          
            1
            ⁢
            K
          
        
      
      )
    
    ×
    100
  
  =
  
    
      
        (
        
          
            Δ
            ⁢
            
              
            
            ⁢
            F
          
          F
        
        )
      
      K
    
    ⁢
    
      (
      %
      )
    
  




A substance has an agonistic activity on the potassium channel if




  
    Δ
    ⁢
    
      
    
    ⁢
    F
  
  F




is greater than





  
    
      
        
          (
          
            
              Δ
              ⁢
              
                
              
              ⁢
              F
            
            F
          
          )
        
        K
      
      :
      
        

      
      ⁢
      
        
          Δ
          ⁢
          
            
          
          ⁢
          F
        
        F
      
    
    〉
  
  ⁢
  
    
      (
      
        
          Δ
          ⁢
          
            
          
          ⁢
          F
        
        F
      
      )
    
    K
  




Independently of the comparison of




  
    Δ
    ⁢
    
      
    
    ⁢
    F
  
  F




with





  
    (
    
      
        Δ
        ⁢
        
          
        
        ⁢
        F
      
      F
    
    )
  
  K




it is possible to conclude that a target compound has agonistic activity if





  
    Δ
    ⁢
    
      
    
    ⁢
    F
  
  F




increases dose dependently.

Calculations of EC50 and IC50 values are carried out with the aid of ‘Prism v4.0’ software (GraphPad SoftwareTM).
Method II
Low-Intensity Tail Flick Test (Rat)
In the low-intensity tail flick test, the determination of the antinociceptive effect of the compounds according to the invention towards an acute noxious thermal stimulus is carried out by measuring the withdrawal reflex of the rat tail (tail flick) in response to a radiant heat beam (analgesia meter; model 2011 of the company Rhema Labortechnik, Hofheim, Germany) according to the method described by D'Amour and Smith (J. Pharm. Exp. Ther. 72, 74 79 (1941). To this end, the rats were placed in a plexiglas restrainer, and a low-intensity radiant heat beam (48° C.) was focused onto the dorsal surface of the tail root. The stimulus intensity was adjusted to result in a mean pre-drug control withdrawal latency of about 7 s, thus also allowing a supraspinal modulation of the spinally mediated acute nociceptive reflex. A cutoff time of 30 s was applied to avoid tissue damage. Male Sprague-Dawley rats (Janvier, Le Genest St. Isle, Frankreich) with weights of 200-250 g were used. 10 rats were used per group. Before administration of a compound according to the invention, the animals were pre-tested twice in the course of five minutes and the mean of these measurements was calculated as the pre-test mean. The antinociceptive effect was determined at 20, 40 and 60 min after peroral compound administration. The antinociceptive effect was calculated based on the increase in the tail withdrawal latency according to the following formula and is expressed as percentage of the maximum possible effect (MPE [%]):

MPE=[(T1−T0)/(T2−T0)]*100

In this, T0 is the control latency time before and T1 the latency time after administration of the compound, T2 is the cutoff time and MPE is the maximum possible effect. Employing variant analysis (repeated measures ANOVA) allowed testing of statistically significant differences between the compounds according to the invention and the vehicle group. The significance level was set to p≦0.05. To determine the dose dependency, the particular compound according to the invention was administered in 3-5 logarithmically increasing doses, including a threshold dose and a maximum effective dose, and the ED50 values were determined with the aid of regression analysis. The ED50 calculation was performed at the time of maximum efficacy (usually 20 min after administration of the compounds).
Pharmacological Data
The pharmacological effects of the compounds according to the invention were determined as described hereinbefore (pharmacological experiments, methods I and II respectively).
The corresponding pharmacological data are summarized in Table 2.










TABLE 2






Fluorimetry





% efficacy

Low intensity tail flick,



(retigabine =
Fluorimetry
rat, peroral, ED50 or


Example
100%)
EC50/IC50 [nM]
MPE (dose) [mg/kg]


















1
160
56
  78 (4.64)


2
171
134
4.3


3
132
233


4
158
124
94 (10)


5
111
269


6
140
3875


7
44


8
71
442


9
174
740


10
176
181
81 (10)


11
41
175


12
210
2010


13
145
1094


14
16


15
93
7063


16
149
2521


17
21


18
224
98


19
155
736
79 (10)


20
140
782


21
146
1221


22
166
790


23
182
113


24
210
308


25
162
211


26
155
132


27
132
151


29
185
236


30
144
1315


31
23


32
166
132


33
110
639


34
37
1832


35
153
635


36
125
6001


37
148
99


38
144
219
61 (10)


39
143
645


40
168
587
84 (10)


41
169
69
  92 (6.81)


42
169
571


43
189
679


44
116
87


45
151
3136


46
143
4834


47
119
2607


48
145
217


49
143
1463


50
−97
63


51
−84
541


52
122
235


53
191
248


54
103
2123


55
162
260


56
167
77


57
169
47


58
173
2286


59
128
70


60
128
126


61
110
528


62
164
47


63
157
585


64
137
216


65
238
1058


66
109
983


67
244
42
100 (10) 


68
134
7371


69
160
4479


70
175
163


71
−102
275


72
93
2085


73
67
3008


74
70
702


75
135
61


76
179
91


77
40


78
31


79
215
206
46 (10)


80
147
2168


81
163
662


82
117
118


83
182
2804


84
203
357


85
−61
107


86
236
172


87
138
311


88
−83
253


89
268
138


90
134
122


91
127
117


92
−79
128


93
103
54


94
111
39


95
62
56


96
173
1098


97
136
67


98
146
2310


99
134
899


100
98
118


101
100
133


102
138
1223


103
142
4522


104
100
1401


105
207
179


106
160
172


107
90
88


108
203
317


109
53


110
163
71


111
153
109


112
130
2742


113
192
212


114
126
9381


115
96
7972


116
210
131


117
128
268


118
3


119
91
2422


120
10


121
35


122
68
8894


123
67


124
149
82


125
152
87


126
145
2093


127
238
385


128
142
785


129
206
221


130
148
74


131
137
1247


132
122
110


133
235
392


134
159
1137


135
43
54


136
171
108


137
151
1066


138
125
170


139
146
770


140
227
1121


141
167
242


142
125
38


143
28


144
59


145
145
673


146
159
2493


147
153
530


148
105
3624


149
136
451


150
98
9647


151
92
12116


152
249
63


153
210
676


154
154
394


155
158
152


156
167
157


157
127
166


158
60


159
149
1258


160
70


161
143
366


162
21


163
73


164
122
237


165
135
230


166
134
117


167
137
113


168
149
132


169
197
24


170
84
1238


171
62
1944


172
246
378


173
259
201


174
221
422


175
114
870


176
215
136


177
174
97


178
147
54


179
190
243


180
123
86


181
167
255


182
146
125


183
221
168


184
228
221


185
238
15


186
240
63


187
242
49


188
154
343


189
225
284


190
207
2504


191
214
265


192
236
46


193
246
29


194
189
31


195
242
13


196
197
103


197
211
142


198
246
19


199
232
50


200
22


201
127
135


202
129
5986


203
220
219


204
239
141


205
205
898


206
207
402


207
183
69


208
61
281


209
192
234


210
223
187


211
225
143


212
200
152


213
131
49


214
194
224


215
191
147


216
181
69


217
181
407


218
194
272


219
212
91


220
166
682


221
259
22


222
56
7306


223
137
3662


224
136
693


225
173
71


226
186
129


227
165
4193


228
180
2451


229
132
719


230
131
12909


231
61
10432


232
131
112


233
196
70


234
195
124


235
235
196


236
227
469


237
148
56


238
164
102


239
125
1820


240
174
394


241
160
558


242
214
366


243
105
1284


245
225
345


246
173
4103


247
38


248
223
313


249
129
82


250
196
371


251
97
1591


252
137
274


253
79
5737


254
113
943


255
121
169


256
221
101


257
125
23


258
170
301


259
133
298


260
127
149


261
96
786


262
182
374


263
114
4142


264
184
1562


265
206
28


266
210
57


267
223
247


268
142
286


269
119
147


270
97
24


271
128
93


272
96
78


273
163
137


274
217
234


275
208
63


276
102
143


277
129
17


278
225
36


279
172
430


280
165
302


281
109
311


282
182
40


283
22


284
94
648


285
126
157


286
198
1754


287
153
971


288
138
435


289
129
2816


290
136
314


291
53
7952


292
32


293
125
488


294
129
1034


295
188
50


296
222
189


297
125
177


298
127
4585


299
104
920


301
132
767


302
93
278


303
54
1148


304
81
348


305
57


306
33


307
104
178


308
249
397


309
168
71


310
174
43


311
146
45


312
135
6699


313
229
62


314
242
18


315
187
314


316
160
29


317
116
1123


318
193
2880


319
233
348


320
192
826


321
162
83


322
193
80


323
130
102


324
166
834


325
153
282


326
163
59


327
173
50


328
230
44


329
170
763


330
156
168


331
144
148


332
166
109


333
169
98


334
124
96


335
162
85


336
183
430


337
237
117


338
73
320


339
202
37


340
152
274


341
22


342
124
291


343
163
6843


344
253
41


345
200
122


346
157
729


347
156
41


348
228
22


349
216
284


350
226
79


351
118
489


352
166
287


353
46


354
204
1535


355
167
721


356
140
6322


357
17


358
234
1126


359
141
237

## Claims

1. A substituted compound of formula:



wherein
R1 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
R2 represents F; Cl; Br; I; CN; CF3; C(═O)H; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a C(═O)—C1-4 aliphatic residue, a C(═O)—O—C1-4 aliphatic residue, a C(═O)—NH—C1-4 aliphatic residue, a C(═O)—N(C1-4 aliphatic residue)2, wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, a S—C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, a S—C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
R6 represents a C2-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
or
denotes, O—R8,
wherein
R8 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;
on the condition that if R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,


in which an “aliphatic group” and an “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated,
in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated,
in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2;
in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a NH—C(═O)—C1-4 aliphatic residue, a NH—S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, CHO, COOH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2;
in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2,





an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, an NH—C(═O)—C1-4 aliphatic residue, an NH—S(═O)2—C1-4 aliphatic residue, OH, OCF3, a O—C1-4-aliphatic residue, a O—C(═O)—C1-4-aliphatic residue, SH, SCF3, a S—C1-4-aliphatic residue, S(═O)2OH, a S(═O)2—C1-4-aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF3, C(═O)H, C(═O)OH, a C1-4-aliphatic residue, a C(═O)—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH2, a C(═O)—NH(C1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2;
said compound being in the form of a free compound, the racemate, a mixture of enantiomers, diastereomers, or of enantiomers and diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of a salt of physiologically acceptable acids or bases.

2. The compound according to claim 1, wherein
R1 denotes a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, a S(═O)2—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,

or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,

and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH)C1-4 aliphatic residue), an N(C1-4 aliphatic residue, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a S(═O)2—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,




 benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, O—CH2—OH, O—CH2—O—CH3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent sleeted from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN and C(═O)—OH,
R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a S—C1-4-aliphatic residue, or a O—C1-4-aliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C1-4-aliphatic residue and an O—C1-4-aliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue, and wherein the C3-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue,
R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, a S—C1-4-aliphatic residue,
wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue;

a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C1-4-aliphatic residue and a O—C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue,

and wherein the C3-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue,
R6 denotes a C2-10-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,

or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, and C(═O)—OH,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and

and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,
or
R6 denotes O—R8,
wherein
R8 represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue,

or represent a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,

and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
on the condition that if R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue.

3. The compound according to claim 1, wherein
R1 represents the partial structure (T1)




wherein
m denotes 0, 1, 2, 3 or 4,
R12a and R12b each independently of one another represent H, F, Cl, Br, I, NO2, NH2, a NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4 aliphatic residue or C(═O)—OH, or together denote ═O, and
R12c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a S(═O)2—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,
or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH,

or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a S(═O)2—C1-4 aliphatic residue, CF3, CN, a C1-4 aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,






 benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and
wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, and
wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH.

4. The compound according to claim 1, wherein
R1 represents the partial structure (T1),




wherein
m denotes 0, 1, or 2 or 3,
R12a and R12b each independently of one another represent H, F, Cl, Br, I, OH, an O—C1-4 aliphatic residue or a C1-4 aliphatic residue or together denote ═O, and

R12c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, CN, a S(═O)2—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF3 and an unsubstituted O—C1-4-aliphatic residue,

or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
wherein the C1-4 aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF3 and an unsubstituted O—C1-4-aliphatic residue,

or an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, OCF2H, CF3, CN, a C1-4-aliphatic residue, CH2—OH, CH2—OCH3, S(═O)2—CH3, SCF3, NO2, N(C1-4 aliphatic residue)2,




 C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,
wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5, preferably with at least one substituent selected from the group consisting of F, Cl, CH3, O—CH3, CF3 and OCF3, and
wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, CF3 a C1-4-aliphatic residue and C(═O)—OH.

5. The compound according to claim 1, wherein
R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a S—C1-4-aliphatic residue, or a O—C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue,
and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an unsubstituted C1-4-aliphatic residue and an unsubstituted O—C1-4-aliphatic residue.

6. The compound according to claim 1, wherein
R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, or a S—C1-4-aliphatic residue,
wherein the C1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4 aliphatic residue.

7. The compound according to claim 1, wherein
R6 denotes a C2-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,

or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a C(═O)—O—C1-4-aliphatic residue, a S—C1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and

and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
or
R6 denotes O—R8 
wherein
R8 denotes a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, CF3, a C(═O)—O—C1-4-aliphatic residue, and a C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4-aliphatic residue,

or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and

wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may be bridged via a C1-8 aliphatic group, preferably a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, and a C1-4-aliphatic residue,
on the condition that if R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

8. The compound according to claim 1, wherein
R6 denotes a C2-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S aliphatic residue, CF3, and a C1-4-aliphatic residue
wherein the C1-4-aliphatic residue in each case is unsubstituted,

or denotes a C3-10-cycloaliphatic residue, or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted O—C1-4-aliphatic residue,

and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted C1-4 aliphatic group,
on the condition that if R6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,
or
R6 denotes O—R8 
wherein
R8 denotes a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF3 and an unsubstituted O—C1-4 aliphatic residue,

or in each case denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SCF3, a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue,
wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and

wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged via an unsubstituted C1-8 aliphatic group,
on the condition that if R7 or R8 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

9. The compound according to claim 1, wherein
R1 represents the partial structure (T1),





wherein
m is 0, 1 or 2, and
R12a and R12b each independently of one another represent H, F, OH, CH3 or OCH3, or together denote ═O,
R12c denotes a C1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, S(═O)2—CH3, an unsubstituted O—C1-4 aliphatic residue, and CF3,
or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4-aliphatic residue,

or
wherein
m is 0 or 2, and
R12a and R12b each independently of one another represent H, F, OH, CH3 or OCH3; and
R12c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, OCF2H, CH2—OH, CH2—OCH3, S(═O)2—CH3, SCF3, NO2, N(CH3)2,






 CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH, C(═O)—O—C2H5 and phenyl,
wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4 aliphatic residue, OCF3, CF3, CN, a C1-4-aliphatic residue, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C2H5,


R2 represents F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; CH2—OH; CH2—O—CH3; CH2—CH2—OH; CH2—CH2—OCH3; O-methyl; O-ethyl; O—(CH2)2—O—CH3; O—(CH2)2—OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl,
R3 represents H; F; Cl; Br; I; CN; CF3; SCF3; NO2; OCF3; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; O-methyl; O-ethyl; O—(CH2)2—O—CH3; O—(CH2)2—OH; S-Methyl; or S-Ethyl,
R6 denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH2—CH(CH3)(C2H5), C(CH3)2(C2H5), CH2—OCH3, C2H4—OCH3, C3H6—OCH3, cyclopropyl, cyclobutyl, or tetrahydropyranyl, ethenyl or propenyl (—CH2CH═CH2, —CH═CH—CH3, —C((═CH2)—CH3), in each case unsubstituted,
or
R6 denotes O—R8 
wherein R8 denotes methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, N(C1-4 aliphatic residue) and an O—C1-4-aliphatic residue, or in each case denote CH2-cyclopropyl or oxetanyl,
wherein the C1-4-aliphatic residue in each case is unsubstituted.

10. The compound according to claim 1, which is selected from the group consisting of:
3 N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
9 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-[(E)-prop-1-enyl]-pyridine-3-carboxylic acid amide;
10 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
19 N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
21 N-[3-Fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
22 2-Ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
23 N-[(3-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
28 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-[(E)-prop-1-enyl]-pyridine-3-carboxylic acid amide;
29 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide
38 2-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
39 N-[(4-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
64 2-Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
86 N-(4,4-Dimethyl-pentyl)-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
87 N-[(3,4-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
88 2-Methoxy-4-methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)-methyl]-pyridine-3-carboxylic acid amide;
89 N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
90 N-[(3,5-Difluoro-phenyl)-methyl]-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
91 N-[(3,4-Difluoro-phenyl)-methyl]-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
92 2-Ethoxy-4-methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)-methyl]-pyridine-3-carboxylic acid amide;
110 2-Butoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
111 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propoxy-pyridine-3-carboxylic acid amide;
117 2-Methoxy-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
132 2-Ethoxy-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
133 2-Ethoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
140 2-Methoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
165 N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
166 N-[(4-Chlorophenyl)-methyl]-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
169 N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
181 N-[(4-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
182 2-Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
185 N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
186 N-(4,4-Dimethyl-pentyl)-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
187 N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
194 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-(1-methyl-propyl)-pyridine-3-carboxylic acid amide;
195 N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-(1-methyl-propyl)-pyridine-3-carboxylic acid amide;
196 2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
197 N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide;
198 2-Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
199 N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide;
214 N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
215 N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
216 N-[(3-Fluorophenyl)-methyl]-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
220 2-tert-Butyl-N-(4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
221 N-(4,4-Dimethyl-pentyl)-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
226 N-[(3,4-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
234 N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
236 2-Methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
238 2-Methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
250 2-tert-Butyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
265 N-[(4-Chlorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
266 N-[(4-Chlorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide;
269 N-[(4-Chlorophenyl)-methyl]-2-(2-fluoro-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
270 N-[(4-Chlorophenyl)-methyl]-2-(2,2-difluoro-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
271 N-[(4-Chlorophenyl)-methyl]-2-(cyclopropyl-methoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
272 2-(2,2-Difluoro-ethoxy)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
273 N-[(4-Chlorophenyl)-methyl]-2-ethoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
276 2-(Cyclopropyl-methoxy)-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
277 N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
278 N-(4,4-Dimethyl-pentyl)-4-methyl-2-(2-methyl-butyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
279 N-(4,4-Dimethyl-pentyl)-2-(1,1-dimethyl-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
282 N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide;
283 N-[(4-Chlorophenyl)-methyl]-2-(2-dimethylaminoethyloxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
285 N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
290 N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-6-[(2S)-2-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide;
309 N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
310 N-[(3,4-Difluoro-phenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
311 2-Isopropyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
313 N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
314 N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
315 2-Isopropyl-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
316 N-[(3,5-Difluoro-phenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
317 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-(oxetan-3-yloxy)-pyridine-3-carboxylic acid amide;
320 4-Methyl-6-morpholin-4-yl-2-propyl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
321 N-[(3,4-Difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
322 N-[(3,5-Difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
323 4-Methyl-6-morpholin-4-yl-2-propyl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
326 N-[(4-Chlorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide;
327 N-[(4-Chlorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
328 2-Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
329 2-Cyclopropyl-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide;
330 2-Cyclopropyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
331 2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
332 2-Cyclopropyl-N-[(3,4-difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
333 2-Cyclopropyl-N-[(3,5-difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
334 2-Cyclopropyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide;
335 N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
347 N-[(4-Chlorophenyl)-methyl]-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
349 N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
351 2-Cyclopropyl-N-[[4-fluoro-3-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
354 N-(4,4-Dimethyl-pentyl)-2-(3-methoxy-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
355 2-Cyclopropyl-N-[[3-fluoro-4-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
356 N-[(3-Fluorophenyl)-methyl]-2-(methoxymethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
357 N-[(4-Chlorophenyl)-methyl]-2,4-diisopropyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
358 N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;
359 N-[(4-Chlorophenyl)-methyl]-2,4-diethyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; and
362 N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-2-tetrahydro-pyran-4-yl-pyridine-3-carboxylic acid amide,
respectively in the form of free compounds; racemic mixtures; mixtures of the enantiomers, diastereomers, or enantiomers and diastereomers in any mixing ratio, or an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases.

11. A pharmaceutical composition comprising at least one compound according to claim 1 and optionally at least one pharmaceutically acceptable auxiliary and/or optionally at least one further active ingredient.

12. A method for the treatment of a disorder and/or disease selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary, incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias, said method comprising administering to a patient in need of such treatment an effective amount therefor of a compound according to claim 1.